Identifying genetic variation contributing to keratoconus by Lucas, SEM
  
 
 
 
IDENTIFYING GENETIC VARIATION 
CONTRIBUTING TO KERATOCONUS 
 
 
 
by 
Sionne Edie Marguerite Lucas 
BMedSci, BMedRes (Hons) 
Menzies Institute for Medical Research | College of Health and Medicine 
 
 
 
 
 
Submitted in fulfilment of the requirements for the degree of Doctor of 
Philosophy (Medical Studies) 
University of Tasmania, December, 2018 
i 
DECLARATION OF ORIGINALITY 
This thesis contains no material which has been accepted for a degree or diploma by the University or 
any other institution, except by way of background information and duly acknowledged in the thesis, 
and to the best of my knowledge and belief no material previously published or written by another 
person except where due acknowledgement is made in the text of the thesis, nor does the thesis contain 
any material that infringes copyright. 
Sionne Lucas 
18/12/2018 
ii 
AUTHORITY OF ACCESS STATEMENT 
The publishers of the papers comprising Chapter 3 hold the copyright for that content, and access to the 
material should be sought from the respective journals. The remaining non-published content of the 
thesis may be made available for loan and limited copying and communication in accordance with the 
Copyright Act 1968. 
Sionne Lucas 
18/12/2018 
iii 
STATEMENT OF ETHICAL CONDUCT 
The research associated with this thesis abides by the international and Australian codes on human and 
animal experimentation, the guidelines by the Australian Government's Office of the Gene Technology 
Regulator and the rulings of the Safety, Ethics and Institutional Biosafety Committees of the University. 
Sionne Lucas 
18/12/2018 
iv 
STATEMENT OF CO-AUTHORSHIP 
Sionne E. M. Lucas has incorporated versions of two first-author papers, Lucas et al. (2017)1 and Lucas 
et al. (2018),2 into Chapter 3. The contribution of co-authors for each paper is presented below. 
Lucas SEM, Zhou T, Blackburn NB, et al. Rare, potentially pathogenic variants in ZNF469 are not 
enriched in keratoconus in a large Australian cohort of European descent. Invest Ophthalmol Vis 
Sci 2017;58(14):6248-56. 
The co-authors and each author’s contribution are outlined as follows: 
Lucas, S. E. M. was involved the study design, data generation and data curation, she conducted data 
analysis and laboratory experiments and wrote the manuscript and prepared the tables and figures; 
Zhou, T. was involved in method development; Blackburn, N. B. was involved in method development, 
conducted preliminary data analysis and was involved in manuscript revision; Mills, R. A. conducted 
clinical examinations and was involved in patient recruitment; Ellis, J. was involved in preliminary data 
analysis; Leo, P. was involved in preliminary data analysis; Souzeau, E. was involved in patient 
recruitment, data curation and manuscript revision; Ridge, B. was involved in patient recruitment and 
data curation; Charlesworth, J. C. was involved in study design and manuscript revision; Brown, M. A. 
was involved in recruitment and data curation; Lindsay, R. conducted clinical examinations and was 
involved in patient recruitment; Craig, J. E. conducted clinical examinations and was involved in patient 
recruitment; Burdon, K. P. was involved in study design, funding acquisition, methodology 
development and manuscript revision. 
Lucas SEM, Zhou T, Blackburn NB, et al. Rare, potentially pathogenic variants in 21 keratoconus 
candidate genes are not enriched in cases in a large Australian cohort of European descent. PLoS 
One 2018;13(6):e0199178. 
The co-authors and each author’s contribution are outlined as follows: 
Lucas, S. E. M. was involved in data generation, data curation, and study design, conducted data 
analysis and laboratory experiments for variant validation, and wrote the manuscript and prepared the 
tables and figures; Zhou, T. was involved in method development; Blackburn, N. B. was involved in 
method development, conducted preliminary data analysis and was involved in manuscript revision; 
Mills, R. A. conducted clinical examinations and was involved in patient recruitment; Ellis, J. was 
involved in preliminary data analysis; Leo, P. was involved in preliminary data analysis; Souzeau, E. 
v 
was involved in patient recruitment, data curation and manuscript revision; Ridge, B. was involved in 
patient recruitment and data curation; Charlesworth, J. C. was involved in study design and manuscript 
revision; Lindsay, R. conducted clinical examinations and was involved in patient recruitment; Craig, 
J. E. conducted clinical examinations and was involved in patient recruitment; Burdon, K. P. was 
involved in study design, funding acquisition, methodology development and manuscript revision. 
Prof. Kathryn Burdon 
Supervisor 
Menzies Institute for Medical Research 
University of Tasmania 
18/12/2018 
Prof. Alison Venn 
Director 
Menzies Institute for Medical Research 
University of Tasmania 
08/05/2019 
vi 
 
ACKNOWLEDGEMENTS 
As anticipated, an almost four-year project generates a long list of ‘thank yous’. 
To the Australian Government for my Research Training Program Scholarship and the Pennicott 
Foundation for the financial support over the last 3 and a half years. 
To all of our collaborators, the clinicians and the participants, without which this study would not be 
possible. A particularly big thank you to both Emmanuelle Souzeau and Sandra Staffieri for being the 
in-betweens and answering my many questions about the patients’ and their clinical data. 
To Kathryn Burdon, my primary supervisor, for being the most incredible mentor, critic, advocate and 
friend. Thank you for inspiring me every single day. 
To Jac Charlesworth, my co-supervisor, for always pushing me to be better and do better. And for 
reminding me, at potentially the most critical moment, that the most amazing things are made from 
crushing pressure and the passage of time. 
To Pat and JoJo, for our many ‘coffees’, lunches and early morning chats - your support over the past 
four years has been immeasurable. You’ve made me laugh on even the hardest of days and helped 
celebrate some of the best. Thank you being my sounding boards, my teachers, my students and such 
good friends. Don’t forget about me now that I don’t get to sit with the cool kids. 
To Bennet for your bioinformatic support, especially your R expertise, and for keeping Sunnydale 
running smoothly. 
To the rest of our CompGen team and 502 office buddies – Ming, Duran, Elise, Kelsie, Alex, Van, 
Emma and Aparna – for your support over the years, both professionally and socially.  
To James Marthick, ‘the boss’, for all of your sequencing expertise and support. 
To Nick, for teaching me all the bioinformatics that you could in the first year of my project. I would 
have been lost without you and such a strong foundation. 
To Sian, for our sporadic and always lengthy phone calls filled with commiserations and 
encouragement. You’ve got this too. 
To Hayley, for being the best cheerleader and friend anyone could ask for. Always. 
To my parents, for your never-ending support, advice (while it was sometimes unsolicited, in retrospect 
it was usually pretty accurate), and encouragement. 
To Jenna, my wife (I still have to get used to that!), for everything. For putting up with the stress, the 
non-existent weekends, and most importantly, the hours of dishes you endured towards the end of my 
PhD. I’m so glad I’ve had you by my side every step of the way.  
vii 
 
ABSTRACT 
Keratoconus (OMIM 148300) is a complex disease characterised by progressive stromal thinning and 
conical protrusion of the cornea. These abnormalities usually develop in the second decade of life and 
can lead to severe visual impairment as a result of high myopia and irregular astigmatism. Due to the 
early onset of disease, keratoconus affects individuals during their most productive years and quality of 
life estimates demonstrate a significant decline over time that is disproportional to visual acuity. The 
global incidence of keratoconus is approximately 1 in 50,000 and the prevalence in Caucasians is 
reported between 55 and 265 per 100,000 individuals. While keratoconus is a complex disease, it has a 
strong genetic basis. Familial examples display both autosomal dominant and recessive inheritance 
patterns and first-degree relatives have at least a 15-fold increased risk of developing keratoconus, 
compared to the general population. Current treatment options for keratoconus are suboptimal, require 
invasive surgical procedures and have limited applicability and effectiveness in early-onset and 
advanced disease. Currently, keratoconus is the second leading indication for corneal transplants in 
Australia and there is a great need to better understand keratoconus aetiology and pathophysiology to 
aid early diagnosis and the development of novel treatments to improve patient outcomes. Therefore, 
the overarching aim of this project was to identify genetic variants involved in keratoconus 
susceptibility through the assessment of individuals and families in our keratoconus DNA repository. 
This aim was achieved through three distinct studies: a candidate gene screen; novel variant discovery 
in families with multiple cases of severe and early-onset keratoconus; and association analysis in a large 
case-control cohort. 
The gene-screen aimed to determine if rare, protein-coding variants predicted to be pathogenic were 
enriched in in keratoconus-candidate genes in our cohort of keratoconus cases of European descent 
compared to ethnically matched controls. By combining whole exome-sequencing and targeted gene 
sequencing, a total of 22 keratoconus candidate genes were assessed in 385 unrelated cases, making 
this the most comprehensive study of its kind to date. Two control cohorts were used for comparison, 
including up to 396 population controls (unassessed for eye disease) and 230 individuals without 
keratoconus. The candidate genes were selected from the literature and included genes near associated 
loci, genes harbouring putative disease-causing variants in family studies, and genes proposed to play 
a role in keratoconus based on a known function in the cornea or involvement in a postulated disease 
process. Specifically, this study examined the frequency of potentially pathogenic variants in MPDZ, 
RXRA, RAB3GAP1, FOXO1, BANP, ZNF469, HGF, COL5A1, IMMP2L, FNDC3B, NFIB, ILRN, 
SLC4A11, CAST, COL4A3, COL4A4, TF, SOD1, VSX1, RAD51, IL1A and IL1B. For all genes, no 
difference was observed in the frequency of rare, protein-coding potentially pathogenic variants 
between the cases and controls, suggesting that rare protein-coding variation in these genes do not play 
a major role in keratoconus susceptibility.  
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The second study utilised whole genome sequencing (WGS) to investigate the genetic basis of disease 
in two families with severe, early-onset keratoconus. The aim of this study was to identify putatively 
disease-causing variants that segregate with disease in these families. One family was Jordanian, 
KCNSW01, with eight cases of keratoconus and three unaffected family members across three 
generations. While the parents in the first generation are both apparently unaffected, the inheritance 
pattern in the second-, and third-, generation was indicative of autosomal dominant inheritance of 
keratoconus. The second family, KSA197, was a family of Italian heritage with two affected brothers 
born to unaffected, second-cousin parents. Both brothers are affected with keratoconus and one has an 
unaffected child, consistent with autosomal recessive inheritance. WGS was obtained for 11 individuals 
from KCNSW01 and five family members from KSA197. A subset of ~250,000 single nucleotide 
polymorphisms (SNPs) across the autosomes were extracted from the WGS and used to conduct linkage 
analysis in KCNSW01 and homozygosity mapping in KCNSW01.  
Two linkage regions with equal maximum logarithm of the odds (LOD) scores of 2.1 were identified 
in KCNSW01: 17q12 and 20p13-12.2. The disease-associated haplotypes at 17q12 and 20p13-12.2 
were inherited from the matriarch and patriarch (both unaffected), respectively. All affected individuals 
carry both haplotypes, suggesting digenic inheritance of keratoconus in this family. For KSA197, a 
single homozygous region shared by the two affected brothers was identified at 16p12.1. For both 
families, variants that segregated with the disease-associated haplotype(s) were extracted and further 
investigated. No rare protein-coding variants fulfilled the criteria for putatively disease-causing in either 
family. Non-coding variation that segregated with disease were therefore prioritised based on the minor 
allele frequencies in the gnomAD database, predictions of deleteriousness and pathogenicity and 
whether or not they were located in known regulatory regions. One putatively disease-causing variant 
was identified in KSA197 and a total of 44 were identified KCNSW01, including a compelling variant 
located in an untranslated region of the spermine oxidase gene (SMOX). This novel candidate gene 
encodes the SMOX protein which plays a role in apoptosis and the cellular response to ultraviolet 
radiation and oxidative stress. These pathways are biologically-plausible in the keratoconus disease 
process and therefore the specific variant and the gene should be further investigated. 
The overall aim of the third study was to identify putatively functional variants with a role in 
keratoconus susceptibility. This study was separated into specific aims. Aim 1 was designed to identify 
novel keratoconus-associated variants in a large case-control study. As keratoconus is a disease in which 
the cornea progressively thins, it was hypothesised that variants that contribute to central corneal 
thickness (CCT) in the general population would also contribute to keratoconus risk. Therefore, 72 
SNPs known to contribute to CCT were assessed for association in a cohort of 536 keratoconus cases 
and 2,574 controls of European descent. Five SNPs were significantly associated with keratoconus 
following correction for multiple testing, including a novel association at rs2268578 in an intronic 
region of the lumican gene (LUM). The remaining four SNPs – rs1536482 and rs3132303 located 
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between RXRA and COL5A1, rs2755238 in the second intron of FOXO1 and rs66720556 between 
MPDZ and NFIB – had previously shown either a significant or suggestive association with 
keratoconus. 
Aim 2 focused on identifying the functional variants that underlie the associations at keratoconus-
associated loci. Six regions were fine-mapped: RXRA-COL5A1, FOXO1, FNDC3B, MPDZ-NFIB, 
RAB3GAP1 and the novel locus LUM. This analysis was conducted in a cohort of 487 keratoconus 
cases and 626 unaffected controls with genome-wide genotyping data. To appropriately capture the 
association peaks during fine-mapping, variants across the surrounding gene were included for intronic 
loci, whereas the region encompassing the flanking genes were included for intergenic loci. Strong 
association peaks were observed at all loci except the previously reported RAB3GAP1 locus, thus this 
locus was not further analysed. To further assess variation carried on the risk-associated haplotypes at 
remaining loci, keratoconus patients carrying the risk allele for the top SNP determined in Aim 2 were 
selected for re-sequencing in Aim 3. A total of 178 cases and 62 controls were re-sequenced across the 
five loci. Variants at each locus were filtered to identify those that were carried on the risk-associated 
haplotype; in high LD with the top SNP as measured by D’ to ensure the capture of both common and 
rare variants; and were more common in the cases compared to the controls and all populations available 
in Genome Aggregation Database (gnomAD). These variants were further prioritised based on 
deleteriousness/pathogenicity predictions and whether or not the variant was likely to disrupt a 
regulatory region. This analysis identified putatively functional variants at all five loci, and proposed 
rs79728429 as a functional variant at the FOXO1 (rs2721051) locus. From this work, it was further 
hypothesised that that rs79728429 alters the expression of a novel uncharacterised gene, AL133318.1, 
and that this altered expression in the cornea confers an increased susceptibility to keratoconus at this 
locus. 
This dissertation comprehensively investigated genetic variation in keratoconus susceptibility in a 
cohort of Australian keratoconus patients of European descent using three distinct studies and 
methodologies. In the largest study of its kind to date, this project demonstrated that rare coding 
variation in 22 keratoconus-candidate genes were unlikely to contribute broadly to keratoconus. The 
family-based study demonstrated strong evidence of digenic inheritance of keratoconus in one family 
with the discovery of two linkage regions of equal significance (17q12 and 20p13-12.2) and identified 
a homozygous region on 16p12.1 in a family with recessive disease. Putatively-disease causing variants 
within these regions were identified and prioritised for further investigation, including an appealing 
variant located in the 5’ UTR of SMOX. Finally, this project identified a novel keratoconus-associated 
locus overlapping LUM with rs3759221 as the top SNP. Putatively functional variants were prioritised 
at five key keratoconus-associated loci, including a compelling novel putatively functional variant 
(rs79728429) at the FOXO1 locus. It was further hypothesised that AL133318.1 is a regulatory target 
of rs79728429. Taken together, these findings have contributed substantially to the field of keratoconus 
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genetics, highlighting the limited contribution of rare coding variation and suggesting a substantial role 
for non-coding variants in disease susceptibility.  
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CHAPTER 1: INTRODUCTION 
 
 AN INTRODUCTION TO KERATOCONUS 
Keratoconus (OMIM 148300) is a disease characterised by progressive thinning and protrusion of the 
cornea at the front of the eye, resulting in severe visual impairment. Reports place the prevalence of 
keratoconus between 17 and 3300 per 100,0003-14 and the incidence from 1.3 to 32.3 per 100,000 per 
year.4-6, 15-18 The prevalence and incidence rates vary greatly between studies, methods of diagnosis, 
population and geographic location, with markedly higher statistics in Asians19 and, anecdotally, in 
Polynesians.20 The most commonly reported prevalence in Caucasians, which this dissertation will 
focus on, is 54.5 per 100,000 with an incidence of 2.0 per 100,000 per year.4 Keratoconus is typically 
bilateral, although the development and progression may be asymmetrical.21 Diagnosis is generally 
made around puberty or during early adulthood, however in the early stages of disease, keratoconus is 
difficult to differentiate from regular refractive errors and may be misdiagnosed.22, 23 Furthermore, 
diagnosis before the age of 19 is associated with severe disease characterised by a faster rate of 
progression as well as diagnosis at a more advanced stage, compared to adults.24 However, the only 
current treatment with the potential to inhibit keratoconus progression, a surgical procedure known as 
corneal collagen cross linking, cannot be used in severe disease as a minimum corneal thickness is 
required to ensure safety.25 This procedure requires early diagnosis of keratoconus and may exclude 
patients most in need of treatment. Unfortunately, all other current treatments merely manage symptoms 
and ultimately one in five keratoconus patients will require corneal transplants.26 Therefore, there is a 
great need for the development of novel treatments as well as a better understanding of the aetiology 
and pathophysiology of disease to aid early diagnosis. 
While our understanding of the aetiology of keratoconus is limited, it is clear that both environmental 
and genetic factors involved in disease susceptibility and development. Furthermore, the aetiology is 
heterogeneous, with the relative contributions of genetic and environmental factors differing between 
individuals. At least one case in the literature seems to have resulted entirely from traumatic injury,27 
however, there are also cases demonstrating clear autosomal dominant patterns of inheritance.28, 29 
Therefore, it is hypothesised that in the majority of cases environmental factors are required to trigger 
keratoconus development in genetically predisposed individuals. As extensively reviewed by Gordon-
Shanng and colleagues,30 environmental risk factors include eye rubbing, atopy (hypersensitivity 
reactions in the form of eczema, asthma and allergy), ultraviolet light exposure and geographic location, 
however, largely the genetic risk factors involved in keratoconus predisposition have not yet been 
elucidated. Identifying specific genetic factors involved in keratoconus susceptibility and pathogenesis 
would allow for improved genetic counselling, earlier diagnosis as well as pave the way for the 
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development of biomarkers, novel therapies and management strategies, which taken together would 
greatly improve patient’s quality of life. 
 
 THE HUMAN EYE AND VISION 
The eye is a complex organ that receives input for the visual sensory system. The eye responds to light 
stimuli and relays this information to the brain, where visual perception occurs. For good vision, the 
coordination of highly specialised structures within the eye is critical and involves the transparency of 
tissues, the regulation of light intensity, and the coordinated refraction of light onto the photosensitive 
cells of the retina. Upon light stimulation, photosensitive cells produce action potentials which are 
conducted along the optic nerve from the eye to the brain. 
1.2.1 Basic anatomy and physiology of the human eye 
The eye is essentially an irregular sphere, comprising of layers of tissues surrounding a largely fluid-
filled space (Figure 1.1). The surface of the eye consists of the sclera and the cornea, both of which are 
collagen-rich connective tissues that provide structural integrity and protect the intraocular structures. 
The sclera is a tough, opaque structure that forms the majority of the surface area of the eye and is 
continuous with the cornea. The cornea is a transparent tissue that forms a dome-shaped at the front of 
the eye. In addition to its protective role, the cornea allows the passage of light into the eye and is 
responsible for two-thirds of the eye’s refractive power. Behind the cornea the iris is clearly visible. 
The iris is a highly pigmented ring-shaped tissue that acts like a diaphragm to regulate the amount of 
light that can pass through the pupil. The crystalline lens is suspended behind the iris and divides the 
eye into the anterior and posterior chambers. Like the cornea, the lens is transparent and is involved in 
the focusing of light onto the retina. In contrast to the cornea which has a constant refractive power, the 
refractive power of the lens can be altered in a process known as accommodation. The retina lines the 
internal surface at back of the eye and consists of layers of neural cells as well as photoreceptors. 
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Figure 1.1 – A diagram of the cross section of a human eye. 
Source: Levin, LA, Nilsson, SFE, Ver Hoeve, J, Wu, SM, Kaufman, PL & Alm, A (eds) 2011, Adler's 
Physiology of the Eye, 11th edn, Saunders Elsevier, Sydney. 
 
1.2.2 The cornea 
The cornea is the transparent portion of the outermost tunic of the eye. On a gross level, the cornea is 
aspherical with an apex where the curvature is the steepest. Corneal curvature gradually decreases 
towards the scleral junction. The thinnest region of the cornea is at the centre with corneal thickness 
increasing towards the sclera. Central corneal thickness (CCT) is a quantitative trait with normal 
distribution in Caucasians around a mean of 0.536 mm with the normal range between 0.473 and 0.597 
mm.31 The cornea is avascular as blood vessels would inhibit the transmission of light and thus the cells 
of the cornea are nourished by the surrounding fluids: the aqueous humour contained within the anterior 
chamber, or the tear film that coats the anterior surface. 
On a finer scale, the cornea is comprised of five discrete layers (from anterior to posterior): the 
epithelium, Bowman’s layer, the stroma, Descemet’s membrane and the endothelium (Figure 1.2). The 
epithelium is a five to seven cell layer that forms the outer surface of the cornea. The primary function 
of the epithelium is to provide a smooth refractive surface, but it also forms a protective barrier against 
and pathogens and fluid loss. Bowman’s layer forms a membrane of woven collagen fibrils between 
the epithelium and the stroma that functions largely to support the shape of the cornea, as well as provide 
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protection for the deeper layers. The central layer, the stroma, makes up the 90% of the corneal thickness 
and is integral for the shape, structural integrity and transparency of the cornea. The stroma consists of 
a collagen-rich extracellular matrix interspersed with supporting keratocytes. Keratocytes have a 
characteristic stellate-like morphology, resulting from numerous lamellapodia that extend from the 
compact cell body, allowing for cell-to-cell communication, whilst minimising light scattering.32 These 
cells are essential for the production and maintenance of the surrounding extracellular matrix, including 
the excretion of collagens and proteogyclycans.33 Collagen type I is the primary collagen found 
throughout the stromal layer.34 The second most abundant collagen is type V and many other collagens 
are present in lesser quantities.32, 34 Along with proteoglycans, these collagens form water-soluble 
fibrils, which are regularly packed and are arranged into lamellae. In the anterior third of the stroma, 
these lamellae are interlaced in three dimensions, and this is thought to contribute to corneal rigidity.35 
The lamellae located in the posterior portion of the stroma form orthogonal layers, which is important 
for transparency.36 Beneath the stroma, the Descemet’s membrane forms an elastic collagen-rich lattice 
structure that supports the underlying endothelium. The endothelium is a single-cell layer and is 
primarily involved in the regulation of the fluid levels in the cornea. For corneal transparency, the 
stroma must exist in a state of relative dehydration.32 This is achieved via the active transport of ions 
into the aqueous humour by endothelial cells, creating an osmotic gradient and draws fluid out of the 
stroma.32  
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Figure 1.2 – A diagram of layers of the mature cornea.  
Adapted from: Levin, LA, Nilsson, SFE, Ver Hoeve, J, Wu, SM, Kaufman, PL & Alm, A (eds) 2011, 
Adler's Physiology of the Eye, 11th edn, Saunders Elsevier, Sydney. 
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 KERATOCONUS 
1.3.1 Signs and symptoms 
Symptoms are subtle in early in keratoconus and patients may simply notice blurred vision. As the 
disease progresses the cornea increasingly protrudes, forming a conical shape, and visual acuity 
diminishes due to the occurrence of high myopia and irregular astigmatism. High myopia is a severe 
form of short-sightedness and is a characteristic of keratoconus due to the increased axial length of the 
eye, resulting from the conical protrusion of the cornea.37 Irregular astigmatism is also characteristic of 
keratoconus and results in multiple focal points and distorted vision due to the irregular surface and 
shape of the cornea. 
Clinically, the first conclusive sign of keratoconus is steepening of the cornea,38 however, corneal 
thinning commonly precedes this.39 In keratoconus, the degree of corneal thinning can vary greatly 
between individuals, however, a meta-analysis of  CCT in  keratoconus patients showed a mean of 
0.434 mm across 12 studies.31 In addition, distortion of keratometric images and abnormal light reflexes, 
such as scissoring of the retinoscopic reflex and oil droplet sign of Charleux, are early signs of 
keratoconus.30, 40 As the disease progresses pigmented iron deposits, known as Fleischer’s ring, are 
commonly observed around the base of the developing cone.39 Fine vertical stress lines, known as 
Vogt’s striae, resulting from the compression of the Descemet’s membrane are also a sign of moderate 
keratoconus. Advance stages of keratoconus are characterised by V-shaped deformation of the lower 
eyelid during downward gaze known as Munson’s sign, Rizzuti’s sign (an abnormal light reflection), 
scaring of the cornea, and corneal hydrops.39 Corneal hydrops is a potentially-blinding complication of 
keratoconus and is caused by breaks in the Descemet’s membrane that results in oedema of the stroma 
and loss of corneal transperancy.39 Corneal hydrops presents with severe pain, corneal opacity and 
photophobia and requires immediate corneal transplantation.41  
The gold standard technique for diagnosis and monitoring of keratoconus progression is corneal 
topography, a computer-assisted method for mapping and analysing the corneal surface and curvature.42 
This highly sensitive method has allowed for the development of a number of highly specific indices 
for the diagnosis of keratoconus43, 44 and also allows for the identification of subtle manifestations that 
don’t meet the strict criteria for keratoconus, commonly referred to in the literature as forme fruste 
keratoconus, keratoconus suspect or subclinical keratoconus.22, 23 Forme fruste keratoconus is important 
to diagnose and monitor as it may progress and develop into true keratoconus later in life. The diagnosis 
of forme fruste keratoconus is particularly critical in individuals undergoing refractive surgery as the 
procedure weakens the cornea and may trigger keratoconus devleopment.45, 46 
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1.3.2 Treatments and management 
In early stages of disease, the refractive errors associated with keratoconus can be corrected with 
glasses, however as the disease progresses, contact lenses are required.47, 48 Contact lens fitting can be 
a complex and it may be difficult to achieve adequate visual acuity with comfort and without 
compromising corneal health.47, 48 A range of contact lenses may be used depending on the severity of 
disease and comfort of the patient including: soft, ridged gas permeable, scleral and hybrid lenses.47, 48 
In addition, piggyback lenses is common and involves wearing two lenses on one eye, generally a soft 
contact lens underneath a gas permeable lens.47, 48 However, as the disease progresses contact lens 
intolerance, corneal abrasions and scaring may develop and corneal transplantation may be required.47 
Currently, keratoconus is the second leading indication for corneal grafting in Australia. Corneal 
transplantation is a surgical procedure in which a central portion of the corneal is replaced with a healthy 
graft from a deceased donor. However, graft survival time is limited and due to the early age of onset 
of disease, keratoconus patients may require multiple grafts throughout their lifetimes.49-53 Like any 
surgical procedure, corneal transplantation is associated with a number of well documented 
complications, however, regrafting is associated with increased complications, decreased graft survival 
and poorer visual acuity.49, 54-56 
In recent years the development of corneal collagen cross-linking, a surgical procedure that induces 
covalent bonds between the collagen fibres of the corneal stroma, has shown promising results in the 
inhibition of keratoconus progression. The procedure involves the removal of the epithelium followed 
by the addition of riboflavin (vitamin B2) and irradiation with long wave ultraviolet light (UVA, 
370nm).57 This results in increased corneal rigidity through a process known as photopolymerisation.57 
However, corneal collagen cross-linking can only be conducted on corneas with a minimum CCT of 
0.400 mm to ensure protection of the sensitive endothelium and therefore cannot be used to treat well 
progressed cases of keratoconus.58 Thus, corneal collagen cross-linking requires timely diagnosis of 
keratoconus. As keratoconus tends to be diagnosed at a later stage and progress faster in paediatric 
cases,24 this may exclude patients most in need of this treatment. Furthermore, as reviewed by 
Mastropasqua,25 corneal collagen cross-linking fails to inhibit disease progression in up to a third of 
cases. A better understanding the underlying genetic risk factors and pathogenesis of disease would lead 
to the development of novel treatments to inhibit keratoconus progression and potentially identify 
biomarkers to aid early diagnosis, which together would greatly improve patient outcomes.  
8 
 
 KERATOCONUS GENETICS 
There is strong evidence for the role of genetic factors in the aetiology of keratoconus. Up to 27.9% of 
patients report a family history of disease, implicating the role of genetic factors in these cases.4, 59-61 It 
is however widely accepted that sporadic cases of keratoconus are a result of environmental triggers in 
genetically predisposed individuals. Evidence for this includes the bilateral nature of the disease, the 15 
to 67 fold higher prevalence in first-degree family members of keratoconus patients compared to the 
general population62 and the identification of undiagnosed keratoconus and forme fruste keratoconus in 
family members of keratoconus cases that were previously believed to be sporadic.62, 63 Taken together, 
this suggests that genetic factors contribute to keratoconus susceptibility in a large proportion of cases. 
1.4.1 Linkage studies 
To date, 16 linkage studies for keratoconus have been published (Table 1.1). These linkage regions map 
to 12 of the human autosomes, demonstrating the heterogeneity of genetic factors involved in 
keratoconus. The identification of the causal variants in these linkage regions has been slow and difficult 
due to the complex nature of keratoconus. Linkage studies rely on highly penetrant traits and clearly 
defined phenotypes and therefore reduced penetrance, the occurrence of phenocopies and 
heterogeneous phenotypes all contribute to the difficulty of identifying specific genetic variants in 
families with keratoconus. Despite this, putatively causal variants have been proposed in four of the 
linkage studies, implicating the role of genetic variation within the associated genes, DOCK9, MIR184, 
SLC4A11 and IL1RN, in keratoconus pathogenesis.64-66 While variation in these genes have not been 
widely investigated, preliminary findings suggest that these genes are involved in the pathogenesis of 
keratoconus, but they may only account for disease in the family in which the gene was first 
implicated,67, 68 or in the case of MIR184, in very few additional cases.69, 70 Genetic screening of 
unrelated keratoconus patients is required to confirm and determine the extent to which these genes 
contribute to keratoconus predisposition. In addition, further analysis of the genetic variation within 
families in which causal variants have not yet been elucidated presents an opportunity to identify novel 
genes involved in keratoconus susceptibility. 
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Table 1.1 – Statistically significant loci from keratoconus linkage studies. 
Locus Statistic Cohort type Population 
Number of 
families 
Number of 
individuals 
(affected) 
Identified 
variants 
Ref 
1p36.23-36.21* 
LOD = 3.4; 
NPL = 7.8  
(P = 0.00024) 
Large family 
Australian 
(Caucasian) 
1 19 (9)  71 
2p24 HLOD = 5.13 Small families 
Caucasian, Arab 
and Caribbean 
African 
28 253 (112)  72 
2q13-q14.3# NPL = 2.4 Large Family Ecuadorian 1 21 (9) 
IL1RN 
c.214+242C>T 
66 
3p14-q13 LOD = 3.09 Large family Italian 1 21 (11)  28 
5q15-q21.1 LOD = 3.48 Large family 
American 
(Caucasian) 
2 (intermarried) 27 (14)  73, 74 
8q13.1-q21.11* 
LOD = 3.4; 
NPL = 7.8  
(P = 0.00024) 
Large family 
Australian 
(Caucasian) 
1 19 (9)  71 
9p21 (34 cM) 
LOD = 3.8; 
NPL = 5.55  
( P = <0.001) 
Families with 
affected 
sibling pairs 
Hispanic 
17 (sibling pair 
families) 
93 (≥ 17 sibling 
pairs) 
 75 
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Locus Statistic Cohort type Population 
Number of 
families 
Number of 
individuals 
(affected) 
Identified 
variants 
Ref 
9q34 (159cM) LOD = 4.5 
Families with 
affected 
sibling pairs 
Caucasian and 
Hispanic 
67 (sibling pair 
families) 
351 (110 sibling 
pairs) 
 75 
13q32 LOD = 4.1 
Small and 
large families 
Ecuadorian 18 143 (76) 
DOCK9 
c.226A>C 
29, 64 
14q24.3 LOD = 3.58 
Small and 
large families 
Caucasian, 
Iranian, Indian 
and Pakistani 
6 36 (21)  76 
15q22.33-q24.2 LOD = 8.13 Large family Northern Irish 1 30 (16) 
MIR184 
r.57C>U 
65, 77 
16q22.3-q23.1 
LOD = 4.10; 
NPL = 3.27  
(P = 0.00006) 
Small families Finnish 20 76 (42)  78 
17p13 LOD = 3.21 Large family Pakistani 1 (consanguineous) 18 (4)  79 
17q24 (86cM) 
LOD = 3.9; 
NPL = 3.32  
(P = <0.001) 
Families with 
affected 
sibling pairs 
Hispanic 
17  
(sibling pair 
families) 
93  
(≥ 17 sibling 
pairs) 
 75 
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Locus Statistic Cohort type Population 
Number of 
families 
Number of 
individuals 
(affected) 
Identified 
variants 
Ref 
20p13-p12.2# NPL = 2.7 Large Family Ecuadorian 1 21 (9) 
SLC4A11 
c.2558+149_255
8+203del154 
66 
20q12 P = 2.1x10-5 
Identity-by-
descent 
Northern 
Tasmanian 
(Caucasian) 
1 six-generation 
family identified  
(4 of 8 cases were 
distantly related) 
8 (8)  80 
* refers to digenic inheritance. 
# indicates a suggestive locus were a putatively causative variant was identified. 
LOD = logarithm of the odds. 
HLOD = heterogeneity LOD. 
NPL = nonparametric LOD. 
P = P-value.  
Ref = reference. 
Adapted from Lucas, SEM.81 
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1.4.2 Genome-wide association studies  
Association studies aim to identify variants that are more commonly observed in cases compared to 
controls. Recently, high throughput DNA genotyping technology has allowed for genome-wide 
association studies (GWAS) which detect associations throughout the genome, without a priori 
hypotheses. Genome-wide association studies (GWAS) aim to detect associations between the 
genotypes at thousands of single nucleotide polymorphisms (SNPs) and complex traits in hundreds of 
unrelated cases and controls. GWAS are designed to exploit linkage disequilibrium (LD), the non-
random association (or co-inheritance) of alleles at different loci, at a population level. LD is broken 
down by recombination events over generations, and therefore within a given population, LD blocks 
reflect haplotype blocks interspersed by recombination hotspots.82 SNPs are selected such that they 
‘tag’ LD blocks and therefore SNPs that meet the stringent significance threshold of 5 x10-8 identify 
risk-associated loci for further investigation. An important next step is fine-mapping associated loci, 
which requires genotyping additional SNPs across the LD block and assessing them for association with 
the trait. This method aims to confirm the association signal, identify the specific risk-associated 
haplotype(s) and ultimately is important for elucidating the functional variant(s).83 
Two significant, or highly suggestive, keratoconus-associated loci have been identified through GWAS 
for keratoconus: rs3735520 and rs17501108 on 7q21.11 (upstream of HGF)84 and rs4954218 at 2q21.3 
(upstream of RAB3GAP1).85, 86 In addition, Lu and colleagues87 elegantly demonstrated that two loci 
associated with the quantitative trait, CCT, were also associated with keratoconus: rs2721051 on 
13q14.11 (downstream of FOXO1) and rs4894535 on 3q26.31 (in an intronic region of FNDC3B). This 
study genotyped 26 CCT-associated loci in keratoconus patients based on the hypothesis that genetic 
factors involved in CCT may also contribute to keratoconus as reduced CCT is a feature of the disease. 
Four additional CCT-associated loci showed a suggestive association with keratoconus in this study: 
rs1536482 and rs7044529 on 9q34.3 (between RXRA and COL5A1 and in an intron of COL5A1, 
respectively), rs1324183 on 9p23 (between MPDZ and NF1B) and rs9938149 on 16q24.2 (between 
BANP and ZNF469). The MPDZ-NFIB locus later reached genome-wide significance following 
replication and meta-analysis.88 Together these studies identified four susceptibility loci for 
keratoconus, implicated a further four loci with highly suggestive association with keratoconus, and 
demonstrated the effectiveness of assessing CCT-associated SNPs in keratoconus patients to identify 
novel disease-associated loci.  
1.4.3 Functional gene candidates 
There have been many candidate genes suggested to be involved in keratoconus based on the known 
function or expression in the cornea: CAST, COL4A3, COL4A4, TF, SOD1, VSX1, RAD51, IL1B, IL1A, 
FLG, ZEB1, LOX. Of these genes, VSX1, 67, 89-102 SOD195, 96, 102-106 and LOX96, 107-110 have been screened 
in a number of relatively small case-control studies, however, the findings have been inconsistent and 
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therefore further analysis is warranted. The remaining functional candidates have not been widely 
assessed in keratoconus and thus large case-control studies are required to confirm the role of these 
genes in keratoconus susceptibility.  
1.4.4 The future of keratoconus genetics 
While progress in the field of keratoconus genetics has been slow, currently 30 candidate genes have 
been proposed to play a role in disease susceptibility (Table 1.2). To date, four keratoconus-associated 
loci have reached genome-wide significance and another four show a suggestive association. Nearby 
genes have been hypothesised to play a role keratoconus susceptibility, however, the keratoconus-
associated loci require fine-mapping to identify the functional variants. Additionally, the success of 
assessing CCT-associated loci in keratoconus patients warrants the analysis of additional CCT-
associated loci in keratoconus to elucidate novel genetic factors. Moreover, linkage studies have 
identified four putative susceptibility genes, however the contribution of these genes to keratoconus 
development more broadly is not yet known and requires further study. The complexity of keratoconus 
genetics has impeded the identification of casual variants in the remaining linkage studies, although, it 
is expected that due to the increased accessibility to massively parallel sequencing techniques, such as 
whole exome sequencing (WES) and whole genome sequencing (WGS), the number of causal variants 
identified in keratoconus families will increase substantially in coming years. The utility and 
effectiveness of this technology was recently demonstrated through the identification of a novel 
potentially-causative variant in the transforming growth factor beta-1 gene (TGFB1; c.T1209G) in an 
Iranian family with keratoconus.111 This gene had previously been suggested to play a role in 
keratoconus susceptibility based on the role of the protein in cellular interactions with the extra-cellular 
matrix in healthy corneas and its decreased expression in keratoconic corneas.112 This example 
highlights how an understanding of corneal biology can successfully identify candidate genes and the 
role of massively parallel sequencing techniques in the assessment of these genes. Furthermore, WES 
in large cohorts of unrelated keratoconus patients may allow for the identification of additional 
candidate genes without a priori hypotheses. Therefore, it is hoped that massively parallel sequencing 
techniques will aid family studies, as well as population-based studies, and represent a prosperous new 
chapter in the field of keratoconus genetics.  
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Table 1.2 – Candidate genes for keratoconus proposed in the literature. 
Gene Study Type Why Studied? Initial Studies 
CAST Case-control Candidate gene within linkage region 74, 113 
COL4A4 Case-control Expression/function in the cornea 114 
TF Case-control Functional candidate 115 
COL4A3 Case-control Functional candidate and corneal expression 114 
ZNF469 GWAS Proximity to GWAS signal 87 
MPDZ GWAS Proximity to GWAS signal 87 
RXRA GWAS Proximity to GWAS signal 87 
RAB3GAP1 GWAS Proximity to GWAS signal 85, 86 
IL1RN Linkage Candidate gene within a linkage region 66 
FOXO1 GWAS Proximity to GWAS signal 87 
BANP GWAS Proximity to GWAS signal 87 
HGF GWAS Proximity to GWAS signal 84 
SOD1 Case-control Functional candidate 103 
VSX1 Case-Control Corneal expression 89 
COL5A1 GWAS Proximity to GWAS signal 87 
RAD51 Case -control Functional candidate 116 
IMMPL2 GWAS Proximity to GWAS signal 85, 86 
SLC4A11 Linkage Candidate gene within a linkage region 66 
VPS13D Linkage Candidate gene within a linkage region 71, 81 
IL1B Case-control Functional candidate 117 
IL1A Case-control Functional candidate 117 
FNDC3B GWAS Proximity to GWAS signal 87 
NFIB GWAS Proximity to GWAS signal 87 
CBS GWAS Proximity to GWAS signal 118 
TGFB1 Case-control Functional candidate and family study 111, 112 
FLG Case-control Functional candidate 119 
DOCK9 Linkage Candidate gene within a linkage region 29, 64, 120 
MIR184 Linkage Candidate gene within a linkage region 65, 77 
ZEB1 Case-control Functional candidate 121 
LOX Linkage Candidate gene within a linkage region 75, 107 
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 PROJECT SUMMARY 
The heterogeneous nature of the genetic basis of keratoconus suggests that keratoconus is in fact a 
collection of disorders, perhaps caused by defects in various proteins that function within the same 
biological pathway, all of which result in the same phenotype. The identification of novel candidate 
genes would aid our understanding of keratoconus pathogenesis, as well as contribute to our 
understanding of corneal biology. This could lead to the development of novel treatments and the 
identification of biomarkers to aid early diagnosis to improve patients’ lives. Therefore, this project 
aims to explore the field of keratoconus genetics in a cohort of more than 620 Australian keratoconus 
patients of European ancestry to identify genetic risk factors involved in keratoconus susceptibility. To 
achieve this, a combination of methodologies will be applied including: whole-exome and whole-
genome sequencing to interrogate genetic variation in familial and severe sporadic cases; targeted 
sequencing of candidate genes in unrelated cases to investigate genetic variation in disease; as well as 
genotyping and association analysis of key loci in a large case-control study. Together, these studies 
will address two distinct but complimentary hypotheses. 
1.5.1 Hypotheses and aims 
Hypothesis 1: Rare, highly penetrant protein-coding variants contribute to keratoconus 
development.  
Overall aim: To investigate the role of rare protein-coding variants that are predicted to be 
damaging (potentially pathogenic variants) in Australian keratoconus patients of 
European descent. 
 More specifically to: 
1. Determine if potentially pathogenic variants are enriched in known candidate genes in 
keratoconus patients compared to controls; and 
2. Identify rare, putatively disease-causing variants in families with multiple cases of 
early-onset or severe keratoconus and a strong Mendelian inheritance pattern of disease. 
Hypothesis 2: Variants associated with keratoconus indicate haplotypes that harbour functional 
variants which directly contribute to keratoconus susceptibility. 
Overall aim: To identify variants that contribute to keratoconus susceptibility in a large cohort 
of unrelated Australian keratoconus patients with European ancestry. 
 More specifically to: 
1. Identify novel keratoconus-associated loci by assessing central corneal thickness-
associated loci in keratoconus patients and unaffected controls;  
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2. Fine-map keratoconus-associated loci in a cohort of unrelated keratoconus cases and 
controls to investigate the extent of the association, identify the top SNP, and select 
genomic regions for re-sequencing. This aim will assess novel keratoconus-associated 
loci identified in Aim 1, as well as, published keratoconus-associated loci that have 
reached genome-wide significance. 
3. Identify putatively functional variants underlying keratoconus-associated loci by re-
sequencing keratoconus patients carrying the risk-associated alleles. This aim will 
focus on fine-mapped regions with strong association peaks identified in Aim 2.  
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CHAPTER 2: GENERAL MATERIALS AND METHODS 
 
 STUDY COHORTS 
All investigations adhered to the principles of the Declaration of Helsinki and were approved by the 
Southern Adelaide Clinical Human Research Committee and the Human Research Ethics Committee 
Tasmania. All participants gave written informed consent.  
2.1.1 Keratoconus patients 
Keratoconus patients were recruited through the Flinders Eye Clinic (Adelaide, Australia) by referral 
from their treating optometrist or ophthalmologist. Additional patients were recruited from across 
Australia via mail through Keratoconus Australia. This cohort currently consists of approximately 630 
patients. All clinical examinations were performed by an experienced ophthalmologist. Individuals 
were diagnosed with keratoconus if they had videokeratographic features of keratoconus or any of the 
following signs: conical corneal protrusion, central or paracentral stromal thinning or other distinctive 
features such as Fleischer’s ring, Vogt’s striae, epithelial or sub-epithelial scarring, or oil droplet sign 
and/or scissoring of the retinoscopic reflex. In addition, individuals with a history of corneal 
transplantation for keratoconus were also classified as cases. Where a family history of disease was 
reported, both affected and unaffected family members were invited to be involved in the study. Family 
pedigree figures were generated using Cranefoot122 (version 3.2.3). Cohorts of unrelated keratoconus 
patients were used in Chapters 3 and 5, while key families were investigated in Chapter 4. 
Peripheral blood samples were collected from the recruited individuals and DNA was extracted using 
the QiaAmp DNA Maxi Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. For 
a small number of individuals saliva samples, rather than blood samples, were collected using the 
Oragene OG-500 DNA collection kit (DNA Genotek Inc., Ottawa, Ontario, Canada) and DNA was 
extracted with the Prep-It reagent (DNA Genotek Inc.) according to manufacturer’s instructions. 
2.1.2 Control cohorts 
Throughout this dissertation, older cohorts of individuals without clinical signs of keratoconus were 
selected as controls, wherever possible. As keratoconus generally develops during early adulthood, but 
can develop at any age, older control cohorts were selected to minimise the risk that these individuals 
would develop the disease and therefore be misclassified as unaffected individuals. The various control 
cohorts are outlined in sections 2.1.2.1 through to 2.1.2.4. 
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2.1.2.1 Population controls from the Anglo-Australasian Osteoporosis Genetic 
Consortium (AOGC) 
This cohort consists of 993 individuals from the Anglo-Australasian Osteoporosis Genetics Consortium 
(AOGC) were used as a population control cohort in Chapter 3. These individuals were ethnically 
matched females with moderately high, or low, bone mineral density measurements (1.5<|BMD|<4.0). 
These individuals were not examined for eye disease and therefore the frequency of keratoconus in this 
cohort is expected to be equal to the population frequency (approximately 1 in 1,500). This cohort has 
been described in detail previously.123 
2.1.2.2 Screened controls from the Australian and New Zealand Registry of 
Advanced Glaucoma (ANZRAG) 
This cohort consists of 230 individuals that were examined for eye disease by experienced 
ophthalmologists at the Flinders Eye Clinic. While these individuals had no clinical evidence of 
keratoconus, the majority of these individuals had advanced glaucoma (n=195). The remaining 
individuals either had no evidence of eye disease (n=22) or were unaffected individuals from families 
with congenital cataract (n=9) and nanophthalmos (n=4). This cohort was used in Chapter 3. 
2.1.2.3 Screened controls from the Blue Mountain Eye Study (BMES) 
These individuals were examined by an ophthalmologist and were deemed to be unaffected by 
keratoconus, although have other eye diseases such as glaucoma and cataract at normal population 
frequencies. All individuals in this cohort were above the age of 50 at the time of recruitment. This 
cohort includes 2574 individuals and has previously been described in detail by Mitchell and 
colleagues.124 These individuals were used as a screened control cohort in Chapter 5. 
2.1.2.4 NSA controls 
These individuals were examined for glaucoma, including a family history, but were not examined for 
other eye diseases, although any obvious eye conditions were noted during the examination. This cohort 
included 199 individuals who were over age 50 at the time of recruitment and were living in residential 
care facilities in Adelaide, South Australia. This cohort was used as population controls in Chapter 5. 
 
 MASSIVELY PARALLEL SEQUENCING 
Massively parallel sequencing was used throughout this dissertation, with targeted re-sequencing 
methods used in Chapters 3 and 5 and whole genome sequencing in Chapter 4. Specific details of the 
data generation and variant calling methods are outlined in the relevant chapters, however, in all 
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chapters, identified variants were output into variant call format (VCF) files. Methods for the 
manipulation of these files was consistent across the chapters and are outlined below. 
2.2.1 Adding confidence tags to genotypes in VCF files 
Confidence tags based on read depth and genotype quality were added to all genotypes within a VCF 
using the VariantFiltration tool from GATK125 in R.126 Variants with a depth of at least 10 and a 
genotype quality score of at least 20 were tagged as ‘high confidence’, those with a depth below 10 and 
a genotype quality score of at least 20 were tagged as ‘low coverage’, variants with a depth of at least 
10 and a genotype quality score below 20 were tagged as ‘low quality’, and those with a depth below 
10 and a quality score below 20 were tagged with ‘low confidence’. The script was developed by Dr. 
Nicholas Blackburn (Menzies Institute for Medical Research, University of Tasmania, TAS, Australia; 
and South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio Grande 
Valley, Brownsville, Texas, USA). An example is outlined in Appendix 1. 
2.2.2 Converting variants with low coverage/quality/confidence genotype calls to 
missing calls in VCF files 
Variants with low coverage, low genotype quality or low confidence tags (as outlined in Section 2.2.1) 
were converted to missing genotype calls using a custom R script. This script was developed in 
combination with Dr. Nicholas Blackburn and Dr. Bennet McComish (Menzies Institute for Medical 
Research, University of Tasmania, TAS, Australia) and an example is presented in Appendix 2. 
2.2.3 Annotating VCF files with ANNOVAR 
ANNOVAR127 (2017Jun01 version) was used throughout this dissertation to annotate variant call 
format (VCF) files with variant identification codes (IDs) from the dbSNP128 147 variant database, gene 
annotations from the RefGene128 database, minor allele frequencies (MAF), as well as, 
deleteriousness/pathogenicity predictions from in silico tools. The Exome Aggregation Consortium 
database129 (ExAC), the Genome Aggregation database129 (gnomAD), Kaviar Genomic Variant 
Database130 (Kaviar) and the 1000 Genomes Project131 (1KGP) were used for MAF annotations. The 
gnomAD database is the largest database with more than 130,000 individuals across seven defined 
ethnic populations (additional individuals are groups together in the population group ‘Other’) and 
includes data from the 1KGP and ExAC, therefore, the MAF observed in these data was of primary 
interest during analyses. Deleteriousness/pathogenicity predictions tools for SNPs included Sorting 
Tolerant from Intolerant132 (SIFT); the HumDIV algorithm from Polymorphism Phenotyping133 
(PolyPhen2); Combined Annotation Dependent Depletion134 (CADD, version 1.3); and Functional 
Analysis through Hidden Markov Models135  (FATHMM) using the FATHMM-MKL136 algorithm. 
Annotation with ANNOVAR was implemented using a custom script outlined in Appendix 3. 
Pathogenicity and deleteriousness predictions for small insertions or deletions (indels) were manually 
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annotated with using CADD134 and the FATHMM-indel137 algorithm using these tools’ online batch 
submission option. 
2.2.4 Interrogating highly prioritised variants using the University of California 
Santa Cruz (UCSC) Genome Brower 
To rank and further interrogate highly prioritised variants, the specific genomic positions were manually 
assessed on the University of California Santa Cruz (UCSC) Genome Brower (available at 
https://genome.ucsc.edu) to obtain evidence of functionality using the data from various tracks. The 
specific data and tracks included: DNaseI Hypersensitivity Clusters in 125 cell types from the ENCODE 
project138 (V3), chromatin state segmentation by Hidden Markov Model (HMM) in nine human cell 
types from ENCODE/Broad,138 and expression quantitative trait loci (eQTL) data from 44 tissues from 
Genotype-Tissue Expression (GTEx) Project139, 140 (midpoint release, V6). 
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CHAPTER 3: SCREENING KERATOCONUS-CANIDATE GENES FOR RARE, 
PROTEIN-CODING POTENTIALLY PATHOGENIC VARIANTS IN A LARGE 
CASE-CONTROL COHORT 
 
Publications arising from this chapter: 
Lucas SEM, Zhou T, Blackburn NB, Mills RA, Ellis J, Leo P, Souzeau E, Ridge B, Charlesworth JC, 
Brown MA, Lindsay R, Craig JE, Burdon KP. Rare, potentially pathogenic variants in 21 
keratoconus candidate genes are not enriched in cases in a large Australian cohort of European 
descent, PLoS One, 2018;13(6):e0199178. 
Lucas SEM, Zhou T, Blackburn NB, Mills RA, Ellis J, Leo P, Souzeau E, Ridge B, Charlesworth JC, 
Brown MA, Lindsay R, Craig JE, Burdon KP. Rare, potentially pathogenic variants in ZNF469 are 
not enriched in keratoconus in a large Australian cohort of European descent, Investigative 
Ophthalmology and Visual Science 2017;58(14):6248-56. 
 
  INTRODUCTION 
To date, several approaches have been used to elucidate genetic variants that underpin keratoconus 
susceptibility and from this many candidate genes have been proposed to play a role in this disease. 
Linkage analysis in extended families has identified more than 20 linkage regions for keratoocus,28, 29, 
64-66, 69, 71, 72, 74-80, 141, 142 however, only regions on chromosome 5q have been replicated.73-75, 141, 142 The 
number of loci identified highlights the heterogeneous nature of the disease. Such family-based studies 
have implicated few candidate variants and genes to date, due to the size of the regions. The most 
promising keratoconus gene identified with this method is mir184. This non-coding microRNA gene 
was found to have a pathogenic variant within the DNA binding domain in a family from Northern 
Ireland.65, 77, 143 The same variant was subsequently identified in an unrelated family from Spain69 and 
similar variants predicted to reduce the stability of the miRNA secondary structures were identified in 
two sporadic cases.70 It is however important to note that these individuals had both keratoconus and 
congenital cataract and therefore may have a phenotype with a different genetic aetiology to isolated 
keratoconus. Variants in other genes, such as IL1RN and SLC4A11, have been hypothesised to play a 
role in disease due to the linkage-based identification of potentially pathogenic variants in an 
Ecuadorian family.66 IL1RN which encodes IL1 receptor antagonist and SLC4A11 which encodes solute 
carrier family 4 member 11 were selected as candidate genes due to their involvement in the immune 
response and apoptosis, respectively. However, these genes have not been assessed in other cohorts of 
keratoconus patients. 
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Genome-wide association studies (GWAS) have led to the identification of four genome-wide 
significant loci as well as several loci that show a suggestive association with keratoconus. A large 
GWAS that assessed loci associated with central corneal thickness (CCT) in keratoconus patients 
identified two single nucleotide polymorphisms (SNPs) associated with keratoconus in intronic regions 
of FOXO1 (rs2721051) and FND3CB (rs4894535).87 The same study found a suggestive association at 
rs1324183, between MPDZ and NFIB, which reached genome-wide significance following replication 
and meta-analysis.87, 88 Similarly, rs4954218, upstream of RAB3GAP1, showed a suggestive association 
in the initial study, but reached significance after replication and meta-analysis.85, 86 Other suggestive 
associations include SNPs in the promoter of HGF,84, 144 rs1536482 between RXRA and COL5A1,87 
rs9938149 between BANP and ZNF469,87 and two intronic SNPs (rs757219  and rs214884) in 
IMMP2L.85 The identification of these loci has provided important insights into keratoconus genetics, 
however, functional variation at these loci have not yet been determined. While the most significant 
SNPs are located in non-coding regions, many of the nearby genes make good biological candidates for 
keratoconus. Thus, we hypothesise that rare protein-coding variation in these genes may be involved in 
keratoconus susceptibility. 
The BANP-ZNF469 locus has been highly controversial. The SNP, rs9938149, reached genome-wide 
significance with CCT and a suggestive association with keratoconus, however the genotype associated 
with a thinner cornea was associated with decreased keratoconus risk.87 This finding was replicated in 
an independent cohort showing the same direction of association,88 indicating that the association is 
likely to be real, if non-intuitive. As ZNF469 is the closest gene to this SNP it has been hypothesised 
that genetic variation within the gene may account for the association at rs9938149 as well as contribute 
to CCT and keratoconus susceptibility. The potential role of ZNF469 in keratoconus pathogenesis is 
further supported by the role of this gene in Brittle Cornea Syndrome type 1 (OMIM 229200). Brittle 
Cornea Syndrome type 1 is a rare, autosomal recessive connective tissue disorder, caused by biallelic 
loss-of-function variants in ZNF469. A key feature of this syndrome is extremely thin corneas that are 
prone to spontaneous rupture, suggesting that ZNF469 is important for the structural integrity of the 
cornea. As an appealing candidate for keratoconus, coding variants in ZNF469 have since been 
investigated. The findings of these studies are conflicting, with two of these studies reporting an 
association of potentially pathogenic variants in ZNF469 with keratoconus,145, 146 while two showed no 
association with disease.147, 148  
Many genes have also been hypothesised to play a role in keratoconus based on their function and 
known corneal expression. The genes selected in the present study can broadly be categorised as 
regulatory genes, such as CAST113 and VSX1;89 structural genes, including the collagen genes COL4A3 
and COL4A4;114 and genes involved in immune responses, such as SOD1,103 TF115 and RAD51,116 IL1A97 
and IL1B.117 The initial studies that implicated CAST, COL4A3, COL4A1, TF, RAD51, IL1A and IL1B 
in keratoconus showed associations at nearby or intronic SNPs. Therefore, the supporting evidence of 
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the involvement of these genes in disease has both a biological-, and positional-, basis. In contrast, the 
genes VSX1 and SOD1, were initially proposed to play a role in keratoconus due to the identification of 
sequence variants in keratoconus patients that were absent in controls. As the first gene postulated to 
contribute to keratoconus, VSX1 has been extensively assessed in many populations with conflicting 
results. Many studies conclude that VSX1 is likely to be involved in keratoconus pathogenesis,89-98, 149-
152 while a similar number of studies do not find evidence of association.99-102, 105, 153-161 Similarly, the 
superoxide dismutase gene (SOD1) has been screened in several populations including Slovenian,102 
Iranian,95, 161 Italian,96 Greek,105 Saudi Arabian106 and multiethnic103 cohorts. A 7 bp intronic deletion 
was observed in cases but not controls in two of these reports96, 103 and was significantly more frequent 
in cases compared to controls in another,105 however, the remaining studies did not observe the 
variant.95, 102, 106, 161 Given the contention surrounding the involvement of VSX1 and SOD1, and the few 
studies that assessed the remaining functional candidates, further analysis is required to determine if 
they contribute to keratoconus susceptibility and pathogenicity. 
Through these different methodologies and approaches, many candidate genes have been hypothesised 
to play a role in keratoconus based on their function, their proximity to associated SNPs or due to the 
identification of putatively causative variants within the gene. However, the majority of these genes 
have not been assessed beyond the initial study, and for those that have, the majority of studies have 
been small, with fewer than 100 keratoconus cases. To address this, our study assessed the role of 22 
candidate genes in the largest cohort of keratoconus cases to date (n = 385), compared to 396 population 
controls. Specifically, our study examines the frequency of potentially pathogenic variants in MPDZ, 
RXRA, RAB3GAP1, FOXO1, BANP, ZNF469, HGF, COL5A1, IMMP2L, FNDC3B, NFIB, ILRN, 
SLC4A11, CAST, COL4A3, COL4A4, TF, SOD1, VSX1, RAD51, IL1A and IL1B in a cohort of 
Australians of European descent.  
 
 HYPOTHESIS AND AIM 
The hypothesis that formed the foundation of this study was that rare, highly penetrant protein-coding 
variants contribute to keratoconus development. More specifically, it was hypothesised that candidate 
genes for keratoconus are enriched in rare protein-coding variants, predicted to be pathogenic (or 
similar) by in silico tools, in cases compared to controls. This led to the following aim: 
To determine if potentially pathogenic variants are enriched in known candidate genes in keratoconus 
patients, compared to controls. 
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 METHODS 
3.3.1 Study participants 
The case cohort consisted of 385 keratoconus patients of European descent (detailed in Section 2.1.1). 
The control cohort consisted of 396 ethnically matched females from the Anglo-Australasian 
Osteoporosis Genetics Consortium (AOGC; described in Section 2.1.2). These control individuals were 
not assessed for eye disease, and therefore are expected to have the population frequency of 
keratoconus. For this reason, this cohort is described as ‘population controls’.  
Due to coverage issues across ZNF469 in the population control cohort, a second control cohort of 230 
Australians of European descent was used for the analysis of this candidate gene. These individuals 
were screened for keratoconus and were found to be unaffected but were affected by other eye diseases 
(largely glaucoma). A full description of this cohort is provided in Section 2.1.3. Throughout this 
chapter, this cohort is referred to as the ‘screened controls’. 
3.3.2 Whole exome sequencing data 
Whole exome sequencing (WES) data were available for 99 keratoconus cases. WES was conducted by 
Macrogen Inc. using the SureSelect Human All Exon V4 enrichment kits (Agilent Technologies Inc., 
Santa Clara, California, USA) with paired-end sequencing on an Illumina HiSeq 2000 (Illumina, San 
Diego, California, USA). The Churchill pipeline162 was used to align raw reads to hg19 using BWA-
MEM163 (version 0.7.12) and variants were joint-called with SAMtools164 (version 1.3.1) and BCFtools 
(version 1.3.1; (https://github.com/samtools/BCFtools). The 230 individuals in the screened control 
cohort (ANZRAG) were sequenced and analysed in parallel with the keratoconus cases, however, these 
data were only used for analysis of ZNF469. 
WES was generated for the population control cohort (AOGC) using Illumina’s TruSeq Exome 
Enrichment on an Illumina HiSeq 2000 at the University of Queensland Centre for Clinical Genomics. 
Raw reads were aligned to the human reference genome (hg19) using novoalign (version 2.08; 
http://www.novocraft.com/products/novoalign/) and variant calling and quality score calibration was 
conducted using GATK125 (version 3.2-2), according to GATK’s ‘Best Practices Guidelines’.165, 166 
These data were provided by Professor Matthew Brown (Queensland University of Technology and 
Translational Research Institute, Princess Alexandra Hospital, QLD, Australia). 
3.3.3 Targeted gene screen in additional cases 
The protein-coding regions of 22 genes of interest were sequenced using a targeted sequencing approach 
in a total of 341 cases across 44 DNA pools using the HaloPlex Target Enrichment System (Agilent 
Technologies). The selected genes are presented in Table 3.1. A custom probe panel was designed using 
Agilent Technologies’ SureDesign Custom Design Tool. DNA samples were quantitated using double 
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stranded DNA (dsDNA) quantitation assays on either a Qubit Fluorometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) using a Qubit dsDNA High Sensitivity Assay Kit or on a Fluoroskan 
plate reader (Thermo Fisher Scientific) with a Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, 
Carlsbad, California, USA). DNA pools containing equimolar DNA samples from eight keratoconus 
patients were prepared as published previously.84 Using Agilent’s HaploPlex Target Enrichment System 
Protocol for Illumina Sequencing (version D.5, May 2013), each DNA pool was indexed with a unique 
indexing primer cassette, allowing for multiplexed sequencing. Enriched libraries were validated and 
quantified using Agilent’s Bioanalyzer High Sensitivity DNA Assay Kit on a 2100 Bioanalyzer (Agilent 
Technologies Inc.). Sequencing was conducted in batches of 11 DNA pools on the MiSeq platform 
(Illumina) using a MiSeq V2 Reagent kit (300 cycles) with paired-end reads. SureCall (Agilent 
Technologies Inc.) was used for sequencing analysis using standard trimmer parameters, the BWA-
MEM algorithm to align reads and the SNPPET SNP Caller (part of SureCall) to call variants. Variants 
were called if a minimum read depth of 10 and quality score of 20 was reached. As variants were called 
from pooled DNA samples it was expected that if a single alternate allele was present it would be 
observed on 6.25% of the reads mapping to that position. To account for this, the minimum allele 
frequency for heterozygous variants was set to 0.035 and the threshold for calling insertions and deletion 
variants (indels) was ≥ 0.04. It is important to note that 55 cases included in this pooled gene screen 
were included in the whole exome sequencing; providing additional cross-validation between the two 
sequencing strategies, however, variants from these samples were only counted in the analyses once.  
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Table 3.1 – Genes included in the targeted gene screen. 
Gene Transcript 
COL4A3 NM_000091 
COL4A4 NM_000092 
IL1A NM_000575 
IL1B NM_000576 
IL1RN NM_173841 
RAB3GAP1 NM_012233 
TF NM_001063 
FNDC3B NM_022763 
CAST NM_00104244
2 HGF NM_000601 
IMMP2L NM_032549 
COL5A1 NM_000093 
NFIB NM_005596 
MPDZ NM_003829 
RXRA NM_00129192
1 FOXO1 NM_002015 
RAD51 NM_002875 
BANP NM_017869 
ZNF469  NM_00112746
4 SLC4A11 NM_032034 
VSX1 NM_014588 
SOD1 NM_000454 
 
3.3.4 Included genomic regions and variant annotation 
To ensure a sound comparison when comparing the frequency of variants between data with different 
capture methods, only target regions that were common to all three capture methods (exome captures 
for the cases and population controls, as well as, the targeted sequencing) with a mean read depth 10 
were included in the analysis. For the WES data, all included individuals had high confidence genotypes 
for ≥ 90% of the included regions. Due to limited coverage of ZNF469 in the population control cohort 
and the recent interest in this gene in keratoconus susceptibility, ZNF469 was investigated separately 
as outlined in Section 3.3.10. 
Variants identified within the included regions were annotated with ANNOVAR127 as described in 
detail in Section 2.2.3. Notably,  the variants were annotated with the minor allele frequency (MAF) 
observed in the non-Finnish European population of the Exome Aggregation Consortium database129 
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(ExAC NFE) and pathogenicity/deleteriousness predictions from Sorting Tolerant from Intolerant132 
(SIFT), the HumDIV algorithm from Polymorphism Phenotyping133 v2 (PolyPhen2) and Combined 
Annotation–Dependent Depletion134 (CADD; version 1.3).  
3.3.5 Filtering strategy to identify potentially pathogenic variants 
Variants were only included in analyses if a sequencing depth of 10 and a quality score of 20 was 
obtained. Variants meeting these thresholds were then filtered to include single nucleotide 
polymorphsism (SNPs) that were predicted to be pathogenic by SIFT or PolyPhen2 with a MAF <0.01. 
In addition, SNPs with a scaled CADD score 15 that met the MAF threshold were included in this 
filtering strategy. These variants were considered ‘potentially pathogenic variants’ and were included 
in our statistical analysis. Insertions and deletions were not included. 
3.3.6 Determining thresholds for variant inclusion from the pooled gene screen 
Extensive assessment of variants in the pooled gene screen dataset was conducted to determine 
thresholds to classify variants called as real or artefact, as well as to determine the likely number of 
alternate alleles present in the DNA pool. The information in the VCF file, including the frequency of 
a variant call across DNA pools, along with manual inspection of the reads mapping to a variant in the 
SureCall Triage View, were used to predict whether unassessed variants were likely to be real or 
sequencing artefacts. Suspected artefacts and real variants were selected for validation by direct 
sequencing in all individuals included in the DNA pool (described in Section 3.3.7), to identify 
thresholds for the inclusion of variants.  
3.3.7 Variant validation by direct sequencing 
To validate variants identified in the case cohort, primers were designed using Primer3Plus167 or 
PrimerBlast.168 DNA was amplified with MyTaq HS Mix (Bioline, London, UK) and purified using 
either Agencourt AMPure XP (Beckman Coulter, Brea, CA, USA) according to the manufacturer’s 
instructions, or equivalent magnetic beads prepared in-house. Purified amplicons were sequenced using 
the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on an 
ABI 310 or ABI 3500 (Applied Biosystems). DNA sequences were aligned to the human reference 
genome (hg19), and chromatograms were manually inspected at the position of each variant using 
Sequencher 4.10.1 (http://www.genecodes.com/; Gene Codes Corporation, Ann Arbor, MI, USA) to 
assess validation.  
3.3.8 Comparing variant calls between WES and the pooled gene screen data 
Fifty-five individuals were included in both the WES and pooled gene screen datasets. Potentially 
pathogenic variants called in these individuals were compared between these two methods to assess the 
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consistency of variants calls and the utility of the pooled targeted gene screen. Variants were only 
included in the statistical analysis once. 
3.3.9 Statistical analysis 
Following variant filtering, genes with at least one alternate allele identified in the case cohort were 
included in the statistical analysis. For each of these genes separately, the number of potentially 
pathogenic variants were compared between cases and controls using a Yates corrected chi squared test 
or a Fishers’ exact test, where appropriate. Odds ratios and 95% confidence intervals were also 
calculated. As 21 genes (not including ZNF469, see Section 3.3.10) were assessed in the present study, 
a significance threshold of p < 0.0024 (0.05/21) was determined using the Bonferroni correction for 
multiple testing. 
3.3.10 Additional investigations of rare protein-coding variants in ZNF469 
A detailed analysis of potentially pathogenic variants in ZNF469 was conducted separately due to 
limited coverage of the gene in the population controls, as well as, previous studies of the gene providing 
a strong a priori hypothesis for the association of rare protein-coding variants in ZNF469 with 
keratoconus. 
3.3.10.1 Genomic regions included in the analysis of ZNF469 
For the analysis for ZNF469, potentially pathogenic variants were compared between cases and two 
control cohorts (the population controls and the screened controls) in separate comparisons. Only 
regions with sufficient coverage across the relevant datasets were included in each comparison to ensure 
high quality sequence data and robust analysis. While it has recently been suggested that ZNF469 is a 
single-exon gene,169 the capture methods in this study were designed under the assumption that ZNF469 
has two exons with a short 84 bp intron. Therefore, only exonic variants defined by transcript 
NM_001127464 were included in the analysis. In contrast with the other 21 genes, this analysis did not 
exclude indels from the statistical analysis. Annotation of variants identified in ZNF469 was performed 
as described in Section 2.2.3.  
3.3.10.2 Variant filtering strategies for ZNF469 
Two filtering strategies were used to define rare and very rare potentially pathogenic variants to make 
the results comparable to previous studies. Filtering Strategy 1 included nonsynonymous variants with 
a MAF < 0.01 (rare) with a damaging or probably/possibly damaging prediction by SIFT and/or 
PolyPhen2. As SIFT and PolyPhen2 do not assess indels, all exonic indels with a MAF < 1% were 
included in Filtering Strategy 1. Filtering Strategy 2 was identical to the first filtering strategy, except 
variants were required to have a MAF < 0.001 (very rare). These filtering strategies were designed to 
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allow direct comparison with previous studies and therefore did not include CADD predictions of 
deleteriousness like the other 21 genes included in this study. 
3.3.10.3 Statistical analyses for ZNF469 
For both filtering strategies, the number of alternate alleles was compared between cases and the two 
control datasets separately using chi squared or Fisher’s exact tests, where appropriate. The odds ratio 
(OR) and 95% confidence interval (95% CI) were calculated. In addition, the Sequence Kernel 
Association Test (SKAT)170 was used to assess if potentially pathogenic variants were enriched in the 
case WES data compared to the two control cohorts. For this analysis, all nonsynonymous variants 
predicated to be potentially pathogenic, regardless of MAF, were included. Using the two control 
cohorts as a separate comparison, SKATBinary was run using the quantile adjusted moment matching 
(QA) method and the default weight parameter, Beta (1, 25). This weighting applies strong weights to 
rare variants, non-zero weighting to uncommon variants (MAF 0.01 – 0.05) and almost zero weights to 
common variants.170  
3.3.10.4 Genetic power calculations for ZNF469 
Power calculations were conducted using the ‘case-control for discrete traits’ module of the genetic 
power calculator.171 These calculations assumed an additive model where the prevalence of keratoconus 
was 0.00067 (1 in 1500) and D’ prime was equal to 1. The high-risk allele frequency was set for each 
filtering strategy separately, using the frequency of variants identified in the screened controls.  
3.3.10.5 Data visualisation for ZNF469 
Coverage across ZNF469 was plotted for the WES datasets based on the mean depth at variant positions 
using the R126 package ggplot2.172 To demonstrate the differences in coverage across the entire gene, 
this plot was aligned to a schematic of ZNF469 outlining the position of the exons and zinc finger motifs 
(based on the positions obtained from UniProt;173 entry Q96JG9) using the R package cowplot.174 
Variants included in Filtering Strategy 1 were plotted as a bar plot for each group using custom R scripts 
and the ggplot2 package. Each variant was plotted along the x-axis according to its genomic position 
and the frequency of the variant in the study group was indicated by the height of the bar. Indels were 
plotted according to the position of the first affected base. To indicate the conservation of each variant 
position, the bars were coloured using a colour gradient corresponding to the 100-way vertebrate 
PhastCons175, 176 score as available from the University of Santa Cruz (UCSC) Genome Browser.177 
Similarly to the coverage plot described above, the plots for each group were aligned to a schematic of 
ZNF469 using the R package cowplot, to allow for comparison of the variants across the gene.  
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 RESULTS 
3.4.1 Determining thresholds for variant inclusion from the pooled gene screen 
A total of 46 variants called in the pooled gene screen, including 27 variants in ZNF469, were assessed 
for validation to identify thresholds for the inclusion of variants or the number of alternate alleles 
present in the DNA pool. Evidence that a variant was an artefact included: the variant was present in 
three or more pools, despite having a MAF < 0.001 or no dbSNP ID; the variant was observed on an 
unexpectedly high frequency of the reads in a single pool (ie. > 40%); the variant was only present in a 
single population of amplicons; the variant was called in a region with low coverage (ie < 20 reads); 
the variant was present on reads with multiple spurious variants; or the variant had previously been 
sequenced by direct sequencing in another DNA pool and was identified as an artefact. If, after collating 
the evidence, it was still not clear if the variant was likely to be real or not, the variant was validated by 
direct sequencing. Based on the selected validation experiment, variants deemed to be real with a DNA 
pool frequency of 3.7% – 10.6% were predicted to have a single alternate allele, whereas two alternate 
alleles were predicted for variants with a frequency between 10.7% and 15.5%. 
3.4.2 Comparing variant calls between WES and the pooled gene screen data 
Across all 22 genes of interest, 34 variants were identified 35 times in the WES data, including two 
small deletions and 12 SNPs identified in ZNF469. Thirty of these variants were also were identified in 
the pooled gene screen data, with four SNPs and one small deletion (in ZNF469) not meeting the 
minimum alternate allele threshold of 3.5% of reads. This alternate allele threshold of 3.5% was, 
however, carefully selected to minimise the inclusion of spurious variant calls. In contrast, a ZNF469 
variant was identified in an individual that was included in both sequencing strategies through the 
targeted gene screen that was not called in the WES dataset. Upon manual investigation of the WES 
data, the variant was in fact called, but had a depth of only five reads and was thus not included in the 
filtered data. This variant was therefore included in the chi squared test which included the pooled gene 
screen data but was excluded in the SKAT analysis which only used the WES data. 
3.4.3 Rare potentially pathogenic variants in 21 candidate genes 
Demographic details for keratoconus cases and controls are provided in Table 3.2. 
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Table 3.2 – Demographics of keratoconus cases and controls at the time of 
examination. 
Cohort n Mean age* (range) % Female Disease status 
Cases 385 45.2 (14-85) 44.2 affected 
Controls 396 69.7 (46-86) 100 unscreened 
n = the number of individuals 
* Age is reported in years 
 
Coverage statistics for each of the 21 genes included in the analysis are summarised for the protein-
coding portions of the longest transcript that best fit the capture designs in Table 3.3. A full list of the 
included regions for these gene are presented in the supporting information of the published article 
(available at: https://doi.org/10.1371/journal.pone.0199178.s001). Due to a high GC content, the 
coverage of BANP was poor, particularly in the control data and the targeted sequencing dataset. When 
considering regions captured by probes across the three datasets, only 58% of the gene was captured, 
however, 70% of these regions had sufficient coverage for analysis. Similarly, 77.4% of VSX1 was 
captured across all datasets due to insufficient capture of GC-rich regions and 60.6% of these captured 
regions met the coverage threshold for inclusion in the analysis. Despite this poor coverage, a number 
of previously reported VSX1 variants in keratoconus were sufficiently covered for analysis. The 
captured regions of the remaining genes ranged from 75.3 – 97.5% and, apart from FOXO1, 99% - 
100% of the coding bases in captured regions were included in analysis. For FOXO1, the included 
portion of the captured region dropped to 82.5% as part of the first exon did not meet the minimum 
depth threshold for variant calling in the WES datasets. It is important to note that additional regions, 
including non-protein-coding regions, may also have been included in analysis. 
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Table 3.3 – Coverage statistics for each gene of interest.  
Gene 
Coding 
bases 
Captured coding 
bases (%) 
Analysed coding bases 
(%) 
COL4A3 5,013 4,136 (82.5) 4,096 (99.0) 
COL4A4 5,073 4,200 (82.8) 4,184 (99.6) 
IL1A 816 762 (93.4) 762 (100) 
IL1B 810 629 (77.7) 629 (100) 
IL1RN 543 499 (91.9) 499 (100) 
RAB3GAP1 2,946 2,797 (94.9) 2,797 (100) 
TF 2,233 1,683 (75.3) 1,681 (99.9) 
FNDC3B 3,615 3,015 (83.4) 3,015 (100) 
CAST 2,310 1,978 (85.6) 1,968 (99.5) 
HGF 2,187 2,116 (96.8) 2,116 (100) 
IMMP2L 528 501 (94.9) 501 (100) 
COL5A1 5,517 4,550 (82.5) 4,548 (100) 
NFIB 1,263 1,068 (84.6) 1,068 (100) 
MPDZ 6,126 5,534 (90.3) 5,477 (99.0) 
RXRA 1,098 940 (85.6) 940 (100) 
FOXO1 1,968 1,893 (96.2) 1,561 (82.5) 
RAD51 1,020 928 (91.0) 928 (100) 
BANP 1,410 818 (58.0) 573 (70.0) 
SLC4A11 2,676 2,610 (97.5) 2,610 (100) 
VSX1 1,098 850 (77.4) 515 (60.6) 
SOD1 465 404 (86.9) 404 (100) 
Coding bases = the total number of bases in the protein-coding portion of the transcript. 
Captured coding bases = the total number of the protein-coding bases included in the captured 
regions (and percentage of the total number of protein-coding bases in the transcript). 
Analysed coding bases = the total number of protein-coding bases included in the analysis (and the 
percentage this represents of the captured protein-coding bases). 
 
Following variant filtering, 164 potentially pathogenic variants were identified across both cases and 
controls (Table 3.4). This included 138 nonsynonymous variants, 21 synonymous variants, three 
nonsense variants, one intronic variant and one variant in a 3’ untranslated region. Of these variants, 70 
were unique to the cases, 69 were only observed in the population controls and 25 were identified in 
both groups. For the cases, a total of 146 potentially pathogenic variants were observed, while 192 were 
identified in population controls. Two variants, p.(R85Q) in IL1A and p.(P1379S) in COL5A1, were 
each observed in the homozygous state in a single control. All other variants were observed as 
heterozygotes.   
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No potentially pathogenic variants were identified in IL1RN in either cases or controls. Additionally, 
potentially pathogenic variants were not observed in the case cohort in BANP, IL1B, RAD51 or SOD1. 
However, in the control group, one potentially pathogenic variant was observed in both IL1B and SOD1, 
two variants were identified in BANP, and three were observed in RAD51. For the remaining genes, the 
total number of potentially pathogenic variants identified across both groups ranged from three in RXRA 
up to 102 in MPDZ. Of the genes included in the chi-square or Fishers’ exact tests, COL4A3 and MPDZ 
showed a nominally higher frequency of potentially pathogenic variants in controls compared to the 
case cohort, with both genes obtaining a p <0.05 in the burden analysis, however, neither gene remained 
significant under correction for multiple testing. All other genes showed no difference between groups.  
Statistics for each gene included in the analysis are summarised in Table 3.5. 
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Table 3.4 – Potentially pathogenic variants identified across the 21 genes of interest.  
        Alternate allele frequencies 
Gene Position 
Nucleotide 
Variant 
Protein 
Variant 
Variant ID SIFT PolyPhen2 CADD 
ExAC 
NFE 
Controls 
(AC) 
Cases 
(AC) 
IL1A chr2:113539246 c.254G>A p.(R85Q) rs3783531 D (0.045) D (1.000) 25.00 0.0024 0.0152 (6) 0.0052 (2) 
IL1A chr2:113540315 c.74T>C p.(I25T) rs139798825 D (0.004) P (0.500) 20.60 0.0008 0.0051 (2) 0.0026 (1) 
IL1B chr2:113588006 c.742G>A p.(V248I) rs781114719 D (0.026) D (0.991) 28.10 <0.0001 0.0025 (1) 0.0000 (0) 
RAB3GAP1 chr2:135878409 c.669G>T p.(L223F) rs76927619 D (0.013) D (0.993) 23.30 <0.0001 0.0000 (0) 0.0026 (1) 
RAB3GAP1 chr2:135883787 c.867C>T p.(T289=) NA NA NA 16.20 0.0000 0.0000 (0) 0.0026 (1) 
RAB3GAP1 chr2:135887597 c.1006C>T p.(R336C) rs150478342 T (0.148) B (0.014) 24.30 0.0067 0.0101 (4) 0.0052 (2) 
RAB3GAP1 chr2:135911271 c.2114G>A p.(R705Q) rs367558491 D (0.006) D (1.000) 34.00 <0.0001 0.0000 (0) 0.0026 (1) 
RAB3GAP1 chr2:135926239 c.2834T>G p.(V945G) NA D (0.017) D (0.998) 27.20 0.0000 0.0025 (1) 0.0000 (0) 
COL4A4 chr2:227872132 c.4982T>A p.(F1661Y) rs374119389 D (0.008) P (0.830) 23.30 0.0003 0.0025 (1) 0.0000 (0) 
COL4A4 chr2:227872153 c.4961C>T p.(T1654M) rs771066050 D (0.000) D (1.000) 23.20 <0.0001 0.0025 (1) 0.0000 (0) 
COL4A4 chr2:227872783 c.4760C>G p.(P1587R) rs190148408 T (0.902) P (0.913) 0.90 0.0027 0.0025 (1) 0.0052 (2) 
COL4A4 chr2:227872812 c.4731G>A p.(A1577=) rs200639109 NA NA 17.00 0.002 0.0000 (0) 0.0026 (1) 
COL4A4 chr2:227872894 c.4649C>G p.(P1550R) NA D (0.000) D (0.998) 22.60 0.0000 0.0025 (1) 0.0000 (0) 
COL4A4 chr2:227875029 c.4522G>A p.(G1508S) NA D (0.000) D (1.000) 23.70 0.0000 0.0025 (1) 0.0000 (0) 
COL4A4 chr2:227875065 c.4486C>A p.(L1496M) NA T (0.069) P (0.760) 12.30 0.0000 0.0000 (0) 0.0026 (1) 
COL4A4 chr2:227896939 c.3631G>A p.(E1211K) rs750501128 D (0.03) B (0.006) 23.30 <0.0001 0.0000 (0) 0.0026 (1) 
COL4A4 chr2:227912248 c.3232G>A p.(A1078T) rs77277077 T (0.422) D (0.988) 23.60 0.0001 0.0025 (1) 0.0000 (0) 
COL4A4 chr2:227924228 c.2276C>T p.(P759L) rs36121515 D (0.014) P (0.911) 25.40 0.0004 0.0051 (2) 0.0000 (0) 
COL4A4 chr2:227945181 c.1781A>G p.(E594G) rs35998949 T (0.434) B (0.003) 20.60 0.0003 0.0000 (0) 0.0026 (1) 
COL4A4 chr2:227964372 c.1063C>G p.(P355A) rs368293426 T (0.308) D (1.000) 26.20 <0.0001 0.0000 (0) 0.0026 (1) 
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        Alternate allele frequencies 
Gene Position 
Nucleotide 
Variant 
Protein 
Variant 
Variant ID SIFT PolyPhen2 CADD 
ExAC 
NFE 
Controls 
(AC) 
Cases 
(AC) 
COL4A4 chr2:227973309 c.723A>C p.(Q241H) rs201673987 T (0.056) D (0.990) 20.40 <0.0001 0.0025 (1) 0.0000 (0) 
COL4A3 chr2:228110691 c.346C>A p.(P116T) rs115324397 D (0.027) D (1.000) 24.70 0.0082 0.0429 
(17) 
0.0260 
(10) COL4A3 chr2:228110718 c.373T>C p.(C125R) NA T (0.051) D (0.999) 27.80 0.0000 0.0000 (0) 0.0026 (1) 
COL4A3 chr2:228113204 c.514G>A p.(D172N) rs377575924 T (0.098) D (0.996) 34.00 <0.0001 0.0025 (1) 0.0000 (0) 
COL4A3 chr2:228118867 c.805G>A p.(E269K) rs80109666 T (0.921) P (0.827) 0.01 0.0046 0.0000 (0) 0.0052 (2) 
COL4A3 chr2:228124533 c.1054G>T p.(E352*) NA NA NA 36.00 0.0000 0.0025 (1) 0.0000 (0) 
COL4A3 chr2:228131783 c.1483C>T p.(H495Y) rs200510532 D (0.040) D (0.985) 22.30 0.0013 0.0025 (1) 0.0026 (1) 
COL4A3 chr2:228141146 c.1973C>T p.(P658L) rs770397467 D (0.002) D (0.983) 23.50 <0.0001 0.0025 (1) 0.0000 (0) 
COL4A3 chr2:228153949 c.2965C>T p.(P989S) rs774477588 T (0.648) P (0.896) 21.60 <0.0001 0.0025 (1) 0.0000 (0) 
COL4A3 chr2:228163401 c.3755C>T p.(A1252V) rs761179248 T (0.346) B (0.000) 19.80 <0.0001 0.0025 (1) 0.0000 (0) 
COL4A3 chr2:228163475 c.3829G>A p.(G1277S) rs190598500 D (0.000) D (1.000) 23.50 0.0005 0.0000 (0) 0.0026 (1) 
COL4A3 chr2:228172594 c.4421T>C p.(L1474P) rs200302125 D (0.000) D (1.000) 23.40 0.0046 0.0227 (9) 0.0026 (1) 
COL4A3 chr2:228173618 c.4466C>T p.(T1489I) rs200818438 T (0.140) D (0.997) 25.50 <0.0001 0.0025 (1) 0.0000 (0) 
COL4A3 chr2:228175629 c.4893C>T p.(F1631=) rs183218622 NA NA 16.60 0.0053 0.0152 (6) 0.0130 (5) 
TF chr3:133474263 c.559C>G p.(P187A) rs751656601 T (0.100) B (0.101) 23.60 <0.0001 0.0000 (0) 0.0026 (1) 
TF chr3:133475754 c.771C>A p.(Y257*) NA NA NA 26.30 0.0000 0.0000 (0) 0.0026 (1) 
TF chr3:133485143 c.1352T>C p.(V451A) rs142116896 T (0.197) P (0.582) 20.40 0.0001 0.0025 (1) 0.0000 (0) 
TF chr3:133485196 c.1405T>C p.(C469R) NA D (0.000) D (1.000) 25.80 0.0000 0.0000 (0) 0.0026 (1) 
TF chr3:133489405 c.1676A>T p.(Q559L) rs753682414 D (0.000) P (0.793) 23.90 0.0001 0.0000 (0) 0.0026 (1) 
TF chr3:133496032 c.2012G>A p.(G671E) rs121918677 D (0.000) D (1.000) 28.90 0.0037 0.0202 (8) 0.0104 (4) 
FNDC3B chr3:171830293 c.24C>G p.(T8=) rs539042799 NA NA 16.20 0.0000 0.0000 (0) 0.0026 (1) 
FNDC3B chr3:171965444 c.386A>G p.(H129R) NA T (0.822) D (0.989) 22.90 0.0000 0.0000 (0) 0.0026 (1) 
FNDC3B chr3:172046816 c.1329G>A p.(P443=) rs372880783 NA NA 15.20 <0.0001 0.0025 (1) 0.0000 (0) 
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        Alternate allele frequencies 
Gene Position 
Nucleotide 
Variant 
Protein 
Variant 
Variant ID SIFT PolyPhen2 CADD 
ExAC 
NFE 
Controls 
(AC) 
Cases 
(AC) 
FNDC3B chr3:172052819 c.1727C>T p.(T576I) rs757447664 T (0.369) P (0.818) 23.40 <0.0001 0.0000 (0) 0.0026 (1) 
FNDC3B chr3:172070668 c.2590G>A p.(V864I) rs143064249 T (0.098) B (0.063) 18.00 0.0023 0.0025 (1) 0.0026 (1) 
FNDC3B chr3:172096114 c.3063G>A p.(T1021=) rs561549306 NA NA 15.20 <0.0001 0.0000 (0) 0.0026 (1) 
CAST chr5:96031558 c.157G>A p.(G53S) rs199633496 D (0.048) P (0.559) 8.70 0.0002 0.0000 (0) 0.0026 (1) 
CAST chr5:96031567 c.166C>A p.(Q56K) rs780010534 D (0.028) D (0.982) 23.00 0.0000 0.0000 (0) 0.0026 (1) 
CAST chr5:96031601 c.200C>T p.(S67L) rs776197495 T (0.274) P (0.625) 12.30 0.0000 0.0025 (1) 0.0000 (0) 
CAST chr5:96073629 c.710C>T p.(T237M) rs779432064 T (0.107) D (0.994) 13.40 <0.0001 0.0025 (1) 0.0000 (0) 
CAST chr5:96078437 c.1111C>T p.(R371C) rs377565522 D (0.044) P (0.879) 23.50 <0.0001 0.0000 (0) 0.0026 (1) 
CAST chr5:96078456 c.1130A>G p.(D377G) rs144157006 T (0.066) D (0.999) 23.60 0.0009 0.0051 (2) 0.0000 (0) 
CAST chr5:96079350 c.1134+890C>T NA rs780684334 D (0.004) D (0.984) 17.00 <0.0001 0.0025 (1) 0.0000 (0) 
CAST chr5:96082128 c.1217C>T p.(T406M) rs78054235 T (0.201) D (0.986) 12.60 0.0001 0.0025 (1) 0.0000 (0) 
CAST chr5:96089833 c.1528G>C p.(E510Q) rs773300671 D (0.046) D (0.997) 26.70 0.0000 0.0000 (0) 0.0026 (1) 
CAST chr5:96090383 c.1582C>T p.(R528C) rs142879548 T (0.073) D (1.000) 26.10 0.0007 0.0025 (1) 0.0000 (0) 
CAST chr5:96090425 c.1624T>C p.(Y542H) rs140928951 D (0.003) D (1.000) 25.40 <0.0001 0.0000 (0) 0.0026 (1) 
CAST chr5:96100929 c.1871G>A p.(S624N) rs149919102 T (0.982) P (0.741) 7.80 0.0000 0.0000 (0) 0.0026 (1) 
HGF chr7:81335011 c.1816A>G p.(I606V) rs765890500 T (1.000) P (0.814) 10.40 <0.0001 0.0025 (1) 0.0000 (0) 
HGF chr7:81335013 c.1814C>T p.(T605I) rs147075806 T (0.520) B (0.000) 16.50 <0.0001 0.0025 (1) 0.0000 (0) 
HGF chr7:81346592 c.1361C>A p.(T454K) NA D (0.000) D (1.000) 31.00 0.0000 0.0000 (0) 0.0026 (1) 
HGF chr7:81358978 c.983G>A p.(R328H) rs374484762 D (0.030) B (0.296) 28.30 <0.0001 0.0000 (0) 0.0026 (1) 
HGF chr7:81392140 c.137C>T p.(A46V) rs150267054 T (0.229) D (0.998) 24.40 0.003 0.0076 (3) 0.0026 (1) 
HGF chr7:81399282 c.6G>T p.(W2C) rs745851853 D (0.002) D (0.999) 34.00 0.0000 0.0025 (1) 0.0000 (0) 
IMMP2L chr7:111161438 c.66G>A p.(A22=) rs148496605 NA NA 20.20 0.003 0.0076 (3) 0.0000 (0) 
IMMP2L chr7:111161439 c.65C>T p.(A22V) rs202048991 T (0.247) D (0.978) 23.50 0.0003 0.0000 (0) 0.0026 (1) 
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MPDZ chr9:13107088 c.6002G>A p.(R2001H) rs1802495 T (0.129) D (1.000) 34.00 0.0002 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13108980 c.5934C>G p.(S1978R) rs758152471 D (0.034) D (1.000) 28.30 0.0007 0.0076 (3) 0.0000 (0) 
MPDZ chr9:13109969 c.5837T>C p.(I1946T) rs201230061 T (0.508) D (0.984) 26.40 0.0001 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13119542 c.5338G>A p.(V1780I) rs202112833 T (0.251) D (1.000) 31.00 0.0002 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13122091 c.5032T>G p.(L1678V) rs763372118 T (0.06) P (0.746) 25.60 <0.0001 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13126531 c.4616G>A p.(G1539D) rs779148372 D (0.018) D (1.000) 34.00 0.0002 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13126771 c.4465G>A p.(D1489N) NA D (0.017) D (0.999) 27.20 0.0000 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13136096 c.4378A>G p.(K1460E) rs767920289 T (0.313) B (0.174) 17.30 <0.0001 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13136715 c.4288A>G p.(I1430V) rs765489877 T (0.541) B (0.078) 16.30 0.0001 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13136783 c.4220G>A p.(Y1407C) rs200891478 D (0.049) D (1.000) 28.90 0.0091 0.0101 (4) 0.0026 (1) 
MPDZ chr9:13138020 c.4136G>A p.(G1379E) NA T (0.159) D (1.000) 33.00 0.0000 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13139994 c.3995A>G p.(Y1332C) NA T (0.105) D (0.991) 25.30 0.0000 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13140070 c.3919G>A p.(E1307K) rs199509495 T (0.886) D (0.967) 18.30 0.0013 0.0101 (4) 0.0026 (1) 
MPDZ chr9:13143469 c.3836A>G p.(D1279G) rs370624740 T (0.146) B (0.043) 16.70 <0.0001 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13147602 c.3686G>A p.(R1229Q) rs61753783 T (0.106) D (1.000) 35.00 0.0005 0.0051 (2) 0.0000 (0) 
MPDZ chr9:13147629 c.3659G>A p.(S1220N) NA T (0.086) D (0.998) 28.60 0.0000 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13150558 c.3582T>G p.(S1194R) rs188840960 D (0.033) D (1.000) 25.70 0.0079 0.0227 (9) 0.0052 (2) 
MPDZ chr9:13150617 c.3523C>T p.(R1175W) rs367915328 D (0.004) D (1.000) 29.70 <0.0001 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13158017 c.3452G>A p.(R1151Q) rs367828845 T (0.356) D (0.999) 28.90 <0.0001 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13158026 c.3443A>G p.(Q1148R) rs752969006 T (0.238) D (0.982) 23.20 0.0000 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13158062 c.3407G>A p.(S1136N) rs41265286 T (0.144) D (1.000) 30.00 0.0028 0.0051 (2) 0.0000 (0) 
MPDZ chr9:13162786 c.3263A>G p.(Y1088C) rs372125677 D (0.009) P (0.900) 24.30 <0.0001 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13168369 c.3250A>C p.(I1084L) NA T (0.435) B (0.384) 22.20 0.0000 0.0000 (0) 0.0026 (1) 
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MPDZ chr9:13168435 c.3184A>G p.(T1062A) rs763919393 T (0.291) D (0.983) 24.20 <0.0001 0.0000 (0) 0.0026 (1) 
MPDZ chr9:13175852 c.2954A>C p.(Q985P) rs200272559 D (0.026) B (0.371) 12.30 0.0001 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13183529 c.2537C>G p.(S846C) rs200553028 D (0.012) D (1.000) 25.00 0.0011 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13186355 c.2395A>G p.(K799E) rs150038177 T (0.084) P (0.911) 21.50 0.0067 0.0025 (1) 0.0130 (5) 
MPDZ chr9:13188921 c.2226T>A p.(D742E) NA D (0.029) D (1.000) 24.80 0.0000 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13188953 c.2194T>A p.(S732T) rs200475640 T (0.085) D (0.999) 24.60 0.0021 0.0076 (3) 0.0026 (1) 
MPDZ chr9:13190162 c.2105A>T p.(E702V) rs4740548 D (0.004) D (0.994) 28.30 0.009 0.0227 (9) 0.0208 (8) 
MPDZ chr9:13190163 c.2104G>A p.(E702K) rs4741289 D (0.005) D (0.990) 33.00 0.009 0.0227 (9) 0.0208 (8) 
MPDZ chr9:13190165 c.2102T>C p.(I701T) NA T (0.085) B (0.372) 23.80 0.0000 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13219751 c.893G>C p.(S298T) rs201889514 T (1.000) D (1.000) 25.50 0.0005 0.0025 (1) 0.0026 (1) 
MPDZ chr9:13221466 c.781G>C p.(V261L) rs200611423 T (0.071) B (0.270) 23.00 0.0002 0.0025 (1) 0.0000 (0) 
MPDZ chr9:13223592 c.511C>G p.(Q171E) rs181479224 D (0.030) D (0.995) 23.80 0.0029 0.0076 (3) 0.0000 (0) 
MPDZ chr9:13224441 c.325G>T p.(G109C) rs61753782 T (0.132) D (0.990) 5.50 0.0074 0.0000 (0) 0.0052 (2) 
NFIB chr9:14088119T c.*189A>T NA rs548618850 NA NA 18.20 0.0000 0.0025 (1) 0.0000 (0) 
NFIB chr9:14125753 c.938C>T p.(P313L) NA D (0.001) D (1.000) 34.00 0.0000 0.0025 (1) 0.0000 (0) 
NFIB chr9:14150247 c.703A>G p.(T235A) NA D (0.041) B (0.000) 15.10 0.0000 0.0000 (0) 0.0026 (1) 
NFIB chr9:14307342 c.208C>G p.(Q70E) NA D (0.020) P (0.843) 24.30 0.0000 0.0025 (1) 0.0000 (0) 
NFIB chr9:14307354 c.196C>T p.(P66S) rs140030018 D (0.042) P (0.948) 24.90 0.0001 0.0000 (0) 0.0052 (2) 
RXRA chr9:137321000 c.666C>T p.(A222=) rs137871665 NA NA 21.00 0.0021 0.0051 (2) 0.0026 (1) 
COL5A1 chr9:137582793 c.145C>T p.(H49Y) rs372168541 T (0.073) P (0.837) 24.00 <0.0001 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137591755 c.278C>T p.(A93V) rs41306397 D (0.005) B (0.006) 23.60 0.003 0.0025 (1) 0.0026 (1) 
COL5A1 chr9:137591818 c.341C>A p.(A114D) rs147589613 D (0.007) P (0.896) 34.00 0.001 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137591844 c.367C>G p.(Q123E) rs142114921 T (0.088) D (0.985) 24.60 0.0003 0.0025 (1) 0.0000 (0) 
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COL5A1 chr9:137593038 c.513C>T p.(S171=) rs754997436 NA NA 19.80 0.0000 0.0025 (1) 0.0026 (1) 
COL5A1 chr9:137593088 c.563C>G p.(T188S) NA T (0.146) B (0.370) 24.00 0.0000 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137593122 c.597C>G p.(I199M) rs147008954 D (0.002) P (0.916) 15.30 0.0002 0.0025 (1) 0.0000 (0) 
COL5A1 chr9:137593123 c.598G>A p.(D200N) rs142890619 D (0.045) D (1.000) 24.90 0.0006 0.0025 (1) 0.0000 (0) 
COL5A1 chr9:137619170 c.713A>G p.(E238G) NA T (0.051) D (0.998) 27.20 0.0000 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137619196 c.739G>A p.(A247T) rs769115550 T (0.396) P (0.672) 22.40 <0.0001 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137619218 c.761C>T p.(S254L) rs144844792 T (0.116) D (0.981) 25.00 0.0002 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137623967 c.1383C>G p.(I461M) rs61736827 D (0.005) P (0.662) 17.70 0.0000 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137630636 c.1476C>T p.(V492=) rs141093527 NA NA 17.20 <0.0001 0.0025 (1) 0.0000 (0) 
COL5A1 chr9:137648614 c.1831C>T p.(R611W) rs147329970 D (0.000) D (1.000) 35.00 <0.0001 0.0025 (1) 0.0000 (0) 
COL5A1 chr9:137650103 c.1896C>T p.(F632=) rs376478864 NA NA 15.70 <0.0001 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137657580 c.2088C>T p.(P696=) rs146757272 NA NA 16.00 <0.0001 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137658307 c.2096C>T p.(T699M) rs142313124 T (0.071) P (0.820) 23.90 0.0008 0.0076 (3) 0.0026 (1) 
COL5A1 chr9:137666737 c.2364C>A p.(Y788*) rs778834633 NA NA 37.00 0.0003 0.0025 (1) 0.0000 (0) 
COL5A1 chr9:137674521 c.2439C>T p.(D813=) rs148648778 NA NA 18.10 0.0006 0.0051 (2) 0.0000 (0) 
COL5A1 chr9:137676852 c.2502C>T p.(P834=) rs144775947 NA NA 16.40 <0.0001 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137703220 c.3564C>A p.(I1188=) rs766961124 NA NA 23.20 <0.0001 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137703346 c.3591C>T p.(D1197=) rs370349155 NA NA 17.90 0.0004 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137706723 c.3987C>T p.(P1329=) rs770802769 NA NA 18.70 0.0000 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137708884 c.4135C>T p.(P1379S) rs61739195 D (0.006) D (1.000) 25.80 0.0098 0.0152 (6) 0.0208 (8) 
COL5A1 chr9:137710863 c.4410C>T p.(P1470=) rs41310953 NA NA 18.20 0.0021 0.0025 (1) 0.0052 (2) 
COL5A1 chr9:137714878 c.4643C>T p.(S1548L) rs147398633 D (0.044) D (0.996) 24.60 <0.0001 0.0025 (1) 0.0000 (0) 
COL5A1 chr9:137715269 c.4652C>T p.(T1551I) rs863223460 T (0.173) B (0.002) 23.20 0.0000 0.0000 (0) 0.0026 (1) 
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COL5A1 chr9:137715291 c.4674C>T p.(G1558=) NA NA NA 17.90 0.0000 0.0025 (1) 0.0000 (0) 
COL5A1 chr9:137716512 c.4765G>A p.(A1589T) rs377138881 T (0.218) D (0.998) 23.90 <0.0001 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137716653 c.4906G>A p.(A1636T) rs113452150 D (0.023) D (0.995) 27.00 0.0002 0.0000 (0) 0.0026 (1) 
COL5A1 chr9:137726950 c.5270C>T p.(T1757M) rs2229817 D (0.008) D (0.995) 25.60 0.0019 0.0000 (0) 0.0052 (2) 
COL5A1 chr9:137727015 c.5335A>G p.(N1779D) rs780400029 D (0.050) B (0.183) 23.90 0.0000 0.0000 (0) 0.0026 (1) 
FOXO1 chr13:41134313 c.1315A>G p.(I439V) rs146471778 D (0.038) B (0.000) 11.50 <0.0001 0.0000 (0) 0.0026 (1) 
FOXO1 chr13:41134320 c.1308G>C p.(Q436H) rs767235452 D (0.009) D (0.990) 24.20 <0.0001 0.0000 (0) 0.0026 (1) 
FOXO1 chr13:41134423 c.1205C>T p.(T402M) rs148177044 D (0.002) D (1.000) 25.40 <0.0001 0.0025 (1) 0.0000 (0) 
FOXO1 chr13:41134459 c.1169C>T p.(S390L) rs756553520 D (0.015) D (1.000) 26.40 0.0000 0.0000 (0) 0.0026 (1) 
RAD51 chr15:41001295 c.416C>T p.(T139M) rs148345609 D (0.023) D (0.993) 34.00 0.0003 0.0025 (1) 0.0000 (0) 
RAD51 chr15:41021733 c.675C>T p.(T225=) rs147352002 NA NA 19.00 0.0001 0.0025 (1) 0.0000 (0) 
RAD51 chr15:41022106 c.830C>T p.(A277V) rs532630164 T (0.080) P (0.529) 24.60 <0.0001 0.0025 (1) 0.0000 (0) 
BANP chr16:88017786 c.283A>C p.(K95Q) rs776932248 D (0.046) D (1.000) 23.80 <0.0001 0.0025 (1) 0.0000 (0) 
BANP chr16:88017801 c.298A>C p.(I100L) rs547536427 T (0.073) P (0.885) 23.90 0.0003 0.0025 (1) 0.0000 (0) 
SLC4A11 chr20:3209320 c.2274G>A p.(S758=) rs200879869 NA NA 17.20 0.0002 0.0000 (0) 0.0026 (1) 
SLC4A11 chr20; 3209500 c.2224G>A p.(G742R) rs143965185 D (0.001) D (0.999) 34.00 0.0004 0.0000 (0) 0.0026 (1) 
SLC4A11 chr20; 3210069 c.1820T>G p.(I607S) rs748984296 D (0.009) P (0.629) 23.60 0.0002 0.0025 (1) 0.0000 (0) 
SLC4A11 chr20; 3210079 c.1810G>A p.(V604M) rs771123757 T (0.257) P (0.924) 12.00 <0.0001 0.0025 (1) 0.0000 (0) 
SLC4A11 chr20; 3210278 c.1682C>T p.(T561M) rs755379986 T (0.106) P (0.598) 9.30 0.0000 0.0025 (1) 0.0000 (0) 
SLC4A11 chr20; 3211438 c.1270T>C p.(F424L) NA T (0.129) P (0.951) 22.50 0.0000 0.0025 (1) 0.0000 (0) 
SLC4A11 chr20; 3211846 c.1039C>T p.(R347W) rs138137682 T (0.188) B (0.005) 21.60 0.0016 0.0025 (1) 0.0000 (0) 
SLC4A11 chr20; 3214281 c.656G>C p.(C219S) rs746477170 T (0.053) P (0.817) 14.10 <0.0001 0.0000 (0) 0.0026 (1) 
SLC4A11 chr20; 3214738 c.562C>T p.(R188W) rs200372280 T (0.081) P (0.844) 21.80 <0.0001 0.0000 (0) 0.0026 (1) 
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SLC4A11 chr20; 3214750 c.550G>A p.(G184R) NA T (0.267) D (0.998) 23.20 0.0000 0.0025 (1) 0.0000 (0) 
VSX1 chr20:25058389 c.740C>G p.(P247R) rs576300014 D (0.016) D (1.000) 33.00 0.001 0.0025 (1) 0.0000 (0) 
VSX1 chr20:25058419 c.710T>C p.(L237P) rs143704357 D (0.002) D (1.000) 32.00 0.0000 0.0000 (0) 0.0026 (1) 
VSX1 chr20:25058429 c.700G>A p.(E234K) NA D (0.017) D (1.000) 25.80 0.0000 0.0000 (0) 0.0026 (1) 
VSX1 chr20:25060096 c.479G>A p.(G160D) rs74315433 T (0.571) P (0.692) 18.70 0.0033 0.0000 (0) 0.0052 (2) 
SOD1 chr21:33040833 c.407C>T p.(T136I) rs781031581 T (0.099) B (0.124) 17.60 <0.0001 0.0025 (1) 0.0000 (0) 
Variant ID = as available from the dbSNP147 database. 
CADD = the scaled CADD score. 
ExAC NFE = the alternate allele frequency observed in the non-Finnish European population of the Exome Aggregation Consortium (ExAC) database. 
AC = the alternate allele count in the given cohort. 
SIFT and Polyphen2 classifications: D = deleterious/damaging; P = possibly damaging; T = tolerated; B = benign.
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Table 3.5 – Burden test results for genes in which at least one potentially pathogenic 
variant was identified in the case cohort. 
 Case Alleles Control Alleles   
Gene Alt. WT Alt. WT P OR [95% CI] 
CAST 6 764 7 785 > 0.99* 0.88 [0.26-2.92] 
COL4A3 21 749 39 753 0.02* 0.54 [0.31-0.96] 
COL4A4 7 763 9 783 0.85* 0.80 [0.27-2.35] 
COL5A1 32 738 22 770 0.18* 1.52 [0.85-2.73] 
FNDC3B 5 765 2 790 0.28 2.58 [0.45-19.24] 
FOXO1 3 767 1 791 0.37 3.09 [0.29-77.33] 
HGF 3 767 6 786 0.51 0.51 [0.10-2.30] 
IL1A 3 767 8 784 0.23 0.38 [0.08-1.59] 
IMMP2L 1 769 3 789 0.63 0.34 [0.01-3.67] 
MPDZ 40 730 62 730 0.05* 0.65 [0.42-0.99] 
NFIB 3 767 3 789 > 0.99 1.03 [0.17-6.38] 
RAB3GAP1 5 765 5 787 > 0.99 1.03 [0.26-4.10] 
RXRA 1 769 2 790 > 0.99 0.51 [0.02-7.20] 
SLC4A11 4 766 6 786 0.75 0.68 [0.16-2.74] 
TF 8 762 9 783 > 0.99* 0.91 [0.32-2.59] 
VSX1 4 766 1 791 0.21 4.13 [0.44-97.26] 
Alt. = the number of alternate alleles (ie. the number of alleles that carry a potentially pathogenic 
variant). 
WT = the number of wild type (reference) alleles (ie. the number of alleles that do not carry a 
potentially pathogenic variant). 
P = p-value. 
OR [95% CI] = odds ratio and the corresponding 95% confidence interval. 
* P-values obtained using a Yates corrected chi-square test. All other p-values were obtained using a 
Fisher’s exact test. P-values <0.0024 were considered significant. 
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3.4.4 Potentially pathogenic variants in ZNF469 
A total of 385 cases, 346 population controls and 230 screened controls were included in the following 
analysis. Demographic details are provided in Table 3.6. 
Table 3.6 – Demographics of the keratoconus cases and control groups used in the 
analysis of ZNF469. 
Cohort n Mean age* (range) % Female  Disease status 
Cases 
 
385 45.2 (14 – 85) 44.2 Affected 
Population controls^ 346 69.5 (46 – 86) 100 Unscreened 
Screened Controls 230 68.6 (8 – 92) 56.5 Unaffected 
n = the number of individuals. 
* Age is reported in years. 
^ Age was collected at bone densitometry. For other groups, age was recorded at blood draw. 
 
A stringent coverage filter was applied to all sequence datasets and therefore regions containing the 
majority of the first exon of ZNF469, the beginning of the second exon, and the regions encoding the 
zinc finger domains were excluded from analyses that compared the cases to the population control 
cohort (Figure 3.1). Comparisons using the population controls included a total of 6700 bases across 
ZNF469 with high quality sequence data, corresponding to 56.5% of the coding regions. In contrast, a 
total of 11448 bases (96.5% of the coding regions) obtained sufficient coverage across the gene in both 
the cases and screened controls. For comparisons using the screened controls, only two small regions 
(85 bp and 279 bp) either side of the intron were excluded from analysis due to poor coverage (Figure 
3.1). By removing these regions from analysis, the single region that did not meet the minimum depth 
threshold in the pooled targeted gene screen data was also excluded. In 34 of the 44 DNA pools a 70 
bp region (chr16:88496809-88496879) corresponding to the distal end of exon 1 did not reach the 
minimum depth threshold for inclusion. Of the remaining DNA pools, one had a 140 bp region 
containing bases below threshold (chr16:88496809-88496949), three DNA pools had insufficient 
coverage for a 2 bp region (chr16:88496809-88496810), and six DNA pools had sufficient coverage 
across the entirety of exon 1. A summary of the coverage metrics for the pooled targeted gene screen 
dataset is presented in Table 3.7. 
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Table 3.7 – A summary of the coverage metrics for ZNF469 for the pooled targeted gene 
screen dataset as reported by Agilent Technologies, averaged across all DNA pools. 
Covered 
region 
Position (hg19) 
Mean depth 
(range) 
Mean min. 
depth (range) 
Mean max. 
depth (range) 
Mean bases 
with depth 
<10 (range) 
1 
chr16:88493639-
88494052 
1,676 
(713-2,255) 
282 
(113-452) 
5,058 
(2,249-7,176) 
0 
2 
chr16:88494053-
88502070 
2,559 
(1,149-3,623) 
10 
(0-32) 
8090 
(3,791-12,249) 
57 
(0-140) 
3 
chr16:88502074-
88502132 
1082 
(485-1,897) 
1,054 
(472-1,865) 
1,890 
(871-2,822) 
0 
4 
chr16:88502141-
88503852 
2,627 
(1,168-3,749) 
120 
(45-197) 
5,705 
(2,519-8,305) 
0 
5 
chr16:88503862-
88505962 
3,219 
(1,475-4,570) 
132 
(46-227) 
12,993 
(6,381-19,874) 
0 
Min. = minimum 
Max. = maximum 
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Figure 3.1 – Sequencing coverage in the WES datasets across ZNF469. 
(A) Depicts the coverage across ZNF469 in each dataset, based on the mean read depth at variant positions. The horizontal dashed line indicates the minimum 
depth threshold accepted (10 reads). Regions where the mean read depth in the population controls was below this threshold are shaded light grey and were 
excluded from analyses in which these controls were used. Regions with insufficient coverage in all cohorts are shaded dark grey. (B) A schematic of ZNF469 
where dark grey boxes indicate the position of the zinc finger motifs and the small intron is indicated by the horizontal line. 
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Across all cohorts, 49 variants (46 single nucleotide variants and three small deletions) fulfilled the 
criteria for rare potentially pathogenic variants in ZNF469 under Filtering Strategy 1 (Table 3.8). Of 
these, nineteen variants were observed in cases only, while 17 were unique to the control cohorts and 
the remaining 13 were in both cases and controls. Eleven variants had been observed in previous studies 
in either cases or controls, with an additional two variants that are not identical, but occur at the same 
amino acid as a previously reported variant. A total of 33 rare potentially pathogenic variants were 
observed 73 times in cases and 23 variants were called 48 times in the screened controls, which was not 
significantly different (p = 0.66, Table 3.9). When considering the comparison between the cases and 
the population controls, 17 variants were identified 31 times in cases and 10 variants were observed 22 
times in the controls, with no significant difference between groups (p = 0.47, Table 3.9). 
Filtering Strategy 2 identified 33 very rare potentially pathogenic variants in ZNF469 across all cohorts 
(Table 3.7). Sixteen of these variants were unique to keratoconus patients and two, p.(C1693F) and 
p.(P2548L), were identified in two cases each. Fifteen variants were observed in the control cohorts 
only, including p.(P3372L), which was identified in two individuals. Two variants, p.(P626_G628del) 
and p.(E3781K), were identified in both a case and a control. All other variants were observed in a 
single individual. Two variants, p.(S2242Y) and p.(P3372L), were previously observed in the study by 
Lechner et al.145 and p.(E935G) is located at the same amino acid as a variant identified in the study by 
Davidson and colleagues.147 In total, 18 variants were identified 20 times in cases and 12 variants were 
observed 13 times in the screened controls. For the population control comparison, 10 variants were 
observed in 12 cases and 5 variants were identified in the controls. Similar to the results for rare variants, 
very rare variants were not enriched in cases compared to either the screened controls (p = 0.96) or the 
population controls (p = 0.15, Table 3.8). Furthermore, the SKAT analyses demonstrated no significant 
enrichment of variants predicted to be damaging (p = 0.06, Table 3.10). 
For the power calculations, the high-risk allele frequency was assumed to be the frequency of variants 
identified by the filtering strategies in the 230 screened controls. This was determined to be 0.104 
(48/460) for Strategy 1 and 0.028 (13/460) for Strategy 2. Using these values, the present analysis of 
ZNF469 had 80% power to detect a relative risk of 1.5 and 2.0, respectively. 
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Table 3.8 – Rare potentially pathogenic variants in ZNF469 variants included in analysis under Filtering Strategy 1 
    Alternate allele frequencies   
Position (hg19) 
Nucleotide 
Variant 
Protein Variant PhastCons 
ExAC 
NFE 
Cases (AC) 
Screened 
Controls (AC) 
Population 
Controls (AC) 
FS2 Ref 
chr16:88494603 c.725G>T p.(S242I) 0.9930 0.0024 0.0013 (1) 0.0022 (1) * N  
chr16:88494809 c.931G>A p.(G311R) 0.0000 0.0000 0.0013 (1) 0.0000 (0) * Y  
chr16:88495361 c.1483C>T p.(P495S) 0.0040 0.0015 0.0013 (1) 0.0022 (1) * N  
chr16:88495385 c.1507C>T p.(R503W) 0.9980 0.0003 0.0013 (1) 0.0000 (0) * Y  
chr16:88495400 c.1522G>A p.(A508T) 0.0000 0.0003 0.0013 (1) 0.0000 (0) * Y  
chr16:88495443 c.1565G>T p.(G522V) 0.0010 0.0000 0.0000 (0) 0.0022 (1) * Y  
chr16:88495461 c.1583C>G p.(P528R) 0.0000 0.0000 0.0013 (1) 0.0000 (0) * Y  
chr16:88495487 c.1609G>A p.(V537M) 0.0000 0.0010 0.0038 (3) 0.0022 (1) * N 145 
chr16:88495568 c.1690G>C p.(G564R) 0.3100 0.0002 0.0013 (1) 0.0000 (0) * Y  
chr16:88495575 c.1697C>T p.(A566V) 0.0000 0.0098 0.0115 (9) 0.0283 (13) * N 146, 147 
chr16:88495753 c.1875_1883del p.(P626_P628del) 0.0000 0.0000 0.0013 (1) 0.0022 (1) * Y  
chr16:88495872 c.1994C>T p.(P665L) 0.0420 0.0062 0.0102 (8) 0.0109 (5) * N 145 
chr16:88495913 c.2035G>A p.(E679K) 0.6550 0.0064 0.0013 (1) 0.0022 (1) * N 147 
chr16:88496430 c.2552T>C p.(M851T) 1.0000 0.0000 0.0000 (0) 0.0022 (1) * Y  
chr16:88496682 c.2804A>G p.(E935G) 0.0040 0.0000 0.0013 (1) 0.0000 (0) * Y 147† 
chr16:88497443 c.3481C>A p.(P1161T) 0.0000 0.0000 0.0000 (0) 0.0022 (1) * Y  
chr16:88497830 c.3868G>A p.(D1290N) 0.0020 0.0000 0.0000 (0) 0.0022 (1) * Y  
chr16:88498350 c.4388C>T p.(T1463M) 0.0020 0.0035 0.0000 (0) 0.0022 (1) 0.0058 (4) N 145 
chr16:88499040 c.5078G>T p.(C1693F) 0.0000 0.0002 0.0026 (2) 0.0000 (0) 0.0000 (0) Y  
chr16:88500687 c.6725C>A p.(S2242Y) 0.0000 0.0001 0.0000 (0) 0.0000 (0) 0.0014 (1) Y 145 
chr16:88500713 c.6751C>T p.(P2251S) 0.0040 0.0000 0.0000 (0) 0.0022 (1) 0.0000 (0) Y  
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    Alternate allele frequencies   
Position (hg19) 
Nucleotide 
Variant 
Protein Variant PhastCons 
ExAC 
NFE 
Cases (AC) 
Screened 
Controls (AC) 
Population 
Controls (AC) 
FS2 Ref 
chr16:88500822 c.6860C>G p.(P2287R) 0.0010 0.0002 0.0013 (1) 0.0000 (0) 0.0000 (0) Y  
chr16:88500957 c.6995C>T p.(P2332L) 0.0000 0.0033 0.0064 (5) 0.0000 (0) 0.0000 (0) N  
chr16:88501145 c.7183C>A p.(P2395T) 0.0000 0.0044 0.0038 (3) 0.0022 (1) 0.0000 (0) N  
chr16:88501224 c.7262G>A p.(R2421H) 0.0000 0.0002 0.0013 (1) 0.0000 (0) 0.0000 (0) Y  
chr16:88501344 c.7382G>A p.(R2461Q) 1.0000 0.0002 0.0000 (0) 0.0022 (1) * Y  
chr16:88501431 c.7469C>A p.(P2490H) 0.0000 0.0034 0.0013 (1) 0.0000 (0) 0.0000 (0) N 145 
chr16:88501605 c.7643C>T p.(P2548L) 0.0000 0.0000 0.0026 (2) 0.0000 (0) 0.0000 (0) Y  
chr16:88501749 c.7787C>T p.(P2596L) 0.0000 0.0010 0.0000 (0) 0.0000 (0) 0.0058 (4) N  
chr16:88501995 c.8033C>T p.(A2678V) 0.0000 0.0000 0.0013 (1) 0.0000 (0) 0.0000 (0) Y  
chr16:88502222 c.8260C>T p.(H2754Y) 0.0000 0.0009 0.0000 (0) 0.0022 (1) 0.0000 (0) Y  
chr16:88502276 c.8314C>A p.(L2772M) 0.0000 0.0000 0.0000 (0) 0.0000 (0) 0.0014 (1) Y  
chr16:88502304 c.8342C>T p.(P2781L) 0.0000 0.0000 0.0013 (1) 0.0000 (0) 0.0000 (0) Y  
chr16:88502583 c.8621C>T p.(T2874M) 0.0000 0.0011 0.0026 (2) 0.0000 (0) 0.0000 (0) N  
chr16:88502666 c.8704G>T p.(D2902Y) 0.9700 0.0010 0.0038 (3) 0.0000 (0) 0.0029 (2) N 145 
chr16:88502723 c.8761C>G p.(P2921A) 0.0030 0.0000 0.0000 (0) 0.0000 (0) 0.0014 (1) Y  
chr16:88502862 c.8900C>T p.(A2967V) 0.0030 0.0000 0.0013 (1) 0.0000 (0) 0.0000 (0) Y  
chr16:88502972 c.9010_9024del p.(L3004_T3008del) 0.0000 0.0043 0.0051 (4) 0.0022 (1) 0.0014 (1) N 147†, 
145† chr16:88503039 c.9077A>C p.(E3026A) 0.9690 0.0000 0.0013 (1) 0.0000 (0) 0.0000 (0) Y  
chr16:88503372 c.9410A>G p.(E3137G) 1.0000 0.0000 0.0013 (1) 0.0000 (0) * Y  
chr16:88503596 c.9634A>T p.(R3212W) 0.0000 0.0000 0.0000 (0) 0.0022 (1) * Y  
chr16:88503838 c.9876G>T p.(E3292D) 0.0010 0.0000 0.0000 (0) 0.0022 (1) * Y  
chr16:88504077 c.10115C>T p.(P3372L) 1.0000 0.0000 0.0000 (0) 0.0043 (2) * Y 145 
chr16:88504239 c.10277G>A p.(R3426Q) 0.3970 0.0078 0.0140 (11) 0.0196 (9) * N 145, 147 
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    Alternate allele frequencies   
Position (hg19) 
Nucleotide 
Variant 
Protein Variant PhastCons 
ExAC 
NFE 
Cases (AC) 
Screened 
Controls (AC) 
Population 
Controls (AC) 
FS2 Ref 
chr16:88504492 c.10530delC p.(I3510fs) 0.0000 0.0000 0.0000 (0) 0.0000 (0) 0.0014 (1) Y  
chr16:88504766 c.10804C>T p.(R3602C) 0.0000 0.0031 0.0013 (1) 0.0022 (1) 0.0087 (6) N 145 
chr16:88504775 c.10813T>G p.(C3605G) 0.0000 0.0000 0.0000 (0) 0.0000 (0) 0.0014 (1) Y  
chr16:88505303 c.11341G>A p.(E3781K) 1.0000 0.0005 0.0013 (1) 0.0022 (1) 0.0000 (0) Y  
chr16:88505654 c.11692G>A p.(E3898K) 1.0000 0.0000 0.0013 (1) 0.0000 (0) 0.0000 (0) Y  
Position = the position of SNPs or the start position of insertions or deletions (based on hg19). 
PhastCons = the 100-way vertebrate PhastCons score (which ranges from 0 to 1, with 1 being highly conserved). 
ExAC NFE = the alternate allele frequency observed in the non-Finnish European population of the Exome Aggregation Consortium (ExAC) database. 
AC = the alternate allele count in the given cohort. 
FS2 = indicates whether or not the variant was included in Filtering Strategy 2, where Y = yes and N = no. 
Ref = References of previous studies if the variant had been previously reported in keratoconus. 
* = variant with insufficient coverage. 
† = variant previously reported at the same amino acid, but a different nucleotide. 
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Table 3.9 – Association analyses using chi square or Fisher’s exact test under each 
filtering strategy used for ZNF469. 
Filtering 
Strategy 1 
Cohort Alt.  WT  AAF P 
OR 
[95%CI] 
Comparison 1 cases 73 697 0.09 
0.66 
0.90 
[0.60-1.34]  screened controls 48 412 0.10 
Comparison 2 cases 31 739 0.04 
0.47 
1.28 
[0.71-2.31]  population controls 22 670 0.03 
Filtering 
Strategy 2 
Cohort Alt.  WT  AAF P 
OR 
[95%CI] 
Comparison 1 cases 20 750 0.03 
0.96 
0.92 
[0.43-1.97]  screened controls 13 447 0.03 
Comparison 2 cases 12 758 0.02 
0.15* 
2.18 
[0.71-7.11]  population controls 5 687 0.01 
Alt. = the number of alternate alleles (ie. the number of alleles that carry a potentially pathogenic 
variant). 
WT = the number of wild type (reference) alleles (ie. the number of alleles that do not carry a 
potentially pathogenic variant). 
AAF = the alternate alleles frequency (Alt./total alleles). 
P = p-value obtained using a Yates corrected chi-square test. 
*Fisher’s exact p-value. 
 
Table 3.10 – SKAT results for ZNF469. 
Comparison Alt. MAC Carriers P 
Cases vs screened controls 38 415 271 0.06 
Cases vs population controls 20 473 337 0.06 
Alt. = the number of alternate alleles (ie. the number of variants observed). 
MAC = the total number of minor alleles observed within the cohorts (ie. the number of times the 
minor allele was observed for all variants included in the analysis). 
Carriers = the number of individuals carrying the alternate alleles. 
P = p-value. 
 
For each cohort, the allele frequencies were plotted against the variant position and mapped to a 
schematic of the gene (Figure 3.2). The first exon showed a similar pattern of variation between the 
cases and screened controls. Due to insufficient coverage of this region in the population controls, 
variation in this group could not be assessed. Of the 13 variants identified in cases in exon 1, two 
variants, p.(S242I) and p.(R503W), were located at highly conserved nucleotides (PhastCons score > 
0.99) and p.(E679K) was at a relatively conserved position with a PhastCons score of 0.655. The 
p.(R503W) variant was observed in a single case (frequency of 0.0013), whereas both p.(S242I) and 
p.(E679K) were identified in one case and one screened control (frequency of 0.0022).  
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Few variants were located in the proximal region of exon 2, with only one variant identified in cases. 
In contrast, a cluster of variants was observed in cases in the distal half of exon 2 (Figure 3.2). 
Specifically, variants were observed in the cases in the region spanning just proximally to the first zinc 
finger motif to midway between the second and third zinc finger motif, with noticeably fewer variants 
were observed in the control cohorts within the same region. Three variants identified in cases within 
this cluster were highly conserved with PhastCons scores greater than 0.96: p.(D2902Y), p.(E3026A) 
and p.(E3137G). The p.(D2902Y) variant was present at a similar frequency in cases (0.0038) and the 
population controls (0.0029), while p.(E3026A) and p.(E3137G) were present in one case and absent in 
controls. Two additional variants, p.(E3781K) and p.(E3898K), were identified at highly conserved 
residues at the very distal end of exon 2 (PhastCons score = 1). These variants were both identified a 
single case and neither of these variants were observed in the population controls despite good coverage 
in this region, however, the p.(E3781K) variant was observed in a one screened control.  
Across ZNF469, three variants – p.(A566V), p.(P665L), and p.(R3426Q) – were identified at a 
frequency > 0.01 in both the cases and the screened control cohort, despite a MAF < 0.01 in the public 
ExAC NFE database. The frequency of these variants could not be assessed in the population controls 
due to insufficient coverage, however all three variants were observed in cases at a similar or lower 
frequency than the screened controls. 
52 
 
 
Figure 3.2 – Summary of variants indentified in ZNF469. 
(A) Depicts a schematic of ZNF469 with zinc finger motifs shaded dark grey and (B-D) presents bar plots indicating the position and alternate allele 
frequency (AAF) of rare potentially pathogenic variants in 784 case alleles, 460 screened control alleles and 692 population control alleles respectively. The 
bars are coloured according to the 100-way vertebrate PhastCons Score for the corresponding position, where dark blue is a score of 0 and red is a score of 1. 
Light grey shading on the plots for the control cohorts indicate regions with insufficient coverage for variant calling that were excluded from analysis when 
using these data. The gene schematic and all graphs are aligned vertically to share the same x-axis to allow for comparison.
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 DISCUSSION 
This study demonstrates that rare potentially pathogenic variants in 22 candidate genes were not 
enriched in keratoconus in our large cohort of Australians of European descent. A total of 213 rare 
potentially pathogenic variants were identified across cases and controls in 21 of the 22 genes, however, 
variants fulfilling these criteria were equally common between cases and controls. No potentially 
pathogenic variants were identified in IL1RN in either cases or controls, suggesting that this gene is 
highly conserved. Additionally, no potentially pathogenic variants were observed in our cases in BANP, 
IL1B, RAD51 or SOD1. Based on these findings, we suggest that rare protein-coding variants that are 
predicted to be potentially pathogenic within the 22 genes assessed do not contribute broadly to 
keratoconus development in our cohort.  
This study is the largest and most comprehensive study of keratoconus candidate genes to date, 
including 22 genes and combining WES data and targeted gene sequencing using pooled DNA samples. 
Following extensive validation experiments, we demonstrated a high level of consistency of variant 
calls for individuals sequenced by both methods, validating the utility of pooling DNA samples to 
maximise cost-effectiveness. Furthermore, these validation experiments were used to develop stringent 
thresholds that were then applied to remaining data to ensure only high-quality variants were included 
in analyses. While variants were not assessed for validation in the control cohorts, the inclusion of 
additional control variants that were filtered out due to the stringent quality and depth thresholds would 
only strengthen our findings of no association. Furthermore, gaps in coverage, occurring either at the 
probe design stage or at the sequencing phase, were a limitation of this study. Similarly, the capture 
methods were specifically designed to capture protein-coding regions, and although non-coding variants 
were not excluded, very few were observed. In addition, for all genes except ZNF469, insertion and 
deletion variants were not assessed due to the challenges of calling such variants from the targeted 
sequencing data generated using pooled DNA. These limitations mean that some variants will have 
been missed, but this is not expected to be a major bias between cases and controls due to limiting the 
analysis to regions adequately covered by all methods. Some specific variants that have previously been 
reported in keratoconus could not be assessed. This is particularly important for SOD1, as the variant 
previously associated with keratoconus was a 7 bp intronic deletion, outside of the capture regions in 
this study. Similarly, IL1RN and SLC4A11 were implicated by an intronic SNP and a 54 bp intronic 
deletion (respectively) which almost completely co-segregated with keratoconus in an Ecuadorian 
family.66 Although these specific variants could not be assessed in our study, the overarching design 
and aim was to examine the protein-coding regions of the selected candidate genes for enrichment of 
potentially pathogenic variants in keratoconus. 
For the few genes that have previously been investigated in keratoconus cohorts, in silico tools that 
predict the pathogenicity of variants such as PolyPhen2 and SIFT have been used to help differentiate 
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between benign variants and potentially pathogenic variants. These algorithms, however, can only 
assess nonsynonymous variants. These two tools were used to classify variants as potentially pathogenic 
in ZNF469, allowing for direct comparison of the results from the present study and those previously 
published, however, for all other genes, scaled CADD scores were also used to aid the classification of 
these variants. CADD uses a machine learning method to predict the deleteriousness of variants such 
that a scaled score above 10 refers to the top 10% of variants ranked by deleteriousness, a scaled score 
of 20 or above includes the top 1% of variants and so on.134 Unlike SIFT and PolyPhen2, CADD also 
scores synonymous and non-coding variants, allowing for the inclusion of these types of variants in the 
present study. A scaled CADD score of 15 was selected as the minimum threshold for synonymous and 
non-coding variants. Nonsynonymous variants with a MAF < 0.01 were included if they were predicted 
to be damaging by SIFT; or damaging/possibly or probably damaging by PolyPhen2; or obtained a 
CADD scaled score of ≥ 15. This broad definition of potentially pathogenic variants was designed to 
minimise the exclusion of likely important disease-related variants.  
This study compared the frequency of potentially pathogenic variants between Australian keratoconus 
cases and controls, using a control cohort consisting of 396 females. These individuals were not 
screened for keratoconus, however, considering the prevalence of keratoconus in Caucasians is between 
approximately 1 in 375 and 1 in 20004, 6, 178 it is unlikely that more than one or two individuals in this 
cohort have keratoconus, if any. Considering the large sample size for both the case and control cohorts, 
this is unlikely to affect our findings. Additionally, the controls were 100% female while 44.2% of the 
cases were female. This is a potential limitation, however, while epidemiological studies report a 
slightly higher prevalence in males compared to females in Caucasian populations, these differences 
are not significant.4, 6, 178 Moreover, all of the genes assessed in the present study are autosomal, making 
sex-based differences in the frequency of variants unlikely. Consequently, the use of this all-female 
cohort is unlikely to affect the outcomes of the present study. Due to poor coverage of ZNF469, 
particularly in the WES data for the population controls, a screened control cohort consisting of 230 
individuals was also used for analysis. These individuals were almost all affected by advanced 
glaucoma. However, the GWAS that identified the association between the SNP upstream of ZNF469 
(rs9938149) and CCT as well as keratoconus, also assessed this SNP for association with glaucoma and 
demonstrated no association.87 Based on this, we do not expect the use of this cohort to confound our 
findings. 
VSX1, which encodes a vertebrate paired-like homeodomain transcription factor with known ocular 
expression,179, 180 is the most studied gene in keratoconus. It was initially studied as a candidate gene 
for posterior polymorphous corneal dystrophy (PPCD; OMIM 122000) as it was located within a 
linkage region for this disease.89, 181 PPCD is a rare, bilateral corneal dystrophy that primarily affects 
the endothelium and results in variable degrees of visual impairment and has been associated with 
keratoconus.182-186 It was therefore hypothesised that the two diseases may share a common genetic 
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basis. The original paper identified four VSX1 variants in keratoconus cases that were absent in 277 
controls,89 as well as p.(G160D) and p.(P247R) in a family with PPCD.89 Subsequently, the p.(G160D) 
variant has been identified in keratoconus cases in two Italian studies90, 96 a European cohort,94 and in 
two cases in the current study. This was the only variant observed in our cases that had been reported 
in other keratoconus cases. In contrast, the p.(G160D) variant was found at similar frequencies in both 
cases and controls in a Han Chinese cohort,97 indicating that this variant is not highly penetrant for 
keratoconus, at least in the Chinese population. Interestingly, the p.(G160V) variant, which results in a 
different amino acid substitution at the same position, has been observed in cases in two Korean 
studies.92, 156 The p.(P247R) variant originally reported in the PPCD family89 and subsequently reported 
in keratoconus90, 96, 100 was observed in a single control subject in our study. As our controls were not 
screened for eye disease it is possible that a small number of individuals in this group may have 
keratoconus or PPCD and therefore the involvement of this variant in disease cannot be ruled out. 
Furthermore, as keratoconus is a complex disease it is likely that unaffected individuals may carry risk 
alleles, without ever developing disease, therefore, to assess the potential role of specific variants such 
as p.(P247R), a large meta-analysis is required. Additionally, p.(L237P) and p.(E234K) were identified 
for the first time in a keratoconus cohort, each observed in one case. Taken together, the VSX1 gene 
may contribute in a very small number of cases with clear segregation in families identified,90, 91, 95, 98 
however, rare potentially pathogenic variants in this gene do not contribute widely to keratoconus 
susceptibility in our cohort. 
The present analysis of ZNF469 included more keratoconus cases than the combined number of cases 
previously studied.145-148 This allowed the location of the rare potentially pathogenic variants to be 
mapped across the gene in cases and both control cohorts, demonstrating that rare potentially pathogenic 
variants span the whole gene, with particular aggregation in the first exon and the distal half of the 
second exon. Only eight variants observed in cases were located at highly conserved nucleotides. Four 
of these variants were identified at similar frequencies in both cases and controls and four were only 
observed in a single case. It is possible that some of the rare protein-coding variants may contribute to 
keratoconus susceptibility in these few cases, and based on our power calculations it is feasible that our 
study was underpowered to detect an association of variants with small odds ratios (OR ≤ 1.5 for rare 
variants and OR ≤ 2 for very rare variants), but on the whole, the evidence indicates that rare, potentially 
pathogenic variants in ZNF469 do not make a substantial contribution to keratoconus risk. This finding 
is consistent with the work by Davidson and colleagues,147 which showed that uncommon variants 
(MAF < 0.025) did not segregate with disease in families with keratoconus and therefore, at least in 
isolation, do not contribute to keratoconus susceptibility. Furthermore, the results of a Polish study148 
indicate that potentially pathogenic variants are not enriched in keratoconus, and that ZNF469 is highly 
allelic in the general population. 
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The first reports to investigate coding variants in ZNF469 were conducted in small cohorts from 
UK/Swiss and New Zealand populations, published by Lechner et al.145 and Vincent et al.146 
respectively.  Subsequent studies, including this one, have used similar filtering strategies to allow for 
direct comparison. Our Filtering Strategy 1 was based on the criteria used in Vincent et al., while 
Filtering Strategy 2 was based on the method used by Lechner et al. with two key changes. Firstly, 
Lechner et al. removed any variants from analysis that were present in both their cases and controls. 
We did not do this as keratoconus is a complex disease and therefore it is likely (and expected) that 
unaffected individuals will carry risk associated variants without ever developing disease. Secondly, 
Lechner et al. only used SIFT predictions to classify variants as potentially pathogenic. SIFT uses 
protein conservation to calculate pathogenicity by comparing a query sequence to similar sequences 
with similar function.132 As ZNF469 is a highly variable gene with low conservation in lower mammals 
and vertbrates,187 SIFT may misclassify deleterious variants in regions of low conservation. In contrast, 
PolyPhen2 uses the properties of the substituted amino acids and the proximity to functional domains 
or structural features, as well as protein conservation to predict pathogenicity.133 As the structure and 
function of the ZNF469 protein remains largely unknown,187 PolyPhen2 is likely to better assess regions 
with poor conservation, particularly the regions that flank the zinc finger domains. Therefore, our study 
used both SIFT and PolyPhen2 to better capture the pathogenicity of nonsynonymous variants identified 
in ZNF469. Our study used these robust and complementary methods to replicate the analytical 
strategies of the previous studies; however, our findings do not support any enrichment of rare 
potentially pathogenic variants in ZNF469 in keratoconus cases. 
As suggested by Davidson et al.147 it is likely that variation in ZNF469 is under-represented in public 
databases as a result of the poor coverage of the gene by the older WES capture techniques. According 
to the ExAC Browser the mean coverage for ZNF469 (ENSG00000225614) is 7.3 reads and the 
proportion of individuals with at least 10X coverage is less than 20%. The poor coverage of ZNF469 in 
the population control dataset, as well as the occurrence of three variants that were identified in our 
cases and screened controls at a frequency of > 0.01, despite being annotated with a MAF < 0.01 in the 
ExAC NFE database, supports this. As one might expect, these variants could not be assessed in the 
population controls due to insufficient coverage. All three of these variants were located at relatively 
non-conserved nucleotides (PhastCons scores < 0.4). Two of these variants, p.(P665L) and p.(R3426Q) 
were observed at similar frequencies in both our cases and controls and therefore were hypothesised to 
be benign polymorphisms. These variants were similarly classified in the study by Lechner and 
colleagues, but were not identified in other reports.145-148 The third variant, p.(A566V), was identified 
at more than twice the frequency in the screened controls (0.028) than the cases (0.012). Vincent et 
al.146 reported this variant in one Indian and two Caucasian keratoconus cases, while Davidson et al.147 
identified the variant in two cases and two unaffected individuals from two separate consanguineous 
families of Middle Eastern origin. In addition, the work by Lechner et al.145 excluded the variant from 
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analysis due to a MAF > 0.01 in their control cohort. Therefore, we propose that these variants are 
benign, uncommon polymorphisms. Overall, this work demonstrates that the previously reported large 
effects of rare variants in ZNF469 are likely spurious and are brought about by biased reporting of 
variants. 
 CONCLUSION 
This study demonstrated that the overall the frequency of potentially pathogenic variants was not 
different between cases and controls in 22 candidate genes in our large cohort of Australians of 
European descent. The included genes were all literature-based candidates, proposed to play a role in 
disease based on their proximity to GWAS hits or because they map to linkage regions identified in 
family studies, as well as, the function of the encoded protein. While specific rare protein-coding 
variants in these genes may contribute to keratoconus-risk in a small proportion of cases, the work 
presented in this chapter suggests that they do not contribute to disease in the vast majority of 
keratoconus patients. Perhaps some of these genes do contribute to keratoconus susceptibility, but via 
an alternative mechanism of disease such as altered regulation and expression. Fine-mapping and re-
sequencing techniques are required to identify the functional risk-associated variants at keratoconus-
associated loci, determine the mechanism of disease and aid our understanding of key biological 
pathways involved in keratoconus. Furthermore, as demonstrated by the success of identifying the 
keratoconus-associated gene mir184,65, 77, 143 family studies paired with massively-parallel sequencing 
technologies may be a powerful method for elucidating specific disease-causing variants. Together, 
these methods would allow for less biased approaches for variant identification and candidate gene 
selection without a prior hypothesis. Overall, these findings do not support the overarching hypothesis 
of this study, that rare protein-coding variants contribute to keratoconus development, and instead 
suggest that alternative hypotheses should be explored. 
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CHAPTER 4: IDENTIFIYING PUTATIVELY DISEASE-CASUSING VARIANTS IN 
FAMILIES WITH MULTIPLE CASES OF KERATOCONUS 
 
 INTRODUCTION 
Studying families enriched for disease is a powerful strategy for identifying rare, disease-causing 
variants. Linkage analysis is a statistical method that has been used for decades to identify regions of 
the genome that segregate with disease through a family. Parametric linkage analysis is used when the 
inheritance pattern of the disease or trait of interest is known as it applies a specific disease model. 
Conversely, non-parametric linkage analysis does not make any assumptions about the disease model 
and instead tests for increased allele sharing between affected individuals. This method is applied when 
the inheritance pattern is less clear. Furthermore, homozygosity mapping is the most robust discovery 
strategy for identifying the disease-causing variant in families with recessive disease and a recent 
history of consanguinity. This method identifies alleles that are homozygous identical-by-descent in 
affected individuals. Traditionally, these disease mapping methods were conducted using a relatively 
small number of polymorphic microsatellite markers across the genome and the identified regions of 
interest were then fine-mapped using a denser selection of markers surrounding the region. More 
recently, single nucleotide polymorphism (SNP) arrays that genotype hundreds of thousands of SNPs 
across the genome have become the norm, reducing the need for fine-mapping. The regions of interest 
are then sequenced, traditionally using direct sequencing methods to sequence the coding regions of 
highly prioritised genes, to identify the causative variants. 
In families, keratoconus is often inherited as an autosomal dominant trait, usually with reduced 
penetrance, but can also be inherited as a recessive trait. Digenic inheritance has also been reported as 
a likely inheritance pattern in an Australian family of European descent.71 In this family, the inheritance 
pattern was consistent with autosomal dominance, however, two suggestive linkage regions with equal 
LOD scores were identified and all affected family members carried both disease-associated haplotypes. 
A two-locus linkage analysis was performed and together, the two linkage regions surpassed the 
significance threshold. In total, more than 20 significant or highly suggestive linkage regions for 
keratoconus have been identified to date.28, 29, 64-66, 69, 71, 72, 74-80, 120, 141, 142 These linkage regions map to 
the majority of the autosomes and few regions have been replicated, suggesting that the linkage regions 
are largely family-specific. The only significant linkage region that has been replicated is a region on 
chromosome 5. The region 5q14.1-q21.3 reached significance in a four generation Caucasian family74 
and a suggestive peak was identified at 5q21.2 in a study of 23 small families from southern Italy.141 
An adjacent region on 5q also showed suggestive linkage with keratoconus in a study that investigated 
sibling pairs from a mixed population75 and this region appears to overlap a highly suggestive linkage 
region at 5q31.1-q35.3 identified in an Ecuadorian family with autosomal dominant disease.142 The 
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heterogeneity of keratoconus, along with the large number of genes harboured within the identified 
linkage regions, has made the identification of causal variants and key genes difficult.  
Current candidate genes for isolated keratoconus identified through linkage studies include IL1RN,66 
SLC4A1166 and DOCK9,29, 120 however, as very little is known about the mechanism of disease, or key 
biological pathways involved, prioritising genes in linkage regions remains challenging. With the recent 
emergence of massively parallel sequencing, however, candidate genes within regions of interest can 
now be screened efficiently for variants without a priori hypotheses. It is therefore hypothesised that 
these technologies, paired with disease mapping in families with multiple cases of keratoconus and clear 
patterns of inheritance, will aid the identification of causative variants and key genes involved in 
keratoconus development and pathogenesis. A recent study demonstrates the potential of this strategy 
with the identification of a variant within the seed region of a non-coding RNA gene, mir184, via 
targeted sequencing of the genes within a linkage region on chromosome 15 in a family from Northern 
Ireland.65, 77, 143 Affected individuals in this family had both keratoconus and congenital cataract and the 
same variant was found to co-segregate with keratoconus and congenital cataract in an unrelated family 
from Spain.69 While this gene is involved a broader ocular phenotype, the identification of mir184 in in 
these families provide a critical insight into biologically relevant pathways and may aid the 
identification of candidate genes in isolated keratoconus. The present study will go one step further by 
using whole genome sequencing (WGS) data to conduct disease gene mapping. Variation within any 
regions of interest, including both protein-coding and non-coding variants, will then be interrogated 
directly from the WGS data.  
 
 HYPOTHESIS AND AIM 
The overarching hypothesis for this study was that rare, highly penetrant protein-coding variants 
contribute to keratoconus development. More specifically, we hypothesised that families with multiple 
cases of keratoconus with early onset or severe disease, and strong Mendelian inheritance patterns of 
disease, would aid the identification of putatively disease-causing variants involved in keratoconus 
development. This led to the following aim: 
To identify rare, putatively disease-causing variants in families with multiple cases of early-onset or 
severe keratoconus and a strong Mendelian inheritance pattern of disease. 
 
 OVERALL STUDY DESIGN 
This chapter focuses on the identification of putative disease-causing variants in two families: one with 
autosomal recessive inheritance of keratoconus and known consanguinity and another with apparent 
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autosomal dominant inheritance with reduced penetrance. This achieve this, WGS data was generated 
and used to conduct keratoconus mapping with an LD-pruned scaffold of SNPs that mimic a SNP array, 
as well as, investigate variation within the identified regions of interest. The WGS data were also used 
to determine the individuals’ ancestry and confirm reported relationships in the families. A flow 
diagram of the study design is presented in Figure 4.1. 
 
 
Figure 4.1 – A flow diagram of the overall study design. 
Light blue boxes indicate data and dark blue boxes indicate methods. WGS = whole genome 
sequencing; LD = linkage disequilibrium; and SNP = single nucleotide polymorphism. 
 
 METHODS 
4.4.1 Study participants 
Families with multiple cases of keratoconus were recruited as described in Section 2.1.1. 
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KSA197 
KSA197 is a small family of Italian heritage living in 
South Australia (Figure 4.2). The parents are second 
cousins and have two sons with keratoconus. Neither 
parent has keratoconus, but both have thin central 
corneas. The proband (KSA197.0) has a child 
(KSA197.4) that is reported as unaffected, however, has 
not been assessed by our ophthalmologists. A summary 
of the available clinical data is present in Table 4.1. The 
pattern of inheritance of keratoconus in this family is 
consistent with autosomal recessive disease. 
DNA samples were collected from five family members: 
the two affected brothers, their parents and the 
unaffected child. WGS data was obtained for these five 
family members. 
 
 
 
 
 
Table 4.1 – Clinical data for KSA197 family members. 
Individual 
Keratoconus 
Status 
K readings CCT (µm) 
RE LE RE LE 
KSA197.0 affected 
 
40.25/40.5 52.25/54.00 497 385 
KSA197.1 unaffected 43.0/41.87 42.75/42.37 509 521 
KSA197.2 affected 
 
46.75/48.20 44.60/45.00 378 408 
KSA197.3 unaffected 42.75/42.75 43.0/42.75 480 473 
KSA197.4 unaffected* NA NA NA NA 
K = keratometry; a measure of the curvature of the cornea in dioptres (D). 
CCT = central corneal thickness; a measure of the thickness of the cornea. 
RE = right eye. 
LE = left eye. 
NA = not assessed. 
* Self reported.  
Figure 4.2 – The KSA197 family 
pedigree. 
Females are indicated by circles, males 
by squares, individuals with unknown 
sex by diamonds, and deceased 
individuals are depicted by a slash. 
These symbols are coloured black for 
individuals with keratoconus and white 
for unaffected individuals. Red arrows 
indicate that DNA was collected and 
whole genome sequencing (WGS) data 
was generated. 
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KCNSW01 
KCNSW01 is a Jordanian family with eight individuals with severe and early-onset keratoconus (Figure 
4.3). The proband, KCNSW01-2, is a severely affected child who was diagnosed at five years of age. 
KCNSW01-2 is known to have a de novo deletion at 15q26.3 (chr15:96,725,466-100,200,967), but no 
other clinical details were disclosed. The proband and his father (KCNSW01-1), who is mildly affected, 
live in Sydney, where they were recruited for this study. A severely affected uncle (KCNSW01-3) also 
lives in Sydney. All remaining family members live in Jordan, however written informed consent was 
obtained, and samples were collected remotely by saliva collection kit. The proband’s father reports 
severe and early-onset disease (development at 6-7 years) in three of his four sisters, and variable 
severity in three of his six brothers. The parents of these individuals are reported to be unaffected and 
unrelated, although these individuals have not been formally examined for mild disease. In total, seven 
of the 11 siblings in the second generation of KCNSW01 are affected with keratoconus.  
The second and third generation of KCNSW01 is consistent with autosomal dominant inheritance, 
however, the parents in the first generation are reported as unaffected. Both parents have 9 siblings, all 
of whom are reported to be unaffected with keratoconus. KCNSW01-1 reported that there was no 
consanguinity in recent generations. Saliva samples for DNA extraction were collected from eleven 
individuals across the three generations. 
 
Figure 4.3 – The KCNSW01 family pedigree. 
Females are indicated by circles and males by squares. These symbols are coloured black for 
individuals with keratoconus and white for unaffected individuals. Red arrows indicate that DNA was 
collected and WGS data was generated. 
 
4.4.2 Whole genome sequencing 
Whole genome sequencing was performed using Illumina’s TruSeq Nano Library Prep v2.5 with 150 
bp paired-end sequencing on the Illumina XTen platform (30x coverage) at the Kinghorn Centre for 
Clinical Genomics (Sydney, Australia). All family members across KSA197 and KCNSW01 who 
provided DNA samples were sequenced (n=16). Raw sequence data were provided as unmapped 
FASTQ files. These data were mapped to the human reference genome (hg19) using BWA188 and 
variants were joint-called using GATK125 in concordance with GATK’s “Best Practices” guidelines in-
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house using the Churchill162 pipeline. This resulted in variant caller format (VCF) files for SNPs and 
small insertions and deletions (indels). 
4.4.3 Generating a linkage disequilibrium-pruned SNP set for LD-sensitive 
analyses 
A linkage disequilibrium (LD)-pruned SNP set was generated using an independent cohort consisting 
of 1585 unrelated Caucasians genotyped on the Human Omni Express v1.1 BeadChip (Illumina). The 
cohort has previously been described in detail.189 Using these data, pairwise LD SNP pruning was 
performed for autosomal SNPs in PLINK190 (version 1.90) with the following parameters: window 
size=50, step=5, pairwise r2 threshold=0.5. This identified a SNP set of 266,025 LD-pruned SNPs. For 
each family separately, the genotypes at these SNPs were extracted from the joint-called VCF files 
using version 1.5 of BCFtools (available from https://github.com/samtools/BCFtools). An example 
command is outlined in Appendix 4. If the alternate allele was not observed in any of the family 
members, the SNP was not captured in the family-specific VCF file. A total of 191,684 SNPs were 
included for KCNSW01 and 189,747 SNPs were included for KSA197.  
To ensure only high confidence genotypes were included in subsequent analyses, confidence tags were 
added to the genotypes in the VCF as described in Section 2.2.1. ‘Clean’ VCF files were generated by 
converting any genotypes with low coverage or low quality scores to missing calls (‘./.’) as outlined in 
Section 2.2.2. For the KSA197 family, this ‘clean’ VCF file was used for homozygosity mapping as 
described in Section 4.4.6.1. Additionally, PLINK binary files were created by reading the ‘clean’ VCF 
files into PLINK using the ‘--vcf’ and ‘--keep-allele-order’ parameters and the PLINK format sample 
information (FAM) files were manually updated with the family IDs, parent IDs, and sex and phenotype 
information. The PLINK binary files were subsequently used for LD-sensitive analyses such as 
determining the ancestry of the families (Section 4.4.4), relationship testing (Section 4.4.5), parametric 
linkage analysis for KCNSW01 (Section 4.4.7.1), identifying runs of homozygosity in KSA197 using 
PLINK (Section 4.4.6.1), and haplotype analysis for both families (Sections 4.4.6.2 and 4.4.7.2). 
4.4.4 Determining ancestry using principle components analysis  
Principle components analysis (PCA) was used to determine the ancestry of KCNSW01 and KSA197 
on a continental-scale using the International HapMap191 Project Phase III (HapMap3) genotype data 
from Europe (CEU), Asia (CHB + JPT) and Africa (YRI) as described by Anderson and colleagues.192 
Using PLINK, a list of SNPs that were common between the LD-pruned SNP-set in the two families 
(described in Section 4.4.3), as well as, the HapMap3 data for the four ethnic populations was generated. 
Multi-allelic SNPs and A/T and C/G SNPs were excluded. 145,229 SNPs were common to the genotype 
data in both families and the HapMap3 data. Using PLINK, the genotype data for these SNPs from the 
families and HapMap3 were merged and PCA was performed using EIGENSTRAT.193 A scatter plot 
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of the first two principle components was generated using the ggplot2172 package in R.126  An example 
of the code presented in Appendix 5. 
4.4.5 Relationship testing 
To confirm the reported relationships in each family, identity-by-descent (IBD) estimation was 
conducted in PLINK, using the ‘--genome parameter’. The family-specific genotype data for the LD-
pruned SNP set (as described in section 4.4.3) was used for this analysis. For each pair of individuals 
included in the analysis, PLINK estimates the probability that zero alleles are IBD (Z0), the probability 
that one allele is IBD (Z1), and the probability that two alleles are IBD (Z2) at a given locus. PLINK 
also estimates the summary statistic PI_HAT which represents the overall IBD proportion. 
To visualise the output, 3D plots (Z0 vs Z1 vs Z2) were generated using the Plotly194 package in R. To 
easily distinguish between the relationship clusters, pairs of individuals were coloured based on their 
reported relationship. Example code is available in Appendix 6. 
4.4.6  Keratoconus mapping in KSA197  
4.4.6.1 Homozygosity mapping 
Due to the known relationship between the parents and autosomal recessive inheritance pattern of 
keratoconus in KSA197, it was hypothesised that the causative variant was located in a homozygous 
region shared by the two affected brothers. Homozygosity mapping was conducted using the online 
program HomozygosityMapper195 (available at http://www.homozygositymapper.org/) using the 
‘clean’ VCF file containing only high confidence variant calls for the 189,747 LD-pruned SNPs present 
in the family (described in 4.4.3). Homozygosity was required in both cases (KSA197.0 and 
KSA197.2), however, homozygous stretches longer than 2,000 bp that were also homozygous in the 
unaffected family members (KSA197.1, KSA197.3 and KSA197.4) were excluded. The default 
maximum block length of 250 SNPs was applied. Homozygosity scores were downloaded and plotted 
using the ggplot2 package in R as outlined in Appendix 7. In addition, runs of homozygosity were 
identified in PLINK using the binary PLINK files generated in Section 4.4.3. An example command is 
outlined in Appendix 8. This analysis identifies runs of homozygosity shared between pairs of 
individuals, however, only regions shared by the two affected brothers (KSA197.0 and KSA197.2) were 
of interest. 
4.4.6.2 Identifying regions of interest 
Regions identified by both HomozygosityMapper and PLINK’s runs of homozygosity utility were 
selected as regions of interest in KSA197 and further investigated. Haplotype estimation was used to 
confirm the homozygosity region and determine the disease-associated haplotype. 
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The binary PLINK files containing high confidence genotypes for the family members at the LD-pruned 
SNP set described in Section 4.4.3 were used for this analysis. The centimorgan (cM) positions for the 
SNPs were extracted from SHAPEIT-format recombination map files for the HapMap phase II b37 data 
(available from: http://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html#gmap) using the 
‘--cm-map’ flag in PLINK. Mega2196 was used to convert these PLINK files to MERLIN197 input format 
files. A custom R script, developed by Ms. Johanna Jones (Menzies Institute for Medical Research, 
University of Tasmania, TAS, Australia) and Mr. Michael Sumner (University of Tasmania, TAS, 
Australia), was applied to the Merlin format map files to identify and amend non-unique cM positions 
caused by the large number of included variants (Appendix 9). This script identified pairs of SNPs with 
duplicate cM position and adds a very small number (0.0000001) to the cM position of one SNP in each 
pair, resulting in unique cM positions without affecting the linkage analysis results. Unlikely genotypes 
were detected using the ‘--error’ flag in MERLIN197 and were removed from analysis using MERLIN’s 
utility program Pedwipe. 
Haplotype estimates for the relevant chromosome was subsequently generated using the most likely 
haplotype reconstruction in MERLIN. The regions of interest were manually inspected to determine the 
disease-associated haplotype. An example of the MERLIN command is outlined in Appendix 10. 
4.4.6.3 Extracting variants from the whole genome sequencing data 
SNPs and small indels called in the KSA197 family members within the region of interest were 
extracted from WGS data using BCFtools (available from https://github.com/samtools/BCFtools). 
These variants were annotated as described in Section 2.2.3. Key annotations included variant 
identification codes (IDs) from the dbSNP128 147 database; genes from the RefGene128 database; minor 
allele frequencies (MAF) from the Genome Aggregation Database129 (gnomAD); and 
deleteriousness/pathogenicity predictions for SNPs from the Combined Annotation Dependent 
Depletion134 (CADD) and Functional Analysis through Hidden Markov Models135 (FATHMM), 
specifically the FATHMM-MKL136 algorithm for SNPs and the FATHMM-indel137 algorithm for small 
insertions or deletions (indels). 
Coverage in the WGS data across the region of interest in all family members was determined using the 
depth utility in SAMTools164 (version 1.8). Using R, the mean depth and the standard deviation was 
calculated across all bases within the region and all family members. Bases with a mean depth < 10 
were written to a BED format file in R and, using the merge utility of BEDTools198 (version 2.26.0), 
consecutive bases were combined into a single region. Examples of these commands are outlined in 
Appendix 11. 
4.4.6.4 Identifying putatively disease-causing variants 
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As the inheritance pattern of keratoconus in KSA197 is consistent with recessive disease and there is a 
history of consanguinity, it was hypothesised the causative variant is present in the homozygous state 
in the two affected brothers. Segregating variants were therefore classified as those that were 
homozygous in KSA197-0 and KSA197-2, but heterozygous in the unaffected parents and child 
(KSA197-1, KSA197-3 and KSA197-4), within the region of interest. It was also hypothesised that the 
causative variant was likely to be rare in the general population and have an intermediate prediction of 
deleteriousness/pathogenicity, as it only causes disease in the homozygous state. Based on these 
hypotheses, two filtering strategies were designed to identify putatively disease-causing variants in 
KSA197. 
Filtering Strategy 1 
To address the overarching hypothesis of the study, Filtering Strategy 1 included rare protein-coding 
variants located within the homozygosity region. More specifically, putatively-disease causing variants 
were defined as those that were located in protein-coding regions, were rare (MAF < 1%) in all 
populations in gnomAD, segregated, and had either a CADD score ≥ 10 or a FATHMM score ≥ 0.5.  
Filtering Strategy 2 
As WGS data was available, Filtering Strategy 2 did not limit the analysis to protein-coding variants 
and classified putatively disease-causing variants as those that segregated, were rare (MAF < 1%) in all 
populations in gnomAD, and either had a CADD score ≥ 10 or a FATHMM score ≥ 0.5. 
4.4.7 Keratoconus mapping in KCNSW01 
4.4.7.1 Parametric linkage analysis 
Parametric linkage analysis was performed for KCNSW01 as the pattern of keratoconus in this family 
was consistent with autosomal dominant inheritance with reduced penetrance. MERLIN format files 
were generated for KCNSW01 using the method described in Section 4.4.6.2. To complete the pedigree, 
the mother of KCNSW01-2 was manually added to the PLINK files prior to the conversion of PLINK 
files to MERLIN files, however as this individual wasn’t sequenced all genotypes were coded as 
missing. As the parents in the first generation (KCNSW01-4 and KCNSW01-5) are reported as 
unaffected individuals, but have not been examined by our ophthalmologists, they were coded with an 
unknown phenotype. 
As the second and third generation of KCNSW01 was consistent with an autosomal dominant 
inheritance of keratoconus, parametric linkage analysis was performed in MERLIN using a dominant 
model with reduced penetrance (0.0001, 0.9, 1). The detection and removal of unlikely genotypes, as 
well as the parametric linkage analysis for all autosomes, was automated using a custom script presented 
in Appendix 12. The tabulated output files for each autosome were concatenated and an autosome-wide 
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plot was generated using the ggplot2 package in R. The code used to generate the plot is outlined in 
Appendix 13. 
4.4.7.2 Identifying regions of interest 
Regions of interest were defined as regions with a parametric LOD score above 2. To determine the 
disease-associated haplotypes and assess the coverage across the regions of interest, haplotype analysis 
was performed in MERLIN as outlined in Section 4.4.6.2.  
4.4.7.3 Identifying putatively disease-causing variants 
SNPs and small indels called in the KCNSW01 family members within the regions of interest were 
extracted from the WGS data using BCFtools and were annotated as previously described in Section 
4.4.6.3 (for KSA197). Segregating variants were classified as heterozygous variants that were present 
in individuals all carrying the disease-associated haplotype and absent in non-carriers, regardless of 
affection status. As two regions of interest were identified in KCNSW01, two hypotheses were 
developed to aid the identification of putatively disease-causing variants.  
The first hypothesis states that one of these regions is real and harbours the causative variant, while the 
other linked region co-segregates with disease by chance. This hypothesis is consistent with an 
autosomal dominant inheritance pattern of disease and from here on will be called the ‘autosomal 
dominant hypothesis’. Under this hypothesis, putatively disease-causing variants are likely to be rare 
and predicted to be highly deleterious/pathogenic, however two distinct filtering strategies were used 
to investigate the role of both protein-coding variation and non-coding variants. Filtering Strategy 1 
was designed to address the overarching hypothesis of the study and therefore putatively disease-
causing variants were defined as variants that were located within protein-coding regions, segregated 
with the disease-associated haplotypes, were rare (MAF < 0.01) in all populations in gnomAD, and had 
either a scaled CADD score ≥ 15 or a FATHMM-MKL/FATHMM-indel score ≥ 0.8. Filtering Strategy 
2 was very similar but did not limit the analysis to protein-coding variants. Under Filtering Strategy 2, 
putatively disease-causing variants included those that segregated with the disease-associated 
haplotypes, were rare (MAF < 0.01) in all populations in the gnomAD database and had either a scaled 
CADD score ≥ 15 or a FATHMM-MKL/FATHMM-indel score ≥ 0.8.  
The second hypothesis, the ‘digenic hypothesis’ states that keratoconus in KCNSW01 is inherited in a 
digenic fashion and therefore one variant from both of the disease-linked regions is required, and only 
in combination, cause keratoconus. Qiagen’s Ingenuity Pathways Analysis (IPA) was used to identify 
published interactions between pairs of genes located within the risk-associated haplotypes. Gene sets 
containing the list of genes located within the regions of interest were added to the ‘my pathways’ tool 
and the Ingenuity Knowledge Base was interrogated to identify direct and indirect interactions between 
pairs of gene products, including protein-protein binding interactions and gene expression changes. 
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Under the digenic hypothesis, putatively disease-causing variants were not required to both be rare, but 
in combination must be rare, therefore no MAF filter was applied under this hypothesis as even the 
most common variant observed together with a novel variant is a rare event. Furthermore, as it is 
hypothesised that neither variant is sufficient to cause disease in isolation, a lower threshold of 
deleteriousness/pathogenicity was considered. Therefore, putatively disease-causing variants were 
defined as those that were located within potentially interacting genes (or located the flanking non-
coding regions) with a scaled CADD score ≥ 10 and/or a FATHMM-MKL/FATHMM-indel score ≥ 
0.5. 
4.4.8 Interrogating putatively disease-causing variants identified in the families 
Putatively disease-causing variants were further prioritised manually as described in Section 2.2.4. 
 
 RESULTS 
4.5.1 Determining ancestry using principle components analysis  
The PCA analysis demonstrated both families were of largely European ancestry (Figure 4.4). The 
individuals cluster in family groups on the European-African axis as expected, with the KSA197 family 
members clustering slightly closer to the Northern and Western European population from HapMap3 
than KCNSW01. 
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Figure 4.4 – A scatter plot for the first two principle components including individuals in 
HapMap Phase III and family members from KCNSW01 and KSA197. 
CEU = Utah residents with Northern and Western European ancestry; CHB = Han Chinese living in 
Beijing, China; JPT = Japanese living in Tokyo, Japan; YRI = Yoruba living in Ibadan, Nigeria. 
 
4.5.2 KSA197 
4.5.2.1 Relationship testing 
The recorded relationships for KSA197 were confirmed by IBD estimation (Figure 4.5). The full IBD 
estimates for each pair of individuals are outlined in Appendix 14. As expected, KSA197.1 and 
KSA197.3 were related (PI-HAT = 0.40), however, all PI-HAT estimates were more inflated than 
expected, indicating that a family history of consanguineous unions is likely. 
 
70 
 
 
Figure 4.5  – A 3D plot of the PLINK identity-by-descent estimates for the KSA197 family 
members. 
The coloured data points indicate the relationship between a pair of individuals where green= the 
parents (second cousins), blue = avuncular pairs, pink = grandparent-grandchild pairs, orange = full 
sibling pairs, and yellow = parent-offspring pairs. This plot was generated using the Plotly194 package 
in R.126 An online and interactive version of this plot is available at https://plot.ly/~semlucas/7. 
 
4.5.2.2 Homozygosity mapping 
A region on chromosome 16 was identified by both HomozygosityMapper and the runs of 
homozygosity analysis in PLINK. A 1.2 Mb region between rs237135 and rs1363749 (spanning 
chr16:26642059-27827381) obtained the maximum homozygosity score of 342 using 
HomozygosityMapper (Figure 4.6). Similarly, the region between rs237135 and rs4787993 
(chr16:26642059-27827858) was flagged by PLINK as a run of homozygosity shared by the two 
affected brothers (KSA197.0 and KSA197.2; Table 4.2). This was the only run of homozygosity 
identified by PLINK that was shared by the brothers. The region identified by PLINK encompasses the 
homozygous region identified by HomozygosityMapper, however, the run of homozygosity region 
extends an additional 477 bp downstream. Haplotype analysis in MERLIN confirmed the homozygous 
region shared by KSA197.0 and KSA197.2 extended from rs237135 to rs1363749 (chr16:26642059-
27827381) and this region was selected as a region of interest for further investigation. 
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Table 4.2 – The run of homozygosity shared by KSA197.0 and KSA197.2 
Region Upstream 
flanking SNP 
Downstream 
flanking SNP 
Region Size 
(kb) 
Number of 
SNPs in run 
chr16:26642059–27827858 rs237135 rs4787993 1185.8 174 
 
 
72 
 
 
 
Figure 4.6 – Autosome-wide homozygosity scores for KSA197.  
Homozygosity scores were obtained from HomozygosityMapper195 and plotted using the ggplot2172 package in R.126 
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4.5.2.3 Coverage across the homozygous region 
The homozygous region (chr16:26642059-27827381) had mean depth of 38.4 reads (standard 
deviation, sd = 5.5) across the five KSA197 family members. Only 2,263 bases within this region had 
a mean read depth below 10 (0.19% of bases). These regions are likely to have insufficient coverage 
for high confidence variant calls in the family members, may or indicate deletions in multiple family 
members. 
4.5.2.4 Identifying putatively disease-causing variants 
The homozygosity region harboured 204 SNPs, 17 insertions and 29 deletions that segregated with 
keratoconus in KSA197 (Table 4.3). It’s important to note that 306 indels were called in the 
heterozygous state in the two affected brothers, despite being located within the homozygosity region. 
Upon close inspection, however, all of these heterozygous calls were located at repetitive regions and 
were largely of poor confidence with a read depth below 10 and/or a quality score below 20. 
Filtering Strategy 1 
No variants fulfilled the criteria for Filtering Strategy 1. In fact, only one exonic variant segregated with 
disease within the homozygosity region: a nonsynonymous variant in KIAA0556 (Table 4.4). This 
variant, however, has a MAF ≥ 1.3% in the non-Finnish European, admixed American and ‘Other’ 
populations in gnomAD. Furthermore, the variant has been observed in the homozygous state in 43 
individuals in the non-Finnish European population in gnomAD corresponding to a frequency of 6.8 
x10-4 which is roughly equal to the overall prevalence of keratoconus (1 in 1,500) in Europeans. As 
keratoconus is a highly heterogeneous disease, and the causative variant in KSA197 may be private to 
this family or contribute to a very small proportion of keratoconus cases, this variant is too common to 
account for disease in this family. 
Filtering Strategy 2 
Ten variants were rare, including 5 novel variants, and these variants are presented in Table 4.5. Of the 
ten rare variants, only one fulfilled the criteria for putatively disease-causing under Filtering Strategy 
2: a novel SNP between C16orf82 and KDM8 (chr16:27115706C>A). This variant obtained a CADD 
score of 22, a FATHMM score of 0.96 and occurs within a DNaseI hypersensitive region identified in 
osteoblasts. While the alternate allele (A) identified in KSA197 is not observed in other vertebrate 
species, the reference allele is a ‘T’ in dog, wallaby and green sea turtle and therefore this site is not 
completely conserved across vertebrates. 
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Table 4.3 – A summary of the segregating variants identified in KSA197 within the chromosome 16 homozygous region. 
 Variant Type Variant Location Highly Prioritised Variants 
Region SNPs Ins. Del. Total 
Exonic 
(NC) 
Intronic 
(NC) 
UTRs Intergenic Novel Rare 
CADD ≥ 10 || 
FATHMM ≥ 0.5  
FS1 FS2 
chr16:26642059-27827381 204 17 29 250 1 (0) 21 (1) 1 227 5 10 24 0 1 
SNPs = the number of single nucleotide polymorphisms. 
Ins. = the number of insertions. 
Del. = the number of deletions. 
NC = the number of non-coding RNA variants included in the variant counts for exonic and intronic variants. 
UTRs = the number of variants located in untranslated regions (either 3’ or 5’). 
Novel = the number of variants without minor allele frequencies in any of the populations in the gnomAD database, Kaviar or 1KGP (August 2015 release). 
Rare = the number of variants with a minor allele frequency (MAF) less than 1% in all populations of the gnomAD database. 
CADD ≥ 10 || FATHMM ≥ 0.5 = the number of variants with a scaled CADD score of at least 10 and/or a FATHMM-MKL/FATHMM-indel score of at least 
0.5. 
FS1 = the number of variants that fulfilled the criteria for putatively disease-causing variants under Filtering Strategy 1 (rare protein-coding). 
FS2 = the number of variants that fulfilled the criteria for putatively disease-causing variants under Filtering Strategy 2 (not limited to protein-coding). 
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Table 4.4 – The segregating exonic variant located within the homozygosity region in KSA197. 
Position Ref Alt SNP ID* Gene Variant gnomAD max gnomAD NFE CADD FATHMM 
chr16:27784497 G A rs117316062 KIAA0556 c.G4276A; p.(E1426K) 0.0245 0.0245 24.60 0.96 
Ref = reference allele. 
Alt = alternate allele. 
Variant = the nucleotide variant and inferred protein variant are presented. 
gnomAD max = the maximum alternate allele frequency observed across all populations in the gnomAD database. 
gnomAD NFE = the non-Finnish European population of the gnomAD database. 
CADD = the scaled CADD score. 
FATHMM = FATHMM score for coding variants. 
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Table 4.5 – Rare, segregating variants identified in KSA197 within the chromosome 16 homozygosity region.  
Position Ref Alt SNP ID Gene gnomAD max gnomAD NFE CADD FATHMM 
chr16:26760228 G A rs758556074 HS3ST4 – C16orf82 0.0004 4.00x10-4 5.95 0.1159 
chr16:26777357 - AGATGATAGAT
AGATAGATA 
novel HS3ST4 – C16orf82 0.0000 0.0000 0.22 NA 
chr16:26867292 G T novel HS3ST4 – C16orf82 0.0000 0.0000 0.10 0.04964 
chr16:26934160 T C novel HS3ST4 – C16orf82 0.0000 0.0000 1.97 0.07106 
chr16:26958687 A G rs141230258 HS3ST4 – C16orf82 0.0099 0.0052 3.14 0.09619 
chr16:27030292 C T rs183043552 HS3ST4 – C16orf82 0.0010 0.0000 1.48 0.06647 
chr16:27115706 C A novel C16orf82 – KDM8 0.0000 0.0000 22.00 0.96131 
chr16:27119478 G A novel C16orf82 – KDM8 0.0000 0.0000 5.39 0.0805 
chr16:27432490 T G NA IL21R (intronic) 0.0003 3.00x10-4 6.87 0.23092 
chr16:27659545 T G NA KIAA0556 (intronic) 0.0001 1.00x10-4 3.14 0.06869 
Position = position refers to the position of SNPs and the start position for indels. 
Ref = reference allele. 
Alt = alternate allele. 
gnomAD max = the maximum alternate allele frequency observed across all populations in the gnomAD database. 
gnomAD NFE = the non-Finnish European population of the gnomAD database. 
CADD = the scaled CADD score. 
FATHMM = FATHMM score for non-coding variants. 
NA = this variant wasn’t attributed an ID in the dbsnp 147 database. 
The variant that fulfilled the criteria for putatively disease-causing under Filtering Strategy 2 is bold. 
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4.5.3 KCNSW01 
4.5.3.1 Relationship testing 
The IBD estimation confirmed all reported relationships for KCNSW01 (Figure 4.7). The full IBD 
estimates for each pair of individuals are outlined in Appendix 14. As seen in the plot, avuncular pairs 
(uncle/aunt- nephew pairs) and grandparent-grandchild pairs clustered together as they are both second 
degree relationships, but all other relationship groups cluster separately. The parents obtained a PI-HAT 
of 0.19, thus demonstrating that they are related, but by more than 2 degrees of separation. 
 
Figure 4.7 – A 3D plot of the PLINK identity-by-descent estimates for the KCNSW01 family 
members. 
The coloured data points indicate the relationship between a pair of individuals where green= 
unrelated pairs (the parents), blue = avuncular pairs, pink = grandparent-grandchild pairs, orange = 
full sibling pairs, and yellow = parent-offspring pairs. This plot was generated using the Plotly194 
package in R.126 An online and interactive version of this plot is available at 
https://plot.ly/~semlucas/9. 
 
4.5.3.2 Parametric linkage analysis 
Linkage analysis identified two regions with maximum LOD scores of 2.06: a 1.5 Mb region between 
rs2009472 and rs3213636 at 17q12 and a 10.2 Mb region flanked by rs6040904 and rs6041016 at 
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20p13-12.2 (Figure 4.8). Analysis of the haplotypes at these loci demonstrated that the risk-associated 
haplotype at 17q12 was inherited from the matriarch (KCNSW01-5), the risk-associated haplotype at 
20p13-12.2 was inherited from the patriarch (KCNSW01-4), and all individuals with keratoconus have 
inherited both of these haplotypes (Figure 4.9). The only unaffected individual sequenced in the second 
generation, KCNSW01-9, did not inherit either of the risk-associated haplotypes. Based on these 
observations, segregating variants for the 17q12 locus were defined as those that were present in all 
affected individuals and KCNSW01-5, but absent in KCNSW01-9. Similarly, segregating variants at 
the 20p13-12.2 locus were variants that were observed in all affected individuals and KCNSW01-5, but 
absent in KCNSW01-9.  
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Figure 4.8 – Autosome-wide parametric linkage analysis results for KCNSW01. 
The dashed line indicates a LOD score of 0 and the red line indicates a LOD score of -2. Any region that does not surpass a LOD score of -2 has significant 
evidence against linkage. LOD scores were generated using parametric linkage in MERLIN197 and plotted with the ggplot2172 package in R.126 
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Figure 4.9 – The KCNSW01 pedigree with the addition of each individual’s haplotypes at 17q12 and 20p13-12.2. 
Females are indicated by circles and males by squares. These symbols are coloured black for individuals with keratoconus and white for unaffected 
individuals. Red arrows indicate that DNA was collected and WGS data was generated. Haplotypes are shown below the individual ID, with 17q12 on the left 
of the central bar and 20p13-12.2 on the right. Risk-associated haplotypes are coloured black and all other haplotypes are white. All individuals with 
keratoconus carry both risk-associated haplotypes. 
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4.5.3.3 Coverage across the linkage regions 
For the chromosome 17 linkage region, a mean depth of 34.1 reads (sd = 3.1) was obtained across the 
eleven sequenced KCNSW01 family members. Within this region, 649 bases obtained a mean depth 
below 10 (0.04%). Similarly, the chromosome 20 linkage region obtained a mean depth of 34.6 (sd = 
4.0) across the eleven individuals. A total of 43,133 bases within this region had a mean depth below 
10 reads (0.42%). This included a 25,521 bp region located at chr20:1561108-1586628.  
4.5.3.4 Identifying putatively disease-causing variants  
A total of 3,023 variants segregated with the two disease-associated regions identified in KCNSW01, 
17q12 and 20p13-12.2. These variants are summarised in Table 4.6.  
 
The autosomal dominant hypothesis 
Filtering Strategy 1 
A total of 23 protein-coding variants were identified across the two linkage regions (Table 4.7), 
however, none fulfilled the criteria for putatively disease-causing under Filtering Strategy 1. All but 
one of the exonic variants were common in at least one population in gnomAD. The single rare variant 
(rs370777154), located in the zinc finger gene, ZNF830, was a synonymous variant and was not 
predicted to be likely deleterious/pathogenic using either CADD or FATHMM. 
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Table 4.6 – A summary of number of the segregating variants identified in KCNSW01. 
 Variant Type Variant Location Highly Prioritised Variants 
Region SNPs Ins. Del. Total 
Exonic 
(NC) 
Intronic 
(NC) 
UTRs Intergenic Novel Rare 
CADD ≥ 10 || 
FATHMM ≥ 0.5 
FS1 FS2 
chr17:32949698-34461869 255 28 23 306 7 (2) 80 (3) 5 214 2 13 21 0 3 
chr20:1232032-11479234 2,201 222 294 2,717 42 (24) 1,237 (257) 46 1,392 44 172 216 0 8 
SNPs = the number of single nucleotide polymorphisms. 
Ins. = the number of insertions. 
Del. = the number of deletions. 
NC = indicates the total number of non-coding RNA variants included in the variant counts for exonic and intronic variants. Exonic and intronic variants 
include variants located in protein coding genes as well as non-coding RNA genes. 
UTRs = the number of variants located within untranslated regions (either 3’ or 5’). 
Novel = the number of variants without minor allele frequencies in any of the populations in the gnomAD database, Kaviar or IKGP (August 2015 release). 
Rare = the number of variants with a minor allele frequency (MAF) less than 1% in all populations of the gnomAD database. 
CADD ≥ 10 || FATHMM ≥ 0.5 = the number of variants with a scaled CADD score of at least 10 and/or a FATHMM-MKL/FATHMM-indel score of at least 
0.5. This filter is reminiscent of the digenic hypothesis although isn’t limited to genes with known interactions. 
FS1 = the number of variants that fulfilled the criteria for putatively disease-causing variants under Filtering Strategy 1 (rare protein-coding). 
FS2 = the number of variants that fulfilled the criteria for putatively disease-causing variants under Filtering Strategy 2 (not limited to protein-coding). 
 
 
Table 4.7 – Exonic variants that segregated with the disease-associated haplotypes identified in KCNSW01. 
Position Ref Alt Gene Variant SNP ID gnomAD 
max 
gnomAD 
NFE 
CADD FATHMM 
chr17:33288912 C T ZNF830 c.C327T; p.(D109D) rs370777154 0.0010 0.0001 6.61 0.01 
chr17:33998802 G C AP2B1 c.G2061C; p.(V687V) rs1049379 0.5286 0.5135 5.89 0.90 
chr17:34416537 G A CCL3 c.C180T; p.(P60P) rs1130371 0.3486 0.2409 11.63 0.02 
chr17:34432663 A G CCL4 c.A237G; p.(E79E) rs1049807 0.3180 0.2362 0.38 0.01 
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Position Ref Alt Gene Variant SNP ID gnomAD 
max 
gnomAD 
NFE 
CADD FATHMM 
chr17:34432664 T A CCL4 c.T238A; p.(S80T) rs1719152 0.2909 0.2355 1x10-3 0.03 
chr20:1538266 G A SIRPD c.C34T; p.(L12L) rs11697395 0.3013 0.2268 4.18 0.03 
chr20:1546805 G A SIRPB1 c.C1193T; p.(A398V) rs62623705 0.2173 0.1462 17.08 0.01 
chr20:1552457 G A SIRPB1 c.C660T; p.(D220D) rs16995332 0.2185 0.1512 6.91 <0.01 
chr20:1600524 T C SIRPB1 c.A67G; p.(R23G) rs1535882 0.4522 0.3570 0.09 0.01 
chr20:2082767 G A STK35 c.G240A; p.(Q80Q) rs6106228 0.8360 0.0358 4.62 0.11 
chr20:2291722 A C TGM3 c.A487C; p.(I163L) rs6048066 0.3569 0.0013 22.90 0.95 
chr20:2638579 T C NOP56 c.T1424C; p.(M475T) rs6753 0.5534 0.2762 <0.01 0.02 
chr20:2638880 G A NOP56 c.G1725A; p.(A575A) rs61752514 0.0220 6.67x10-5 6.94 0.06 
chr20:2638882 T C NOP56 c.T1727C; p.(V576A) rs5856 0.5534 0.2782 <0.01 0.01 
chr20:2945759 C T PTPRA c.C326T; p.(P109L) rs1178027 0.5708 0.1038 15.61 0.50 
chr20:3452041 C T ATRN c.C287T; p.(A96V) rs75653676 0.0579 0.0003 25.00 0.56 
chr20:4768282 G A RASSF2 c.C810T; p.(Y270Y) rs6052876 0.1469 0.0002 5.06 0.27 
chr20:5903067 T A CHGB c.T277A; p.(S93T) rs6085324 0.3052 0.3775 0.01 0.18 
chr20:5903323 G A CHGB c.G533A; p.(R178Q) rs910122 0.3932 0.5835 <0.01 <0.01 
chr20:5903848 C G CHGB c.C1058G; p.(A353G) rs236152 0.3949 0.6281 <0.01 0.03 
chr20:5903894 A G CHGB c.A1104G; p.(E368E) rs236153 0.3948 0.6286 0.99 0.01 
chr20:5904040 G A CHGB c.G1250A; p.(R417H) rs742711 0.3047 0.3776 <0.01 <0.01 
chr20:9288522 G A PLCB4 c.G61A; p.(A21T) rs6077510 0.6613 0.7020 16.27 0.96 
Ref = reference allele. 
Alt = alternate allele. 
gnomAD max = the maximum alternate allele frequency observed across all populations in the gnomAD database. 
gnomAD NFE = the alternate allele frequency in the non-Finnish European population of gnomAD. 
CADD = the scaled CADD score. 
FATHMM = FATHMM-MKL score for noncoding variants or FATHMM-indel for insertions or deletions. 
The rare variant is bold.
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Filtering Strategy 2 
Eleven variants fulfilled the criteria for putatively disease-causing under Filtering Strategy 2, with three 
SNPs identified on 17q12 and eight variants at 20p13-12.2 (Table 4.8). 
In terms of high CADD and FATHMM-MKL scores, the top variant located in the 17q12 region is 
rs146598068. This appears to be largely driven by the highly conserved nature of the nucleotide. The 
rs188934690 variant is located in a DNaseI hypersensitive region identified in retinoblastoma tissue, 
which is cancerous eye tissue derived from the ectodermal lineage. An intronic SNP, rs550832436, is 
located within a weak enhancer in both epidermal keratinocytes (NHEK cells) and mammary epithelial 
cells (HMEC cells), however the alternate allele (T) is the reference allele in mouse and rat.  
Two variants within the 20p13-12.2 region obtained CADD scores above 20: a novel SNP 
(chr20:8327708G>A) located in an intron of the gene encoding phospholipase C beta 1 (PLCB1) and a 
previously reported SNP, rs145738299, which is located between a non-coding RNA gene, PDYN-AS1 
and the gene encoding serine/threonine kinase 35 (STK35). Both of these variants are highly conserved, 
however, the alternate alleles observed in this family are the reference alleles in other vertebrate species: 
the A allele at the novel SNP is observed in aardvark and opossum and the T allele at rs145738299 is 
present in pacific walrus. Another notable variant located between MIR8062 – HAO1, rs140651266, 
obtained the highest FATHMM score across both regions with a score of 0.99. This variant is located 
in a DNaseI Hypersensitivity cluster identified in 16 different tissues, including skin fibroblasts and 
melanocytes, conjunctival fibroblasts (eye tissue derived from the ectoderm), as well as, epithelial and 
connective tissues. 
The most compelling variant identified under Filtering Strategy 2 was a variant located in the 5’ 
untranslated region (UTR) of the spermine oxidase gene, SMOX. The SMOX variant, c.-224C>T, occurs 
at the second transcribed nucleotide in the first (entirely untranslated) exon of the gene. This variant is 
positioned within a DNaseI Hypersensitivity cluster in 120 of the 125 cell-types assessed in ENCODE 
and overlaps 18 ChIP-seq peaks from the transcription factor ChIP-seq data for 161 factors from 
ENCODE. This variant is also rare with a maximum allele frequency of 0.38 %, observed in the African 
population of gnomAD. 
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Table 4.8 – Putatively disease-causing variants identified under the autosomal dominant hypothesis in KCNSW01. 
Position Ref Alt Nearest Gene(s) SNP ID gnomAD 
max 
gnomAD 
NFE 
CADD FATHMM 
chr17:33012429-33012429 G A TMEM132E – CCT6B rs188934690 0.0081 0.0029 10.84 0.95 
chr17:33068005-33068005 G A TMEM132E – CCT6B rs146598068 0.0031 0.0021 21.70 0.97 
chr17:33351771-33351771 C T RFFL/RAD51L3-RFFL (intronic) rs550832436 0.0010 6.00x10-4 15.24 0.25 
chr20:2007424-2007424 - G PDYN-AS1 – STK35 novel 0.0033 0.0000 15.05 0.00 
chr20:2009593-2009593 C T PDYN-AS1 – STK35 rs145738299 0.0093 0.0000 22.20 0.97 
chr20:2617106-2617115 ACACACACAC - TMC2 (intronic) novel 0.0000 0.0000 17.23 0.00 
chr20:3398935-3398935 T G C20orf194 – ATRN rs112827558 0.0023 0.0000 15.35 0.78 
chr20:4129427-4129427 C T SMOX (c.-224C>T) NA 0.0038 2.00x10-4 15.07 0.28 
chr20:5945857-5945857 T C MCM8 (intronic) NA 0.0010 0.0000 12.46 0.97 
chr20:7497499-7497499 T C MIR8062 – HAO1 rs140651266 0.0088 0.0000 16.73 0.99 
chr20:8327708-8327708 G A PLCB1 (intronic) novel 0.0000 0.0000 20.90 0.96 
Ref = reference allele. 
Alt = alternate allele. 
gnomAD max = the maximum alternate allele frequency observed across all populations in the gnomAD database. 
gnomAD NFE = the alternate allele frequency in the non-Finnish European population of gnomAD. 
CADD = the scaled CADD score. 
FATHMM = FATHMM-MKL score for non-coding variants or FATHMM-indel for insertions or deletions. 
NA = this variant wasn’t attributed an ID in the dbsnp 147 database. 
The variant identified in the 5’ UTR of SMOX variant is in bold. 
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The digenic hypothesis 
Ingenuity Pathways Analysis identified protein-protein interactions between the genes that encode 
chaperonin-containing T-complex polypeptide 1, subunit 6B (CCT6B) and SMOX,199 as well as, DNA 
ligase 3 (LIG3) and NSFL1 cofactor (NSFL1C).200 Additionally, there was evidence that the chemokine 
gene, CCL5, expression is influenced by mitochondrial antiviral signalling protein (MAVS),201-205 signal 
regulatory protein alpha (SIRPA)206 and prion protein (PRNP).207 No protein-coding variants located 
within any of these eight genes segregated with the disease-associated haplotypes and thus segregating, 
non-protein-coding variants located within the gene or the flanking intergenic regions were further 
investigated (Table 4.9). 
For the genes located within the 17q12 linkage region, seven variants were identified downstream of 
CCT6B (between TMEM132E and CCT6B), but no variants were identified within the non-coding 
regions in or around LIG3 or CCL5. As no variants were identified in or around LIG3 or CCL5, 
bioinformatic investigations focussed on the SMOX and CCT6B variants, as these genes were the only 
pair of interacting genes likely to contribute to keratoconus in this family under the present hypothesis. 
The 5’ UTR SMOX variant previously identified in Filtering Strategy 2 for the autosomal dominant 
hypothesis was the only SMOX variant identified. As this variant was rare in all populations of 
gnomAD, it could therefore occur in combination with either a rare or common variant under the digenic 
hypothesis. Of the seven variants identified downstream of CCT6B (TMEM132E – CCT6B), three are 
the major allele in the non-Finnish European population of gnomAD with alternate frequencies above 
50%, two variants rs35933743 and rs4795019 were common with maximum MAFs of 24% and 35% 
(respectively), and two of the variants were rare (rs188934690 and rs146598068).  
All three variants near CCT6B with alternate frequencies above 50% – rs1006840, rs1860201, and 
rs1860200 – are eQTLs for the non-coding RNA gene, RP11-1094M14.8, in skin (not sun exposed). 
The rs35933743 variant is located in a DNaseI hypersensitivity cluster observed in six cells types across 
all three tissue lineages (mesoderm, ectoderm and endoderm) and the other common variant, rs4795019, 
is located within a weak enhancer in embryonic stem cells derived from the inner cell mass (H1-hESC). 
The two rare variants, rs188934690 and rs146598068, were both also identified as putatively causative 
variants under the autosomal dominant hypothesis. The rs146598068 variant has the highest estimates 
of deleteriousness/pathogenicity for the CCT6B variants, largely owing to the high level of conservation 
of the nucleotide. This variant is also located within a DNaseI hypersensitivity cluster in astrocytes 
derived from the hippocampus. As outlined previously, rs188934690 is within a DNaseI hypersensitive 
cluster observed in a cancerous eye tissue. 
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Table 4.9 – Putatively disease-causing variants identified in KCNSW01 under the digenic hypothesis. 
Position Ref Alt Nearest Gene(s) SNP ID gnomAD max gnomAD NFE CADD FATHMM 
chr17:32970484 T G TMEM132E – CCT6B rs35933743 0.2404 0.1367 12.97 0.11 
chr17:32998000 T G TMEM132E – CCT6B rs4795019 0.3474 0.2271 19.62 0.97 
chr17:33012429 G A TMEM132E – CCT6B rs188934690 0.0081 0.0029 10.84 0.95 
chr17:33057079 G A TMEM132E – CCT6B rs1006840 0.6216 0.5222 10.14 0.09 
chr17:33057467 A G TMEM132E – CCT6B rs1860201 0.6182 0.5186 16.54 0.15 
chr17:33057477 C A TMEM132E – CCT6B rs1860200 0.6156 0.5177 15.13 0.17 
chr17:33068005 G A TMEM132E – CCT6B rs146598068 0.0031 0.0021 21.70 0.97 
chr20:1422862 T C NSFL1C (UTR3; c.*1,532A>G) rs116233763 0.0199 0.0001 11.41 0.20 
chr20:1796729 A G LOC100289473 – SIRPA rs113396592 0.0733 0.0107 14.49 0.11 
chr20:1798513 C G LOC100289473 – SIRPA rs8120497 0.0795 0.0105 10.10 0.81 
chr20:1802552 A G LOC100289473 – SIRPA rs76388170 0.0828 0.0111 16.45 0.18 
chr20:1914782 T C SIRPA (intronic) rs6045522 0.4372 0.2971 7.918 0.83 
chr20:3822099 A G AP5S1 – MAVS rs139856798 0.0533 0.0169 10.16 0.30 
chr20:3851951 T C MAVS (UTR3; c.*5,157T>C) rs6515831 0.4735 0.4586 11.70 0.48 
chr20:4129427 C T SMOX (UTR5; c.-224C>T) NA 0.0038 0.0002 15.07 0.28 
chr20:4288521 T C ADRA1D – PRNP rs8117034 0.1806 0.0302 10.21 0.35 
chr20:4296669 A - ADRA1D – PRNP rs142211335 0.1814 0.0304 19.41 0.01 
chr20:4296675 A G ADRA1D – PRNP rs116181036 0.1813 0.0302 17.02 0.27 
chr20:4306646 G A ADRA1D – PRNP rs4815687 0.5951 0.0884 10.92 0.85 
chr20:4403389 G T ADRA1D – PRNP rs75400769 0.0176 0.0001 5.796 0.68 
chr20:4426668 C G ADRA1D – PRNP rs79099834 0.0226 0.0001 11.98 0.26 
chr20:4436181 C T ADRA1D – PRNP rs115014683 0.0220 0.0001 7.358 0.51 
chr20:4451485 A G ADRA1D – PRNP rs16989700 0.0590 6.66 x10-5 12.23 0.21 
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chr20:4485701 A G ADRA1D – PRNP rs60514595 0.2031 0.0014 13.31 0.09 
chr20:4493690 C T ADRA1D – PRNP rs73893468 0.0504 0.0003 12.90 0.69 
chr20:4502865 A G ADRA1D – PRNP rs374847600 0.3372 0.0036 11.11 0.35 
chr20:4509265 A C ADRA1D – PRNP rs11906771 0.1714 0.0005 10.74 0.57 
chr20:4509511 T - ADRA1D – PRNP rs141573094 0.0614 0.0003 11.52 0.00 
chr20:4523958 T C ADRA1D – PRNP rs73893488 0.0628 0.0003 11.33 0.40 
chr20:4567204 A G ADRA1D – PRNP rs11906818 0.0720 0.0005 7.333 0.87 
chr20:4634737 A T ADRA1D – PRNP rs113394511 0.1671 0.0504 10.36 0.17 
chr20:4644408 T C ADRA1D – PRNP rs74799977 0.2951 0.1997 10.95 0.39 
chr20:4646394 T A ADRA1D – PRNP rs75731019 0.0522 0.0001 10.53 0.11 
chr20:4648760 TT - ADRA1D – PRNP rs796775108 0.0538 0.0023 11.12 0.00 
chr20:4652694 A G ADRA1D – PRNP rs73896119 0.1190 0.0175 8.63 0.69 
chr20:4652735 A C ADRA1D – PRNP rs16989990 0.1193 0.0176 15.82 0.11 
Ref = reference allele. 
Alt = alternate allele. 
Position = the position of SNPs or the start position for indels. 
gnomAD max = the maximum alternate allele frequency observed across all populations in the gnomAD database. 
gnomAD NFE = the alternate allele frequency in the non-Finnish European population of gnomAD. 
CADD = the scaled CADD score. 
FATHMM = FATHMM-MKL score for non-coding variants and FATHMM-indel scores for indels.  
NA = this variant wasn’t attributed an ID in the dbsnp 147 database. 
Variants in CCT6B and SMOX are bold. 
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 DISCUSSION 
This study identified two novel regions linked to keratoconus and replicated a third: a single 
homozygous region on 16p12.1 was identified in the two affected brothers in a family with 
consanguinity (KSA197), and two regions (17q12 and 20p13-12.2) showed equal evidence for linkage 
to keratoconus in a family displaying apparent autosomal dominant disease with reduced penetrance 
(KCNSW01). The inheritance pattern of the two disease-associated haplotypes throughout the 
KCNSW01 pedigree was strongly indicative of digenic inheritance, with all affected individuals 
carrying both disease-linked regions. This suggests that each disease-associated haplotype may harbour 
a single variant that only cause keratoconus when inherited together, with neither sufficient to cause 
disease in isolation.  
KCNSW01 is the second family demonstrating strong evidence of digenic inheritance of keratoconus. 
Another family in our Australian keratoconus cohort previously showed likely digenic inheritance of 
keratoconus with parametric linkage analysis identifying two suggestive linkage regions with equal 
LOD scores: 1p36.23-36.21 and 8q13.1-q21.11.71 These regions reached significance when analysed 
together under a digenic model (LOD = 3.4) and all family members with keratoconus carried both 
disease-associated haplotypes.71 Similarly, all affected family members in KCNSW01 in the present 
study carried both disease-associated haplotypes at 17q12 and 20p13-12.2, while each parent who 
carried only one was reported as unaffected. The 20p13-12.2 linkage region identified in KCNSW01 is 
completely encompassed by a previously published linkage region identified in another family in which 
two suggestive regions were identified.66 The previous study identified suggestive linkage regions at 
2q13-14.3 and 20p13-12.2 (LOD = 2.4) in a large Ecuadorian family, however unlike KCNSW01, the 
inheritance pattern of the disease-associated haplotypes did not clearly indicate digenic inheritance.66 
In the Ecuadorian family the inheritance pattern of the disease-associated haplotype on 2q13-14.3 
suggests autosomal dominant inheritance with reduced penetrance, with all affected individuals and two 
unaffected individuals carrying the risk-associated haplotype, while the segregation of the disease-
associated haplotype at 20p13-12.2 is less clear with only eight of the nine cases sharing the same 
haplotype, along with three individuals who are unaffected or have an unknown phenotype. In both the 
Ecuadorian family and KCNSW01, it is possible that the 20p13-12.2 region showed suggestive 
association with keratoconus by chance, however the fact that the same region was identified in two 
unrelated families – each with a second, equally associated region – is noteworthy. This adds evidence 
for the involvement of variation within this region in keratoconus susceptibility. Potentially, this region 
harbours a variant with an intermediate effect size, and a second variant is required to trigger 
keratoconus development. 
Prioritising variants in keratoconus is challenging, even in families with strong Mendelian inheritance 
patterns such as KSA197 and KCNSW01, as little is known about the types of genes or variants 
90 
 
involved in the disease. This is made even more challenging in non-coding portions of the genome due 
to our limited understanding of these regions in normal biology. To aid the prioritisation of variants 
within the discovered regions of interest, two in silico prediction tools were used in combination: 
CADD134 and FATHMM135. Both of these tools aggregate multiple annotations (including nucleotide 
conservation and known regulatory regions) into a single metric predicting deleteriousness or 
pathogenicity and are commonly used to help differentiate between variants that are likely to be 
functional and those that are likely to be benign. Scaled CADD scores above 10 correspond to the top 
10% most deleterious substitutions possible in the human genome and scores above 20 correspond to 
the top 1% and so on.134 The scores from the FATHMM algorithms range from 0 to 1 with values of 
0.5 or above predicted to be deleterious and the higher the score, the greater the confidence that the 
variant is functional.136 CADD is considered the best tool for detecting pathogenic variants in protein 
coding regions of the genome, while the FATHMM-MKL algorithm outperforms CADD and other 
commonly used in silico tools for the pathogenicity prediction of variants located in the non-coding 
regions.208 Based on this, both tools were used in combination to limit the exclusion of true disease-
causing variation. Unlike the previous generation of pathogenicity prediction tools such as SIFT132 and 
PolyPhen2,133 CADD and FATHMM score both coding and non-coding variation, as well as, indels 
(FATHMM uses an indel specific algorithm: ‘FATHMM-indel’), allowing for consistency across WGS 
data. 
Two separate hypotheses were used to interrogate putatively disease-causing variation within the two 
regions of interest in KCNSW01. The autosomal dominant hypothesis was used to identify rare variants 
with high predictions of deleteriousness or pathogenicity under the assumption that only one variant 
was required to cause keratoconus in KCNSW01. Two filtering strategies were used to identify 
putatively disease-causing variants under this hypothesis, with Filtering Strategy 1 limiting the analysis 
to protein-coding variants and Filtering Strategy 2 including non-coding variation. Both of these 
strategies required the putatively disease-causing variants to obtain high estimates of pathogenicity or 
deleteriousness a scaled CADD score of at least 15 and/or a FATHMM-MKL/FATHMM-indel score 
of 0.8. This CADD threshold was suggest by the authors for identifying potentially pathogenic variants 
as it is the median value for all possible splice site changes and nonsynonymous variants.134 
Commensurate with the autosomal dominant hypothesis, a threshold of 0.8 was applied to the 
FATHMM algorithms to identify likely deleterious variants. No putatively disease-causing variants 
were identified under Filtering Strategy 1, suggesting that rare protein-coding variants are unlikely to 
be the cause of keratoconus in this family. In contrast, Filtering Strategy 2 identified three within the 
17q12 linkage region and eight in the 20p13-12.2 region. Conversely, the digenic hypothesis assumed 
that both linkage regions harbour a variant, that only cause keratoconus in combination and thus focused 
on variants located within or near pairs of genes (one from each of the regions of interest) with 
documented interactions. Under this hypothesis, putatively disease-causing variants were identified 
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using lower thresholds for deleteriousness and pathogenicity – a scaled CADD score of 10 or above 
and/or FATHMM score of at least 0.5 – to account for the fact that these variants are not sufficient to 
cause disease in isolation. Moreover, no minor allele frequency threshold was applied pertaining to the 
fact that the two variants only need to be rare in combination. Putatively disease-causing variants were 
identified at both gene partners in only one pair of interacting genes: SMOX and CCT6B. A single 
putatively-disease causing variant was identified at SMOX and seven were identified within the non-
coding region downstream of CCT6B. 
The SMOX variant, c.-224C>T, was identified within the 20p13-12.2 linkage region of KCNSW01. 
This variant was classified as putatively disease-causing under both hypotheses used to prioritise 
variation in this family. SMOX encodes the enzyme spermine oxidase that catalyses the oxidation of 
spermine to spermidine.209 This reaction also produces the reactive oxygen species, H2O2, and the 
reactive aldehyde, aldehyde 3-aminopropanal.209 Spermine and spermidine are both polyamines, are 
found ubiquitously in all organisms and play an important role in a number of cellar processes including 
protein translation, response to oxidative stress and ultraviolet radiation and apoptosis.210 Spermine 
oxidase is inducible by inflammation, as studied in bronchial epithelial cells211 and gastric epithelia,212, 
213 and has a role in pathologies such as gastritis and epithelial cancers through the induction of DNA 
damage and apoptosis. While keratoconus has long been reported as a non-inflammatory disease, 
studies in the last two decades have demonstrated a likely role of chronic inflammation in keratoconus, 
with significant increases in a number of inflammatory mediators such as interleukin-6,214-217 and 
significantly lower anti-inflammatory markers such as IL-10214 and CCL5217 in tears from keratoconus 
patients compared to controls. Keratoconus patients have also been shown to have increased systemic 
oxidative stress levels compared to age matched healthy controls.218 There is also evidence of the 
association of keratoconus with increased apoptosis, with histopathological studies of keratoconic 
corneas demonstrating marked increases in DNA fragmentation219, 220 and single stranded DNA,219  both 
markers for apoptosis, compared to healthy control corneas. Taken together, SMOX is a strong candidate 
gene for keratoconus and both the variant identified in KCNSW01, and the gene, warrant functional 
investigation.  
As the SMOX variant (c.-224C>T) alters the second nucleotide in the 5’ UTR, we hypothesise that this 
variant will result in an altered transcription start site and ultimately abnormal expression levels of the 
encoded protein and that this contributes to keratoconus susceptibility in KCNSW01. Examples of 
causal variants located within the 5’ UTR of key proteins have been identified for a number of 
monogenic disorders such as Saethre-Chotzen syndrome221 (premature fusion of the cranial sutures) and 
androgen insensitivity syndrome,222 as well as a severe immune deficiency resulting in chronic 
mycobacterial infections.223 There has also been an example of two 5’ UTR variants that cause isolated 
congenital asplenia with incomplete penetrance, 224 a condition in which children are born without a 
spleen in the absence of any other developmental defects caused by haploinsufficiency of a ribosomal 
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protein (RPSA). This study demonstrated that both 5’ UTR variants impaired splicing at the exon 
1/intron 1 junction, resulting in the retention of 67 or 70 nucleotides and introducing a second potential 
translation start site. The resulting mRNA molecule was stable, but depending on the translation start 
site utilised, potentially resulted in a mutant protein. From this work, the authors hypothesised that the 
ratio of mutant and wild-type protein produced determined whether or not the phenotype was observed 
and therefore described the variants as ‘hypomorphic’ as they caused smaller decreases in the functional 
protein than other well characterised heterozygous variants. As the SMOX variant is present in the 
apparently unaffected patriarch of KCNSW01, and variable keratoconus severity is reported across the 
affected family members, a similar mechanism could explain the heterogeneity of disease in this family. 
Furthermore, due to the likely digenic inheritance in KCNSW01, potential interactions between the 
SMOX variant and the variants downstream of CCT6B, or other variants within the 17q12 linkage 
region, may be modifying the phenotype within the family. Functional studies are required to confirm 
the role of this variant in disease, as well as, determine the mechanism of disease. 
A single putatively disease-causing variant (chr16:27115706C>A) was identified within the 
homozygosity region identified on chromosome 16 in KSA197 under Filtering Strategy 2. No rare 
protein-coding variants were identified within the homozygosity region and therefore Filtering Strategy 
1 did not identify any protein-coding putatively disease-causing variants. Due to the inheritance pattern 
and consanguinity in KSA197, it was hypothesised that the causative variant was homozygous in the 
affected individuals and that the variant in the heterozygous state was not sufficient to cause disease. 
For this reason, the same low CADD and FATHMM thresholds as those used under the digenic 
hypothesis for KCNSW01 were applied during the prioritisation of variants in KSA197. Putatively 
disease-causing variants in KSA197 were also required to be rare (MAF < 1%). The putatively disease-
causing variant identified (chr16:27115706C>A) was a novel SNP located between the uncharacterised, 
single exon gene, C16orf82, and a histone lysine demethylase gene, KDM8. Pathogenicity estimates are 
highly suggestive of the functionality of this variant. This variant is also located within a DNaseI 
hypersensitivity region identified in osteoblasts, suggesting that this region may have a regulatory role 
in certain tissues and stages of development. Functional studies in relevant ocular cell types are required 
determine the potential role of this variant in keratoconus.  
The human chromosome 16 contains more repetitive sequence than the other human chromosomes, 
largely due to low-abundance repetitive sequences that uniquely occur on this chromosome.225 Clusters 
of these sequences were identified during the construction of a physical map of chromosome 16, 
including 16p12 which overlaps the homozygosity region identified in KSA197.225 Repetitive DNA 
sequences are difficult to call from short-read sequencing as they create ambiguities in the alignment of 
reads and can lead to incorrect variant calls, including spurious indels.226 This explains why many indels 
located at repetitive DNA sequences within the homozygosity region were called in the heterozygous 
state in one or both of the affected brothers, who should have been homozygous. In the present study, 
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these variants were excluded from analysis as they didn’t segregate with disease, however it is possible 
that these repetitive sequences are relevant to keratoconus-susceptibility in KSA197. Repetitive DNA 
sequences are known to be involved in repeat-expansion disorders such as Huntington’s chorea227 and 
fragile X syndrome,228, 229 but have also been shown to increase susceptibility to disease such as insulin-
dependent diabetes mellitus.230, 231 Nearly 30 disorders have been linked to repetitive sequences within 
the coding portions of genes or nearby non-coding regions,232 and therefore, the repeat regions within 
the homozygosity region identified on chromosome 16 in KSA197 should be further investigated. It 
would be worthwhile exploring short tandem repeat (STR) sequences – which consist of 1-6 bp 
sequences repeated one after another, typically 5-50 times – within the homozygosity region. A recently 
developed software, STRetch,233 has been designed to detect STR sequences and estimate their size, 
allowing for the identification of pathogenic repeat expansions using short-read WGS data. This method 
could be applied to our current WGS data. It is also possible to obtain long-read sequencing data which 
typically generates reads greater than 5 kbp, although this would incur a considerable cost. While long-
read sequencing has high error rates,234 these data would be used as a scaffold for our short-read WGS 
data and together this would improve our ability to accurately call variants, allow us to investigate 
complex structural variation and thoroughly explore the repeat sequences within the homozygosity 
region. 
All putatively disease-causing variants identified in KCNSW01 and KSA197 in the present study were 
non-protein-coding variants. In fact, only one protein-coding variant segregated with disease within the 
homozygosity region identified in KSA197, but this variant was too common in the general population 
to be the causative variant. This finding is consistent with previous linkage studies which have struggled 
to identify strong candidate variants within coding regions of genes located within keratoconus linkage 
regions. As a complex disease, it is quite likely that more complex genetic mechanisms are involved in 
keratoconus, such as non-coding variants in key regulatory regions. This hypothesis is supported by the 
identification of the SMOX 5’ UTR variant in KCNSW01 in the present study as well as other candidate 
genes proposed in previous linkage studies for keratoconus. The gene dedicator of cytokinesis 9 
(DOCK9) was proposed as a candidate gene for keratoconus following the identification of a 
segregating splicing variant in an Ecuadorian family that results in exon skipping and the incorporation 
of a premature stop codon in the gene transcript prior to the functional domains of the protein.29, 120 
Intronic variants in IL1RN and SLC4A11 are hypothesised to alter the expression of these proteins were 
proposed to play a role in keratoconus development following linkage analysis in another Ecuadorian 
family.66 Finally, the recurrent variant associated with a combined keratoconus and congenital cataract 
phenotype is located in the non-protein-coding RNA gene, mir184.65, 69, 77, 143 This gene is highly 
expressed in the cornea and lens and is hypothesised to cause the phenotype by altering the expression 
of key proteins by binding to their mRNA molecules with altered affinity compared to the wildtype 
mir184.65 While these variants need to be further assessed to confirm their involvement in keratoconus 
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and determine the exact mechanism of disease, together they suggest that non-protein-coding variation 
is likely to be important in keratoconus development. Perhaps one of the key reasons that specific 
keratoconus variants have been so elusive is precisely because the field has largely focused on protein-
coding variation in families with multiple cases of disease. 
A key limitation of the study was access to clinical information for KCNSW01 as the vast majority of 
the family are living in Jordan and could not be assessed by our ophthalmologists. Despite this the 
almost complete ascertainment of a family as large as KCNSW01, particularly when family members 
are living internationally, is incredibly difficult and therefore represents one of the strengths of the 
study. Furthermore, the severity of the disease reported in the affected individuals gave us confidence 
for the phenotype assignment in these individuals. It is however possible that one or both of the parents 
in the first generation, and the single individual in the second, may have mild or subclinical keratoconus. 
As the inheritance pattern in the second and third generations was consistent with autosomal dominant 
disease, it was a concern that both the matriarch and the patriarch were reported unaffected, therefore 
these individuals were coded with unknown phenotypes and linkage analysis was conducted using a 
reduced penetrance model. If keratoconus is inherited as a digenic trait as the linkage results and 
haplotype analysis would suggest, it is however, quite likely that these individuals are unaffected. 
Despite these limitations, two regions showed segregation with disease in this family, allowing for 
prioritisation of putatively disease-causing variants. As with almost any family study, the examination 
and recruitment of additional unaffected family members from both families may refine the regions of 
interest and aid the prioritisation of candidate variants for further investigation.  
The strategic use of WGS data to both conduct linkage in two families and interrogate variants 
harboured within the identified regions represents an important strength of this study. This method 
eliminated the need for additional SNP array genotyping and facilitated the interrogation of variation 
within the linked regions without a priori hypothesis. Like any sequencing method, variants located 
within regions with low coverage may have been overlooked, however, WGS consistently outperforms 
WES for the capture of the protein-coding portion of the genome as it is not biased by a probe-based 
capture.235, 236 The WGS data also allowed for the investigation of non-coding variation, making this 
study the most comprehensive family study in keratoconus to date, and these data are likely to become 
more valuable as our knowledge of non-coding variation and specific variants involved in keratoconus 
development and pathogenesis improve over time. Furthermore, these data present a unique opportunity 
to explore novel genetic mechanisms in keratoconus susceptibility by investigating structural variation 
and microsatellites in these families.  
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 CONCLUSION 
This study identified two novel linkage regions for keratoconus (16p12.1 and 17q12), replicated a third 
(20p13-12.2) across two families, with one of the families (KCNSW01) demonstrating likely digenic 
inheritance of keratoconus. Despite the original hypothesis, no rare protein-coding variants were 
classified as putatively-disease causing in either family. When considering non-protein-coding variants 
that segregated with the disease-associated regions, one putatively disease-causing variant was 
identified in KSA197 and 44 in KCNSW01 (combining the results of both hypotheses), including a 
compelling variant located within the 5’ UTR of SMOX. These variants warrant further investigation in 
additional patients with keratoconus, as well as functional analyses in relevant tissues or cell lines. 
Based on the lack of rare, coding putatively disease-causing variants identified in the present study, we 
hypothesis that non-coding variants are likely to contribute to keratoconus development in these 
families and potentially play an important role in keratoconus susceptibility and pathogenesis more 
broadly. 
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CHAPTER 5: MAPPING PUTATIVELY FUNCTIONAL RISK ALLELES AT 
KERATOCONUS-ASSOCIATED LOCI 
 
Work outlined in Aim 1 of this chapter was included in the following publication: 
Iglesias A*, Mishra A*, Vitart V*, Bykhovskaya Y, Hohn R, Springelkamp H, Cuellar-Partida G, 
Gharahkhani P, Cooke Bailey J, Willoughby C, Li X, Yazar S, Nag A, Khawaja A, Polasek O, Siscovick 
D, Mitchell P, Tham YC, Haines J, Kearns L, Hayward C, Shi Y, van Leeuwen E, Taylor K, 
Bonnemaijer P, Rotter J, Martin N, Zeller T, Mills R, Souzeau E, Staffieri S, Jonas J, Schmidtmann I, 
Boutin T, Lucas SEM, Kang J, Wong T, Beutel M, Wilson J, Vithana E, Foster P, Hysi P, Hewitt A, 
Khor CC, Pasquale L, Montgomery G, Klaver C, Aung T, Pfeiffer N, Mackey D, Hammond C, Cheng 
C, Craig JE, Rabinowitz Y, Wiggs J, Burdon KP, Duijn C, MacGregor S. Cross-ancestry genome-
wide association analysis of corneal thickness strengthens link between complex and Mendelian 
eye diseases. Nature Communications 2018;9(1):1864. 
* indicates equal contribution. 
 
 INTRODUCTION 
In genetics, association studies use cohorts of unrelated individuals to identify variants that contribute 
to a heritable trait or disease. In recent decades, high throughput DNA genotyping technology has 
allowed for genome-wide association studies (GWAS), which assess thousands of single nucleotide 
polymorphisms (SNPs) across the genome for association with a disease without a priori hypotheses. 
To account for multiple testing in these studies, a genome-wide significance threshold is applied (5 x 
10-8). In contrast to family-based studies, association studies are well powered to identify common 
variation, and as such, the variants identified often have small to moderate effect sizes. In the context 
of complex disease, this type of analysis identifies variation that confers slight increases or decreases 
in disease susceptibility. It’s important to note that due to linkage disequilibrium (LD) – the co-
inheritance of alleles at different loci within a population – an associated variant may directly contribute 
to the risk of developing the disease or may just be in LD with the true functional variant (assuming 
that the association is not a false-positive). Therefore, while associations are often referred to by the 
associated SNP ID, or a nearby gene, in reality the association implicates a specific haplotype. The 
challenge then remains to identify the functional variant and target gene to gain an insight into the 
underlying biology and pathogenesis of disease.  
Many small case-control studies have assessed variants in and near genes hypothesised to play a role in 
the keratoconus disease process for association in keratoconus cohorts, including VSX1,89 CAST,113 and 
SOD1,103 however with such limited understanding of the types of variants and genes involved in 
97 
 
keratoconus, these studies have not yet lead to substantial insights into the pathogenesis of disease. 
There have also been two published GWAS for keratoconus. The first GWAS for keratoconus was 
performed using our cohort of Australian keratoconus patients and identified a suggestive association 
at rs3735520 (p = 9.9 x10-7) upstream of HGF.84 This association has not been replicated and therefore 
the involvement of this locus in keratoconus susceptibility remains unclear. The second GWAS 
identified a suggestive association (p = 1.6 x10-7) at rs4954218 upstream of RAB3GAP1,85 which 
reached genome-wide significance following replication and meta-analysis in our cases (p = 5.0 x10-
8).86  
Three additional loci have since reached genome-wide significance with keratoconus87 – FOXO1, 
FNDC3B, and MPDZ-NFIB – however, these associations were identified using an endophenotype 
approach, rather than a direct GWAS for keratoconus. The concept of an endophenotype has evolved 
substantially since the term was first used in 1966,237 but currently refers to a quantitative trait that is 
associated with the disease in the population, is heritable, is measurable in both healthy and affected 
individuals, co-segregates within families (like the disease) and found in family members unaffected 
by the disease at a higher rate than the general population.238-241 By definition endophenotypes are 
quantitative, resulting in better statistical power and higher precision when making inferences compared 
to discrete data (such as affected/unaffected). This allows for smaller sample sizes and more efficient 
use of resources. Endophenotypes are also hypothesised to be less complex and closer to the underlying 
genetics than the disorder or disease of interest, as it reflects just one of many pathophysiological 
pathways that contribute to disease susceptibility.238 This allows complex diseases to be dissected, 
directing investigators toward the relevant biological pathways and ultimately aiding the identification 
of functional variants and target genes. In keratoconus, central corneal thickness (CCT) has been used 
as an endophenotype to aid the identification of keratoconus-associated loci. CCT is a quantitative trait 
with a normal distribution in the general population (mean = 536 µm; standard deviation = 31 µm) and 
is measurable in both healthy and keratoconic corneas.31 Though the genetic correlation between CCT 
and keratoconus has not been calculated, keratoconus is associated with extremely low CCT with a 
mean of 434 µm reported in keratoconic eyes,31 which is well outside the variance observed in the 
general population. CCT is one of the most heritable human traits with heritability estimates of up to 
95%.242-245 Unaffected family members of individuals with keratoconus have been shown to have 
thinner corneal measurements when compared to population controls,246, 247 with some evidence of an 
autosomal dominant pattern of inheritance.247 Taken together, CCT is a strong endophenotype for 
keratoconus. 
The first study that used CCT as an endophenotype for keratoconus performed a GWAS for CCT and 
subsequently typed genome-wide significant findings in a cohort of keratoconus patients that included 
our Australian cases and a cohort from the USA.87 The investigators hypothesised that the CCT-
decreasing alleles at CCT-associated loci would also confer an increased risk of keratoconus and that 
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CCT-increasing alleles may be protective for keratoconus. The study identified significant associations 
at rs2721051 in an intron of FOXO1 (p = 2.7 x10-10) and the intronic SNP rs4894535 in FNDC3B (p = 
4.9 x10-9).87 A suggestive association at rs1324183 between MPDZ and NFIB (p = 5.2 x10-6)87 was also 
identified in this study and reached genome-wide significance following replication and meta-analysis 
in an independent cohort (p = 5.0 x 10-8).88 Notably, suggestive associations at rs1536482 (p = 2.6 x10-
7) between RXRA-COL5A1 and rs7044529 in an intron of COL5A1 were also identified.87 Another study 
employed a similar study design and identified another suggestive association with keratoconus at 
rs121908120, located in an exon of WNT10A (p = 5.4 x10-5).248 Again, our keratoconus cohort was used 
in this study and replication in an independent cohort is required to determine if this locus is important 
in keratoconus susceptibility. These studies highlight the success of assessing CCT-associated loci in a 
keratoconus cohort to aid the identification of novel keratoconus-associated loci. 
Finding a significant association between a variant and a disease is only the first step toward a better 
understanding of the underlying biology and mechanism of disease. More often than not, the associated 
variants are located in intronic and intergenic regions and substantial investigations are required to 
elucidate the functional variant and target gene(s). Fine-mapping is a method used to establish the extent 
of an associated region, as well as identify the ‘top SNP’, the variant that is most strongly associated 
with the trait of interest (ie. obtains the smallest p-value). This may involve hard-typing nearby SNPs 
or, more commonly in the era of GWAS, imputation. Imputation uses known genotypes, commonly 
from a SNP array, to infer an individual’s genotype at additional un-genotyped SNPs, based on known 
haplotypes such as those from the HapMap Project191 or 1000 Genomes Project.131 Following fine-
mapping, variants carried on the risk-associated haplotype can subsequently be assessed using in silico 
tools to identify putatively functional variants, which ultimately require functional investigation to 
confirm the role of the variation in disease susceptibility. To date, the functional variants at keratoconus-
associated loci have not yet been investigated.  
 
 HYPOTHESIS AND AIMS 
The hypothesis underpinning this study was that variants associated with keratoconus indicate 
haplotypes that harbour functional variants that directly contribute to disease susceptibility. This led to 
the development of the following aims: 
1. To identify novel keratoconus-associated loci by assessing central corneal thickness-
associated loci in keratoconus patients and unaffected controls;  
2. To fine-map keratoconus-associated loci in a cohort of unrelated keratoconus cases and 
controls to investigate the extent of the association, identify the top SNP, and select 
genomic regions for re-sequencing. This aim will assess novel keratoconus-associated 
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loci identified in Aim 1, as well as, published keratoconus-associated loci that have 
reached genome-wide significance. 
3. To identify putatively functional variants underlying keratoconus-associated loci by re-
sequencing keratoconus patients carrying the risk-associated alleles. This aim will 
focus on fine-mapped regions with strong association peaks identified in Aim 2. 
 
 OVERALL STUDY DESIGN 
The overall objective of this chapter was to investigate the role of common genetic variation in 
keratoconus susceptibility in a large, unrelated case-control cohort. This study includes three specific 
aims as outlined in Figure 5.1. 
 
Figure 5.1  – A flow diagram of the overall study design. 
Dark blue textboxes indicate the three aims, numbered 1 to 3. CCT = central corneal thickness;  
SNPs = single nucleotide polymorphisms. 
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 AIM 1: ASSESSING CENTRAL CORNEAL THICKNESS-ASSOCIATED 
LOCI IN A KERATOCONUS COHORT 
5.4.1 Methods 
5.4.1.1 SNP selection 
Our team and collaborators conducted a cross-ancestry GWAS for CCT using 20 cohorts, including 
17,803 individuals of European descent and 8,107 individuals of Asian ancestry (total n = 25,910). This 
work identified 54 independent association signals for CCT at 44 loci, including 21 novel loci.249 Based 
on this work, 72 CCT-associated SNPs that were novel findings or had not previously been assessed in 
keratoconus were selected for evaluation in our case-cohort. The results from an LD-pruned list of these 
SNPs (n = 36) were included in the published study following meta-analysis with a cohort from the 
United States of America (USA).249  
5.4.1.1 Study participants 
The case cohort consisted of 536 unrelated keratoconus patients as described in Section 2.1.1. The 
control cohort included 2,574 unaffected individuals from the Blue Mountains Eye Study (BMES). This 
cohort is outlined in Section 2.1.4. 
5.4.1.2 Genotyping 
The 72 CCT-associated SNPs were genotyped in cases across three custom plexes by the Australian 
Genome Research Facility (QLD, Australia) using the MassARRAY platform (Agena Biosciences 
Inc., San Diego, California, USA). 
The control cohort were previously typed on the HumanHap 610 array (Illumina) and custom 
CoreExome array (Illumina). Quality control and genome-wide imputation was conducted by Dr Puya 
Gharahkhani (Queensland Institute of Medical Research Berghoefer, QLD, Australia). Using 
PLINK190 (version 1.9) SNPs were excluded if they had a call rate less than 97%, a minor allele 
frequency (MAF) < 0.01 and a Hardy-Weinberg equilibrium p < 0.0001. Individuals with more than 
3% missing genotypes were excluded. Related individuals were identified by calculating identity-by-
descent (IBD) in PLINK using autosomal markers, and one individual from each pair with IBD > 0.2 
was removed from analysis. Principal components analysis (PCA) was conducted in PLINK for all 
individuals and reference samples of known European ancestry from the 1000 Genomes Project: Utah 
residents with Northern and Western European ancestry (CEU), British living in England and 
Scotland (GBR) and Finnish living in Finland (FIN) populations.250 Individuals with PC1 or PC2 
values > 6 standard deviations from the mean of the European 1000 Genomes Project reference 
groups were considered ancestry outliners and excluded from further analysis. Following this quality 
control protocol, 2,574 individuals and 537,548 SNPs were used as the basis of imputation. 
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Genotypes were phased using ShapeIT251 (v2.r790) and imputation was performed using Minimac3252 
(version 2.0.1) through the Michigan Imputation Server with the Haplotype Reference Consortium253 
(release 1.1) as the reference panel. SNPs with imputation quality (r2) > 0.3 and MAF > 0.01 were 
available for analysis. The genotype data for the controls at the 72 CCT-associated SNPs were 
extracted from this dataset. 
5.4.1.3 Statistical analysis 
Genotype data for the case and control cohorts were merged in PLINK. Individuals with more than 
10% missing genotype data were removed from the analysis. SNPs with a missing genotype rate 
greater than 10% or that deviated significantly (p < 0.001) from Hardy-Weinberg Equilibrium were 
excluded. Using PLINK, chi squared tests with odds ratios and 95% confidence intervals were 
calculated. An example of the PLINK command is outlined in Appendix 15. To correct for multiple 
testing Bonferroni correction, a significance threshold of 6.94 x10-4 was applied (0.05/72). 
 
5.4.2 Results 
A total of 72 CCT-associated SNPs were assessed for association with keratoconus using a cohort 
consisting of 536 keratoconus patients and 2,574 controls. The cohort demographics are outlined in 
Table 5.1.  
Table 5.1 – Cohort demographics  
Group n Mean age (range) % Female Disease status 
Cases 536 44.6 (14 – 85) 44.6 affected 
Controls 2,574 70.0 (49 – 96) 43.4 unaffected 
n = the number of individuals in each cohort.  
Mean age = the mean average (and the range) is reported in years. 
 
Hard-typed genotype data were available for all 72 CCT-associated SNPs in the case cohort and 33 of 
the SNPs in the controls. Imputed genotype data were available for the remaining 39 SNPs in the control 
cohort. Twenty-five SNPs were nominally associated with keratoconus (p < 0.05) and five remained 
significant following adjustment for multiple testing (Table 5.2). Of the significant SNPs, rs2268578 
was located at a novel locus in an intronic region of the lumican gene (LUM) and two SNPs between 
RXRA and COL5A1 (rs1536482 and rs3132303) were significantly associated with keratoconus. This 
study also replicated two genomic regions that had previously reached genome-wide association with 
keratoconus: FOXO1 with the significant association at the intronic SNP rs2755238 and MPDZ-NFIB 
with an association at rs66720556, located between the two genes. Based on this analysis, the novel loci 
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LUM and RXRA-COL5A1, along with the known loci FOXO1 and MPDZ, were further fine-mapped in 
Aim 2 (Section 5.5). 
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Table 5.2 – CCT-associated SNPs assessed for association in our cohort of keratoconus patients and unaffected controls.  
SNP Position Locus Ref Alt 
Case 
Freq. 
Control 
Freq. 
Χ2 P OR [95% CI] SE 
rs96067* chr1:36571920 COL8A2 A G 0.22 0.20 2.56 0.11 1.14 [0.97-1.34] 0.08 
rs4846476 chr1:218526228 TGFB2 G C 0.23 0.23 0.35 0.55 1.05 [0.90-1.23] 0.08 
rs115781177 chr2:33348494 LTBP1 A G 0.06 0.07 3.11 0.08 0.78 [0.59-1.03] 0.14 
rs4608502 chr2:228134155 COL4A3 C T 0.38 0.33 8.24 4.11 x10-3 1.22 [1.07-1.40] 0.07 
rs12469734* chr2:235469549 ARL4C A G 0.39 0.36 3.15 0.08 1.13 [0.99-1.30] 0.07 
rs9880211* chr3:136107549 STAG1 G A 0.28 0.24 7.60 5.83 x10-3 1.23 [1.06-1.43] 0.08 
rs28641809 chr3:136290489 STAG1 G A 0.28 0.23 8.17 4.26 x10-3 1.24 [1.07-1.44] 0.08 
rs13092225* chr3:156355404 TIPARP A G 0.36 0.34 1.62 0.20 1.09 [0.95-1.26] 0.07 
rs6807894* chr3:156372177 TIPARP T G 0.36 0.34 1.78 0.18 1.10 [0.96-1.26] 0.07 
rs6441091* chr3:156373580 TIPARP T C 0.36 0.34 1.90 0.17 1.10 [0.96-1.26] 0.07 
rs344066* chr3:156440305 TIPARP A G 0.04 0.02 9.83 1.72 x10-3 1.73 [1.22-2.45] 0.18 
rs1430412 chr3:156521121 TIPARP-LEKR1 C T 0.24 0.23 0.68 0.41 1.07 [0.91-1.24] 0.08 
rs9847692* chr3:156531322 TIPARP-LEKR1 C T 0.25 0.23 0.82 0.36 1.07 [0.92-1.25] 0.08 
rs4857612 chr3:177306621 LINC00578 G C 0.39 0.40 0.27 0.60 0.96 [0.84-1.10] 0.07 
rs3931397* chr4:149079497 NR3C2 G T 0.08 0.08 0.37 0.55 1.08 [0.85-1.37] 0.12 
rs17024437 chr4:149081808 NR3C2 G A 0.08 0.08 0.37 0.55 1.08 [0.85-1.37] 0.12 
rs1309531 chr5:64306311 CWC27 A T 0.43 0.44 1.18 0.28 0.93 [0.81-1.06] 0.07 
rs10471310 chr5:64548961 ADAMTS6 C T 0.39 0.38 0.29 0.59 1.04 [0.91-1.19] 0.07 
rs10064391 chr5:64686659 ADAMTS6 A G 0.36 0.38 2.14 0.14 0.90 [0.79-1.04] 0.07 
rs2047063* chr5:64732237 ADAMTS6 T C 0.39 0.42 2.21 0.14 0.90 [0.79-1.03] 0.07 
rs11746802* chr5:178665185 ADAMTS2 C T 0.36 0.33 2.70 0.10 1.12 [0.98-1.29] 0.07 
rs11743204 chr5:178671014 ADAMTS2 T C 0.38 0.35 2.62 0.11 1.12 [0.98-1.28] 0.07 
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SNP Position Locus Ref Alt 
Case 
Freq. 
Control 
Freq. 
Χ2 P OR [95% CI] SE 
rs340124 chr5:178686590 ADAMTS2 G A 0.45 0.45 0.03 0.87 0.99 [0.87-1.13] 0.07 
rs13191376* chr6:45522139 RUNX2 C T 0.34 0.36 1.30 0.26 0.92 [0.80-1.06] 0.07 
rs1412710 chr6:75837203 COL12A1 C T 0.13 0.16 5.52 0.02 0.79 [0.65-0.96] 0.10 
rs1931656 chr6:82610188 FAM46A T A 0.46 0.45 0.06 0.81 1.02 [0.89-1.16] 0.07 
rs9344230* chr6:82616216 FAM46A T C 0.30 0.29 0.56 0.46 1.06 [0.92-1.22] 0.07 
rs9455877 chr6:169556637 THBS2 A G 0.17 0.15 5.85 0.02 1.24 [1.04-1.48] 0.09 
rs11768292* chr7:65474801 GUSB G T 0.40 0.42 2.10 0.15 0.91 [0.79-1.04] 0.07 
rs3764903* chr7:66098482 KCTD7 G A 0.47 0.49 0.44 0.51 0.96 [0.84-1.09] 0.07 
rs3800817 chr7:66263550 RABGEF1 T A 0.28 0.25 3.99 0.05 1.16 [1.00-1.35] 0.08 
rs4717328* chr7:66352665 SBDS T C 0.28 0.25 3.47 0.06 1.15 [0.99-1.30] 0.08 
rs2106166 chr7:92668332 SAMD9 A T 0.44 0.42 1.17 0.28 1.08 [0.94-1.23] 0.07 
rs3808520 chr8:23164773 LOXL2 G C 0.20 0.21 0.88 0.35 0.92 [0.78-1.09] 0.08 
rs7026684 chr9:4215308 GLIS3 G A 0.38 0.38 0.02 0.89 0.99 [0.86-1.13] 0.07 
rs66720556 chr9:13559717 MPDZ-NFIB T A 0.23 0.18 15.85 6.87 x10-5 1.38 [1.18-1.62] 0.08 
rs9409911 chr9:137434446 RXRA-COL5A1 A G 0.30 0.35 10.77 1.03 x10-3 0.79 [0.68-0.91] 0.07 
rs1536482* chr9:137440528 RXRA-COL5A1 G A 0.42 0.34 24.55 7.24 x10-7 1.40 [1.23-1.61] 0.07 
rs3132303 chr9:137444298 RXRA-COL5A1 G C 0.20 0.26 17.81 2.44 x10-5 0.70 [0.60-0.83] 0.08 
rs11145951* 
 
chr9:139860264 PTGDS C T 0.45 0.48 3.53 0.06 0.88 [0.77-1.01] 0.07 
rs2386136 chr9:139864341 PTGDS G A 0.45 0.49 3.84 0.05 0.88 [0.77-1.00] 0.07 
rs35809595 chr10:63831928 ARID5B G A 0.44 0.42 1.65 0.20 1.10 [0.96-1.25] 0.07 
rs2419835 chr10:115296564 HABP2 T C 0.13 0.13 3.67x10-3 0.95 1.01 [0.83-1.22] 0.10 
rs4938174* chr11:110913240 C11orf53 G A 0.29 0.30 0.12 0.73 0.97 [0.84-1.13] 0.07 
rs2242312* chr11:130275346 ADAMTS8 G A 0.06 0.06 0.07 0.79 0.96 [0.74-1.26] 0.14 
rs10859105* chr12:91473005 KERA-LUM C T 0.32 0.28 5.48 0.02 1.19 [1.03-1.37] 0.07 
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SNP Position Locus Ref Alt 
Case 
Freq. 
Control 
Freq. 
Χ2 P OR [95% CI] SE 
rs2268578* chr12:91501198 LUM G A 0.16 0.12 13.51 2.38 x10-4 1.41 [1.17-1.69] 0.09 
rs10859110* chr12:91504845 LUM G A 0.29 0.24 10.83 9.97 x10-4 1.28 [1.11-1.48] 0.08 
rs7308752 chr12:91527181 DCN A G 0.11 0.08 9.11 2.54 x10-3 1.39 [1.12-1.73] 0.11 
rs116878472 chr12:104210992 NT5DC3 T C 0.037 0.03 1.52 0.22 1.25 [0.88-1.78] 0.18 
rs11553764 chr12:104415244 GLT8D2 C T 0.17 0.18 0.01 0.91 0.99 [0.83-1.18] 0.09 
rs2755238 chr13:41110270 FOXO1 T C 0.15 0.10 23.92 1.00 x10-6 1.61 [1.33-1.96] 0.10 
rs56223983 chr14:81814754 STON2 G T 0.32 0.32 0.03 0.87 0.99 [0.86-1.14] 0.07 
rs62014489 chr15:30171879 TJP1 G A 0.10 0.11 1.33 0.25 0.88 [0.71-1.09] 0.11 
rs785424 chr15:30178544 TJP1 A T 0.09 0.10 1.38 0.24 0.87 [0.70-1.09] 0.11 
rs8030753 chr15:48801935 FBN1 C T 0.14 0.14 0.06 0.80 1.02 [0.85-1.24] 0.10 
rs4601989* chr15:67451954 SMAD3 C T 0.18 0.22 7.94 4.84 x10-3 0.78 [0.66-0.93] 0.09 
rs12912010 chr15:67467143 SMAD3 G T 0.17 0.22 10.29 1.34 x10-3 0.75 [0.63-0.90] 0.09 
rs6496932* chr15:85825567 AKAP13 C A 0.21 0.18 5.85 0.02 1.22 [1.04-1.44] 0.08 
rs4843040 chr15:85838636 AKAP13 C T 0.26 0.23 4.65 0.03 1.18 [1.02-1.38] 0.08 
rs7183651* chr15:85895721 AKAP13 G A 0.26 0.23 6.45 0.01 1.22 [1.05-1.42] 0.08 
rs7183764* chr15:85903051 AKAP13 G A 0.26 0.22 5.84 0.02 1.21 [1.04-1.40] 0.08 
rs4842882* chr15:85984183 AKAP13 A G 0.23 0.19 8.12 4.37 x10-3 1.26 [1.07-1.47] 0.08 
rs2654583* chr15:101002255 CERS3 G A 0.30 0.30 4.26x10-4 0.98 1.00 [0.86-1.15] 0.07 
rs930847* chr15:101558562 LRRK1 T G 0.20 0.22 2.72 0.10 0.87 [0.74-1.03] 0.08 
rs752092* chr15:101781934 CHSY1 A G 0.33 0.33 1.39x10-3 0.97 1.00 [0.87-1.15] 0.07 
rs35193497 chr16:88324821 BANP-ZNF469 G T 0.30 0.34 5.05 0.02 0.85 [0.74-0.98] 0.07 
rs8059298 chr16:88332479 BANP-ZNF469 C T 0.32 0.36 5.28 0.02 0.85 [0.74-0.98] 0.07 
rs11656734 chr17:7426695 POL2A G C 0.36 0.39 5.21 0.02 0.85 [0.74-0.98] 0.07 
rs4792535* chr17:14565130 HS3ST3B1-PMP22 C T 0.29 0.29 0.06 0.80 1.02 [0.88-1.18] 0.07 
106 
 
SNP Position Locus Ref Alt 
Case 
Freq. 
Control 
Freq. 
Χ2 P OR [95% CI] SE 
rs9981981* chr21:47544838 COL6A2 G A 0.04 0.04 0.15 0.70 1.07 [0.76-1.50] 0.17 
rs71313932 chr22:19960198 ARVCF G C 0.29 0.29 4.48x10-7 > 0.99 1.00 [0.86-1.16] 0.07 
Ref = the reference allele. 
Alt = the alternate allele. 
Case Freq. = the frequency of the alternate allele in the case cohort. 
Control Freq. = the frequency of the alternate allele in the control cohort. 
Χ2 = the chi square statistic. 
P = the asymptotic p-value. 
OR = the estimated odds ratio for the minor allele with the major allele as the reference, where 95% CI indicates the 95% confidence interval for this value. 
* Indicates SNPs with hard-typed genotype data available for both cases and controls. 
SNPs significantly associated with keratoconus (p < 6.94 x10-4) are bold. 
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 AIM 2: FINE-MAPPING KERATOCONUS-ASSOCIATED LOCI IN 
KERATOCONUS CASES AND CONTROLS 
5.5.1 Methods 
5.5.1.1 Loci selection 
Keratoconus loci reaching genome-wide significance (p < 5 x10-8) in the literature, as well as, any 
CCT-associated SNPs that were significantly associated with keratoconus following correction for 
multiple testing in Aim 1 (as described in Section 5.4) were fine-mapped. For each of these loci, the 
regions surrounding the reported SNP were selected for fine-mapping such that the intergenic region 
and flanking genes were included for intergenic SNP, whereas the region encompassing the relevant 
gene was included for intronic SNPs. These broad regions were included to ensure the association 
peaks were captured. 
5.5.1.2 Study participants and genotyping data 
The case cohort consisted of 487 unrelated Australian keratoconus patients (described in Section 2.1.1) 
with genome-wide genotyping data generated on the Illumina HumanCoreExome array 
(HumanCoreExome-24v1-1_A). The control cohort consisted of 626 controls, 427 were unaffected 
individuals from the Blue Mountain Eye Study (BMES; as described in Section 2.1.4) and 199 were 
unscreened population controls from the NSA cohort (described in Section 2.1.5). The controls were 
genotyped using a customized Illumina HumanCoreExome array 
(“HumanCoreExome_Goncalo_15038949_A”), as described previously.254 Only SNPs that were 
common to both arrays were included in the current analysis.  
5.5.1.3 Quality control, imputation and statistical analysis 
Quality control and imputation procedures were performed by Dr Bennet McComish (Menzies 
Institute for Medical Research, University of Tasmania, TAS, Australia). Quality control was 
conducted according to a modified version of the protocol outlined by Anderson et al. (2010).192 
Snpflip (https://github.com/biocore-ntnu/snpflip) was used to detect reverse and ambiguous strand 
SNPs. Using PLINK, ambiguous strand SNPs were removed from analysis and reverse strand SNPs 
were flipped. Individuals with a missing genotype rate > 0.08, discordant sex information, or 
heterozygosity more than three standard deviations from the mean were excluded. Related individuals 
were detected across both cases and controls by calculating pairwise identity-by-descent (IBD) in 
PLINK, and the individual with the lower genotyping rate in any pair with IBD > 0.185 was removed 
from analysis. Ancestry outliers were identified by principal component analysis (PCA) using 
EIGENSTRAT193 with the HapMap191 Phase III reference panel and individuals with a PC1 > 0.07 
were excluded. SNPs were excluded if they had a missing genotype rate > 3%, a minor allele 
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frequency < 0.01, deviated significantly (p < 10-5) from Hardy-Weinberg equilibrium, or if the 
missing call counts differed significantly between cases and controls (p < 10-5) as determined by 
PLINK’s case/control non-random missingness test. 
Autosomal genotype data was phased using Eagle255 (version 2.3.5) and genotypes were imputed 
based on the 1000 Genomes Project reference panel250 (Phase III, version 5) using Minimac3252 
(version 2.0.1). Using BCFtools (https://github.com/samtools/BCFtools; version 1.3.1), insertions and 
deletions (indels) were excluded from statistical analysis and SNPs were excluded if they were rare 
(MAF < 0.01), within 5 bp of an indel, or had poor imputation quality (r2 < 0.8). The resulting VCF 
file was converted to PLINK format files and multi-allelic SNPs were removed from analysis. 
For each locus selected for fine-mapping, the included region was extracted from the PLINK format 
files. Association analysis was performed for each included region using the most-likely genotypes 
under a chi-squared model in PLINK as described previously in Section 5.4.1.3.  
5.5.1.4 Selecting regions for re-sequencing 
Loci with strong association peaks identified in the fine-mapping of keratoconus-associated loci were 
selected for re-sequencing. At each locus separately, the region under the association peak was selected 
to include as many of the SNPs with a nominally significant p-value (< 0.05) as were practical. The re-
sequenced regions were also influenced by the best sequencing design.  
5.5.1.5 Data Visualisation 
The results of the association analysis were graphed using the online batch mode of LocusZoom256 
(available at http://locuszoom.org/genform.php?type=hitspecdata). Hard-typed SNPs were plotted as 
squares, while imputed SNPs were plotted as circles. To identify the most significant SNPs at each 
locus, the top SNPs were coloured purple and labelled with their variant ID (rsID). All other included 
SNPs were coloured according to the degree of LD (r2) with the top SNP. LocusZoom calculated LD 
estimates with PLINK (version 1.07) using the ‘European population hg19/1000 Genomes Nov 2014’ 
build. Regions selected for re-sequencing were highlighted in grey along the lower section of the plot 
that contains the location of transcripts. 
5.5.2 Results 
Six loci were selected for fine-mapping, including two novel loci identified in Aim 1 (Section 5.4) and 
four previously published loci that were associated with keratoconus at a genome-wide significance 
threshold (Table 5.3). Following quality control procedures, genotyping data from 487 cases and 626 
controls were used to fine-map the included regions. Cohort demographics are summarised in Table 
5.4. 
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Table 5.3 – Summary of the keratoconus-associated loci for fine-mapping. 
Locus 
Associated 
SNP 
P-value Study Included region (size) 
RAB3GAP1 rs4954218 9.3 x10-9 
Li et al. (2012)85;  
Bae et al. (2013)86 
chr2:135722061-136288806 (5.7 Mb) 
FNDC3B rs4894535 4.9 x10-9 Lu et al.(2012)87 chr3:171757418-172118492 (0.4 Mb) 
MPDZ-NFIB rs1324183 5.0 x10-8 
Lu et al.(2012)87; 
Sahebjada et al. (2013)88 
chr9:3105703-14398982 (11.3 Mb) 
RXRA-COL5A1 rs1536482 7.2 x10-7 Aim 1 (Section 5.4) chr9:137208944-137736688 (0.5 Mb) 
LUM rs2268578 2.9 x10-4 
Aim 1 (Section 5.4); 
Iglesias et al. (2018)249 
chr12: 91300000-91700000 (0.4 Mb) 
FOXO1 rs2721051 2.7 x10-10 Lu et al.(2012)87 13:41048131-41240734 (0.2 Mb) 
Associated SNP = the SNP previously associated with keratoconus, either in the literature or from Stage 1 of this study. 
P-value = The reported p-value for the associated SNP. 
 
Table 5.4 – Cohort demographics  
Group n Mean age (range) % Female Disease status 
Cases 487 44.7 (14-85) 45.0 affected 
Controls 
199 75.5 (42-96) 53.3 unscreened 
427 60.2 (50-89) 46.2 unaffected 
            n = the number of individuals in each cohort.  
       Mean age = the mean average (and the range) is reported in years.
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5.5.2.1 Fine-mapping results for the RAB3GAP1 locus 
Fine-mapping of the RAB3GAP1 locus showed a poor association peak in the present cohort, with no 
SNPs in high LD with the top SNP, rs4954218 (Figure 5.2). The top SNP obtained a p-value of 2.33 
x10-3 and is the same SNP that was previously reached genome-wide significance with keratoconus. 
The minor allele (G) at the top SNP for the RAB3GAP1 locus, rs4954218, was protective for 
keratoconus (OR = 0.75). Due to the lack of a strong association peak, the RAB3GAP1 locus was not 
selected for re-sequencing in Aim 3.  
Figure 5.2 – Fine-mapping for the RAB3GAP1 locus. 
Circles indicate imputed SNP data and squares indicate hard-typed SNPs. The top SNP is coloured 
purple and labelled. All other SNPs are coloured according to their degree of linkage disequilibrium 
(r2) with the top SNP based on the European population of the 1000 Genomes (Nov 2014 build). The 
lower section of the plot indicates the location of nearby genes. 
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5.5.2.2 Fine-mapping results for the FNDC3B locus 
For the FNDC3B locus, a strong association peak was identified with the top SNP, rs4894538, reaching 
a p-value of 2.44 x10-3 (Figure 5.3). The top SNP in the present study, rs4894538, is 3400 bp 
downstream of the published keratoconus-associated SNP at this locus, rs4894535. Based on the fine-
mapping, a 107 kbp region encompassing the association peak was selected for re-sequencing. 
Figure 5.3 – Fine-mapping for the FNDC3B locus. 
Circles indicate imputed SNP data and squares indicate hard-typed SNPs. The top SNP is coloured 
purple and labelled. All other SNPs are coloured according to their degree of linkage disequilibrium 
(r2) with the top SNP based on the European population of the 1000 Genomes (Nov 2014 build). The 
lower section of the plot indicates the location of the gene. The grey section indicates the region 
selected for re-sequencing. 
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5.5.2.3 Fine-mapping results for the MPDZ-NFIB locus 
A tight association peak was identified at the MPDZ-NFIB locus (Figure 5.4). The top SNP, rs7851770, 
obtained a p-value of 8.24 x10-5 and is located 256 bp away from the previously reported keratoconus-
associated SNP, rs1324183. A 36 kbp region under the peak was selected for re-sequencing. 
 
Figure 5.4 – Fine-mapping for the MPDZ-NFIB locus. 
Circles indicate imputed SNP data and squares indicate hard-typed SNPs. The top SNP is coloured 
purple and labelled. All other SNPs are coloured according to their degree of linkage disequilibrium 
(r2) with the top SNP based on the European population of the 1000 Genomes (Nov 2014 build). The 
lower section of the plot indicates the location of nearby genes. The grey section indicates the region 
selected for re-sequencing. 
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5.5.2.4 Fine-mapping results for the RXRA-COL5A1 locus 
Following fine-mapping, a very tight association peak was identified at the RXRA-COL5A1 locus 
(Figure 5.5). The top SNP, rs1536483, reached a p-value of 1.45 x10-5, which was the smallest p-value 
obtained across all loci that were fine-mapped. The SNP rs1536483 is 156 bp away from the 
keratoconus-associated SNP rs1536482, which implicated this locus in keratoconus susceptibility in 
Section 5.4. As few SNPs were captured immediately downstream of the rs1536483, this region was 
selected for re-sequencing in addition to the region under the association peak.  
Figure 5.5 – Fine-mapping for the RXRA-COL5A1 locus. 
Circles indicate imputed SNP data and squares indicate hard-typed SNPs. The top SNP is coloured 
purple and labelled. All other SNPs are coloured according to their degree of linkage disequilibrium 
(r2) with the top SNP based on the European population of the 1000 Genomes (Nov 2014 build). The 
lower section of the plot indicates the location of the nearby genes. The grey section indicates the 
region selected for re-sequencing. 
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5.5.2.5 Fine-mapping results for the LUM locus 
The association peak at the novel LUM locus reached a minimum p-value of 4.51 x10-3 at rs3759221 
(Figure 5.6). Apart from a small spike surrounding the top SNP, the association peak for this locus was 
very broad and therefore a 131 kbp region, encompassing the genes KERA, LUM and the majority of 
DCN, was selected for resequencing. 
Figure 5.6 – Fine-mapping for the LUM locus. 
Circles indicate imputed SNP data and squares indicate hard-typed SNPs. The top SNP is coloured 
purple and labelled. All other SNPs are coloured according to their degree of linkage disequilibrium 
(r2) with the top SNP based on the European population of the 1000 Genomes (Nov 2014 build). The 
lower section of the plot indicates the location of nearby genes. The grey section indicates the region 
selected for re-sequencing. 
 
5.5.2.6 Fine-mapping results for the FOXO1 locus 
Two apparently independent association peaks were identified at the FOXO1 locus as the top SNP, 
rs2755209, and the second top SNP, rs79728429, with a pairwise r2 value below 0.2 in the European 
population of the Nov 2014 build of 1000 Genomes (Figure 5.7). In the present cohort however, all 
homozygotes for the risk-allele (T) at rs79728429 (the rarer of the two SNPs) were also homozygotes 
for the risk-allele (C) at rs2755209. Moreover, all heterozygotes for the risk-associated allele at 
rs79728429 were either heterozygous or homozygous for the risk-associated allele at rs2755209. It was 
therefore hypothesised that both risk-alleles are on the same haplotype and the low r2 value is indicative 
of the difference in allele frequency. Following fine-mapping, a 28.7 kbp region underneath the 
association peak was selected for re-sequencing. 
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Figure 5.7 – Fine-mapping for the FOXO1 locus. 
Circles indicate imputed SNP data and squares indicate hard-typed SNPs. The two top SNPs are not in 
linkage disequilibrium (LD), therefore, the top plot displays the top SNP in purple with all other SNPs 
coloured according to their degree of LD (r2) with the top SNP. The bottom plot displays the second 
top SNP in purple and all other SNPs are coloured according to their degree of LD with the second 
top SNP based on the European population of the 1000 Genomes (Nov 2014 build). The lower section 
of the plot indicates the location nearby genes. The grey section indicates the region selected for re-
sequencing. 
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5.5.2.7 Summary of the fine-mapping results 
The top SNPs at each locus following fine mapping are summarised in Table 5.5. Apart from the 
RAB3GAP1 locus, the minor allele at top SNP(s) for all loci conferred an increased risk of keratoconus, 
with odds ratios above 1. For RAB3GAP1, the minor allele at the top SNP was associated with a 
decreased risk of keratoconus, and therefore is protective. However, due to the limited association peak, 
the RAB3GAP1 locus was not selected for re-sequencing. For the remaining loci, the regions selected 
for re-sequencing are also presented in Table 5.5. 
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Table 5.5 – A summary of the top SNPs at each locus and the regions following fine-mapping. 
Locus Top SNP 
Major 
Allele 
Minor 
Allele 
Case 
Freq. 
Control 
Freq. 
P-value OR [95% CI] 
Regions selected for 
re-sequencing 
RAB3GAP1 rs4954218 T G 0.27 0.33 2.33x10-3 0.75 [0.63-0.90] not selected 
FNDC3B rs4894538 A T 0.24 0.18 2.44x10-3 1.37 [1.12-1.69] chr3:171893935-172001141 
MPDZ-NFIB rs7851770 G T 0.23 0.16 8.24x10-5 1.53 [1.24-1.88] chr9:13534659-13570728 
RXRA-COL5A1 rs1536483 C T 0.42 0.33 1.45x10-5 1.47 [1.23-1.74] chr9:137436967-137484947 
LUM rs3759221 A G 0.17 0.12 4.51x10-3 1.41 [1.11-1.79] chr12:91442305-91573359 
FOXO1 
rs2755209 A C 0.43 0.34 1.50x10-5 1.46 [1.23-1.74] 
chr13:41109288-41138020 
rs79728429 C T 0.10 0.05 2.54x10-5 1.99 [1.44-2.75] 
Top SNP = the top SNP for the locus following fine-mapping. 
Case freq. = the frequency of the minor allele in the case cohort. 
Control freq. = the frequency of the minor allele in the control cohort. 
OR [95% CI] = the odds ratio for the minor allele with the major allele as reference and the 95% confidence interval. 
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 AIM 3: RE-SEQUENCING OF KERATOCONUS-ASSOCIATED LOCI IN 
CASES AND CONTROLS 
5.6.1 Methods 
5.6.1.1 Selecting regions for re-sequencing 
Five regions were selected for re-sequencing following the fine-mapping of key keratoconus-associated 
loci as described in Aim 2 (Section 5.5): FNDC3B, MPDZ-NFIB, RXRA-COL5A1, KERA-LUM-DCN 
and FOXO1. 
5.6.1.1 Study participants 
The case cohort consisted of 178 unrelated keratoconus cases, previously described in Section 2.1.1. 
For each locus, keratoconus patients carrying the risk allele at the top SNPs identified in the fine-
mapping analysis in Section 5.5 were selected for re-sequencing. To predict the carrier status, PLINK 
was used to extract the genotypes at the top SNPs from the fine-mapping data (Section 5.5.1.3). For 
each locus, individuals that were homozygous carriers of the risk allele were prioritised over 
heterozygotes to ensure that any variants identified were carried on the risk-associated haplotype. The 
control cohort consisted of 62 screened individuals without keratoconus from the Blue Mountains Eye 
Study. This cohort is described in Section 2.1.4. Unlike the cases, the controls were not selected based 
on their genotypes at the top SNPs, but instead on DNA availability.  
5.6.1.2 Re-sequencing 
A custom Nextera Rapid Capture Enrichment (Illumina) was designed for the regions of interest 
following the fine-mapping of keratoconus-associated loci using Illumina’s DesignStudio and hg19 as 
the reference. The target regions are summarised in Table 5.6.  
 
Table 5.6 – A summary of the target regions for the re-sequencing capture. 
Locus Region Size (bp) Probes 
FNDC3B chr3:171893935-172001141 107,206 467 
MPDZ-NFIB chr9:13534659-13570728 36,069 157 
RXRA-COL5A1 chr9:137436967-137484947 47,980 209 
LUM chr12:91442305-91573359 131,054 570 
FOXO1 chr13:41109288-41138020 28,732 125 
Probes = indicates the number of probes designed to cover the region selected for re-sequencing. 
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Both the capture and re-sequencing was conducted in-house. DNA samples were uniquely barcoded, 
multiplexed (12-plex), and enriched libraries were generated as outlined in Illumina’s ‘Nextera Rapid 
Capture Enrichment Reference Guide’ (document #15037436 v01; January 2016). Throughout this 
protocol, a TapeStation (Agilent Technologies, Santa Clara, California, USA) was used to assess the 
distribution of each library using either Agilent Technologies’s d1000 or High Sensitivity d1000 
reagents as required. DNA concentrations were determined using a Qubit Fluorometer (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). Following enrichment, the nanomolar (nM) concentration 
for each pooled library was determined as follows: 
concentration in nM =  
(concentration in ng/ul)
(660g mol⁄  × average fragment size)
 × 106 
Enriched libraries were pooled at equimolar concentrations such that 48 DNA samples were included 
in each sequencing run. These pooled libraries were diluted to 15 pM, spiked with 1% 20 pM PhiX 
(1.33% v/v) and denatured with NaOH as outlined in Illumina’s “MiSeq System: Denature and Dilute 
Guide” (document #15039740 v01; January 2016). Paired-end read sequencing was performed on an 
Illumina MiSeq using 150V3 reagents. 
5.6.1.3 Sequence data analysis  
Using bcbio-nextgen (https://github.com/bcbio/bcbio-nextgen), FASTQ files were aligned to the 
reference genome, GRCh37, using BWA188 (version 0.7.17) and variants were joint-called with 
GATK125 (version 3.8)  in line with GATK’s best practices. This generated in a single variant call format 
(VCF) file. To obtain locus-specific VCF files, BCFtools (https://github.com/samtools/BCFtools; 
version 1.5) was used to extract each re-sequenced region separately from the single VCF file. In the 
same command, multi-allelic variants were split into separate entries and indels were normalised and 
left aligned. Confidence tags were added to the genotypes as described in Section 2.2.1. Low confidence 
genotypes at the top SNPs (or second top SNP where relevant) were converted to missing variant calls 
as described in Section 2.2.2.  
To investigate coverage across the re-sequencing regions, depth information at each base-pair position 
was extracted for all individuals from the aligned BAM files using SAMtools164 (version 1.8). An 
example command is outlined in Appendix 16. For each locus, the mean depth and standard deviation 
was calculated across all samples at all base-pair positions and plotted using the ggplot2172 package in 
R.126 An example of the R script used to calculate the coverage statistics and generate the plot are 
presented in Appendix 17.  
5.6.1.4 Variant annotation 
Variants were annotated as outlined in Section 2.2.3. Key annotations used in the present study included 
variant identification codes (IDs) from the dbSNP128 147 database, gene annotations from the 
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RefGene128 database, minor allele frequencies (MAF) from the Genome Aggregation Database129 
(gnomAD), as well as, deleteriousness/pathogenicity predictions for SNPs with Combined Annotation 
Dependent Depletion134 (CADD) and Functional Analysis through Hidden Markov Models135 
(FATHMM), using the FATHMM-MKL136 algorithm. Pathogenicity and deleteriousness predictions 
for small insertions or deletions were annotated separately via the online batch submissions available 
for CADD (https://cadd.gs.washington.edu/score) and the FATHMM-indel137 algorithm 
(http://indels.biocompute.org.uk/) and were manually added to the annotated file. Using R, the 
frequency of each variant in the cases and controls, as well as maximum MAF observed across the eight 
ethnic populations in gnomAD (African, Admixed American, Ashkenazi Jewish, East Asian, Finnish, 
Non-Finnish European and ‘Other’, which includes individuals without an assigned population), were 
calculated and added to the annotated file.  
For each locus separately, pairwise linkage disequilibrium (LD) correlations, D’ and r2, between the top 
SNP and all other variants identified at the locus were determined using HaploView.257 To ensure the 
variant IDs were unique this column in the locus-specific VCFs were updated to a concatenation of the 
chromosome number, position, reference and alternate alleles (in the format: 1:1234C,T) using R. The 
VCF files with the updated ID columns were then converted to binary PLINK format files in PLINK 
whilst using the ‘keep-allele-order’ option to ensure the reference and alternate alleles were coded 
appropriately. To ensure HaploView could handle the insertions and deletions, these files were 
converted to PLINK format MAP and PED files using the modifier ‘--recode 12’ to code reference 
alleles as ‘1’s and alternate alleles as ‘2’s. Phenotype information was also added to the PED file at this 
stage. To match the input format for HaploView, a new file was generated from the PLINK MAP file, 
excluding the columns containing the chromosome and centimorgan. This file, along with the unaltered 
PED file were uploaded to the HaploView under the linkage format option. In HaploView, all markers 
were selected in the ‘check markers tab’ and the data from the ‘LD plot’ tab was downloaded as a text 
file. This file contained pairwise LD correlations between all possible pairs of variants in the given 
locus, namely D’ and r2 values. Comparisons between the top SNP (or second top SNP if relevant) and 
all other variants were transferred into a separate text file. These data were combined with the annotated 
file using the merge function in R.  
5.6.1.5 Variant prioritisation 
To ensure that low frequency variants carried on the risk-associated haplotype were included during 
variant prioritisation, D’ was used to measure pairwise LD correlation between the top SNP and all 
other SNPs identified within each locus. Along with the D’ value, HaploView outputs a log of the 
likelihood odds ratio (LOD) which represents the confidence in the D’ value. This LOD score is defined 
as log10(L1/L0), where L1 is likelihood of the data under linkage disequilibrium and L0 is likelihood 
of the data under linkage equilibrium. Together, the D’ and LOD scores were used to identify variants 
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that were in high LD with the top SNP with high confidence. For each locus separately, variants were 
filtered to identify those with a D’ greater than 0.9; a LOD greater than 2; and variants that obtained 
high confidence genotype calls (depth ≥ 10 and quality ≥ 20) in at least 50% of the re-sequenced 
individuals, including multiple high confidence variant calls. Variants were further prioritised to include 
only variants that were present in more than one case; observed at a frequency more than 1% higher in 
the cases compared to the control cohort; and observed at a frequency more than 1% higher in the cases 
compared to the maximum frequency observed in the gnomAD populations (or absent in gnomAD). 
5.6.1.6 Identifying putatively functional variants 
Highly prioritised variants were further investigated to identify putatively functional variants as 
previously described in Section 2.2.4. CADD and FATHMM scores were also considered at this stage 
of analysis. 
 
5.6.2 Results 
The five keratoconus-associated regions with strong association peaks in the fine-mapping analysis 
were re-sequenced in 178 keratoconus cases and 62 population controls. The cohort demographics are 
summarised in Table 5.7. 
Table 5.7 – Cohort demographics 
Group n Mean age (range) % Female Disease status 
Cases 178 45.8 (16-85) 44.4 affected 
Controls 62 65.1 (51-73) 48.4 unaffected 
n = the number of individuals in each cohort.  
Mean age = the mean average (and the range) is reported in years. 
 
Enriched libraries (containing DNA from 12 individuals) were of high quality with a mean fragment 
size of 384.8 (368-402) for fragments between 150 bp and 1000 bp. A representative electropherogram 
is presented in Figure 5.8.  
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Figure 5.8 – A representive electropherogram of an enriched library analysed with Agilent’s 4200 TapeStation system using high sensitivity d1000 
tapes. 
The electropherogram demonstrates the size distribution of the DNA library, where the x-axis indicates the size of the DNA fragments and the y-axis 
indicates the sample intensity. The lower and upper markers are labelled and gated in blue. The region between 150 bp and 1000 bp is gated in green and 
represents the DNA library. Details for this region are outlined in the region table below the plot. 
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Re-sequencing for all 240 individuals was conducted across five sequencing runs, with 48 individuals 
included in each run. Sequencing quality metrics are outlined in Table 5.8. 
 
Table 5.8 – Re-sequencing metrics by sequencing run 
Run 
Cluster 
Density 
Clusters PF 
(%) 
Total Reads Reads PF 
Total %  
≥ Q30 
1 1,439 ±25 86.55 ±1.46 34,096,024 29,517,874 93.01 
2 1,518 ±25 79.99 ±1.71 35,089,808 28,070,918 91.90 
3 1,656 ±38 80.65 ±1.75 37,810,504 30,510,564 90.13 
4 1,498 ±34 84.97 ±1.09 35,109,640 29,839,604 89.25 
5 1,656 ±31 74.30 ±3.64 36,546,592 27,201,368 85.51 
PF = “passing filters”. 
% ≥ Q30 = the percentage of reads with a quality score greater or equal to 30. 
 
Sufficient coverage (depth ≥ 10) for variant calling was obtained for 84.9% to 96.4% of the target 
region, depending on the locus (Table 5.9).  
Table 5.9 – Coverage statistics by locus 
Locus Total bases Bases with depth < 10 
(n regions) 
% with depth < 10 
FNDC3B 107,207 8,418 (79) 7.85 
MPDZ-NFIB 36,070 2,465 (13) 6.83 
RXRA-COL5A1 47,981 7,254 (36) 15.12 
LUM 131,055 4,675 (51) 3.57 
FOXO1 28,733 2,751 (21) 9.57 
Total bases = the total bases in the re-sequenced target region. 
Bases with depth < 10 = the number of bases with a mean depth less than 10. 
n regions = the number of regions with a mean depth less 10, where a region may be an isolated base 
with depth below 10 or multiple consecutive bases with depth below threshold. 
% with depth < 10 = the percentage of the re-sequenced target region with a mean depth less than 10 
 
 
The re-sequencing data was used to determine the carrier status that the top SNP for each locus as the 
fine-mapping data was imputed and the genotypes at these SNPs were not known in the control cohort. 
These data are outlined in Table 5.10. For the FNDC3B locus, the top SNP from the fine-mapping 
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analysis (rs4894538) was found to be within a repetitive sequence and therefore the genotypes at this 
SNP were poorly called. For this reason, the second top SNP (rs4894414), located 1,506 bp downstream 
of rs4894538, was used for all subsequent analysis of this locus. For the FOXO1 locus, three individuals 
had low confidence genotype calls for the top SNP (rs2755209), and therefore the genotype for these 
individuals were converted to missing so they did not affect the pairwise LD estimates with the other 
identified variants. A comparison of the top SNPs selected for the re-sequencing analysis and the 
previously reported SNPs are presented in Table 5.11. 
 
125 
 
 
Table 5.10 – Carrier status at the SNPs of interest for each re-sequenced region. 
    Cases Controls Total 
Locus Top SNP Ref Alt Hom Het NC Miss Hom Het NC Miss Hom Het NC Miss 
FNDC3B rs4894414* C T 28 60 90 0 4 17 41 0 32 77 131 0 
MPDZ-NFIB rs7851770 G T 23 70 85 0 4 17 41 0 27 87 126 0 
RXRA-COL5A1 rs1536483 C T 54 76 48 0 6 27 29 0 60 103 77 0 
LUM rs3759221 A G 11 58 109 0 0 16 46 0 11 74 155 0 
FOXO1 rs2755209 C T 51 90 35 2 12 27 22 1 63 117 57 3 
Ref = the reference allele. 
Alt = the alternate allele. 
Hom = the number of homozygotes (individuals carrying two copies of the alternate allele). 
Het = the number of heterozygotes (individuals carrying one copy of the alternate allele). 
NC = the number of non-carriers (individuals with no copies of the alternate allele). 
Miss = the number of individuals with missing (unknown) genotype calls. 
*Indicates the second top SNP for the locus and that this SNP was used for analysis. 
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Table 5.11 – A comparison of the top SNPs selected for the re-sequencing analysis and the previously reported SNPs 
     Alternate allele frequencies    
Locus Reported SNP Top SNP Ref Alt Cases Controls gnomAD max D' (LOD) r2 Distance (bp) 
FNDC3B rs4894535 rs4894414* C T 0.3119 0.1855 0.3207 1.00 (89.1) 0.93 1,894 
MPDZ-NFIB rs1324183 rs7851770 G T 0.6629 0.7903 0.8544 1.00 (91.2) 0.95 256 
RXRA-COL5A1 rs1536482 rs1536483 C T 0.5028 0.3145 0.4708 1.00 (102.8) 0.96 156 
LUM rs2268578 rs3759221 A G 0.7865 0.9113 0.9109 0.93 (51.5) 0.76 6,363 
FOXO1 rs2721051 rs2755209 C T 0.2247 0.0887 0.0925 0.97 (17.1) 0.21 26,920 
Reported SNP = The keratoconus-associated SNP reported in the literature or from Aim 1 of the present study. 
Top SNP = The SNP with the smallest p-value identified at the locus in the fine-mapping experiment (Aim 2). 
Ref = the reference allele. 
Alt = the alternate allele. 
gnomAD max = the maximum frequency of alternate allele observed across the populations available in the gnomAD database. 
D' (LOD) = the pairwise D prime value for the reported SNP and the top SNP. The LOD score for the D prime value is presented in the parenthesis.  
r2 = the pairwise r squared value for the reported SNP and the top SNP. 
Distance (bp) = the distance between the reported SNP and the top SNP in base pairs. 
*Indicates the second top SNP for the locus and that this SNP was used for analysis in Aim 3. 
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5.6.2.1 Re-sequencing results for the FNDC3B locus 
Coverage across the target region at the FNDC3B locus was generally of high quality with mean depth 
of 140 and standard deviation (sd) of 37.3. A total of 8,418 bases spread across 79 regions had 
insufficient read depth for high confidence variant calling, corresponding to 7.85% of the re-sequenced 
region. The largest of these was a region 1.9 kb region (3:171959424-171961339) that co-located in a 
long terminal repeat element as observed on the ReapeatMasker258 track available on the UCSC Genome 
Browser. A coverage plot for this locus is presented in Figure 5.9.  
A total of 853 variants were identified across the re-sequenced region. As highlighted previously, the 
second top SNP (rs4894414) at this locus was used as a proxy for the top SNP. Five variants were highly 
prioritised, including four SNPs and one deletion (Table 5.12). Despite meeting all other filtering 
conditions, the reported SNP for the FNDC3B locus from the literature (rs4894535) was not included 
in this list as the alternate allele was more frequent in the East Asian population in gnomAD (32.1%) 
than our keratoconus cases (31.2%). The highly prioritised variants were all located within introns of 
FNDC3B and span approximately a 50 kb region. None of these variants obtained CADD or FATHMM 
scores indicative of functionality, however, some noteworthy annotations were identified following 
investigations using the UCSC Genome Browser. Three of the highly prioritised variants, rs76047624, 
rs77351096 and rs7635832, were located in DNase1 hypersensitivity clusters in six to ten of the cell 
types available from ENCODE. These three variants, along with rs35417004, are also located within 
an annotated enhancer region in at least one cell line. Additionally, rs77351096 is located within 
chromatin immunoprecipitation (ChIP) peaks for 19 transcription factors, indicating that these factors 
bind within this region.  
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Figure 5.9 – Coverage of the re-sequenced region at the FNDC3B locus. 
The black line indicates the mean depth, the red horizontal line indicates a depth of 10 (the minimum depth required for variant calling) and the blue shaded 
area indicates the area between the mean ± 1 standard deviation. The position of the top SNP and second top SNP are indicated by the purple and orange dots 
(respectively). 
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Table 5.12 – Highly prioritised variants at the FNDC3B locus. 
      Alternate allele frequencies   
Position Ref Alt Variant ID CADD FATHMM Cases Controls gnomAD max D' (LOD) r2 
3:171940636-171940636 G A rs76047624 7.71 0.19 0.0646 0.0161 0.0542 1.00 (3.30) 0.02 
3:171947244-171947244 T - rs145117275 3.62 0.03 0.0702 0.0484 0.0336 1.00 (11.93) 0.17 
3:171961459-171961459 C T rs35417004 4.88 0.06 0.1854 0.1210 0.1097 0.92 (31.14) 0.42 
3:171988707-171988707 T C rs77351096 1.69 0.18 0.0843 0.0645 0.0504 1.00 (15.38) 0.21 
3:171989276-171989276 T G rs7635832 1.13 0.16 0.3343 0.2097 0.3240 1.00 (95.69) 0.96 
3: 171997499- 171997499 C T rs4894414 5.04 0.20 0.3258 0.2016 0.3220   
Ref = the reference allele. 
Alt = the alternate allele. 
Variant ID = the variant identifier from the avsnp147 database. 
CADD = the scaled CADD score.  
FATHMM = the FATHHMM-MKL or FATHMM-indel score. 
gnomAD max = the maximum frequency of alternate allele observed across the populations available in the gnomAD database. 
D' (LOD) = the pairwise D prime value for this variant and the top SNP. The LOD score for the D prime value is presented in the parenthesis.  
r2 = the pairwise r squared value for the variant and the top SNP. 
The row containing the information for the top SNP is shaded grey. 
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5.6.2.2 Re-sequencing results for the MPDZ-NFIB locus 
A mean depth of 102.6 reads (sd = 29.9) was obtained for the re-sequenced region at the MPDZ-NFIB 
locus. A total of 2,465 bases across thirteen regions had insufficient coverage for variant calling (6.8% 
of the re-sequenced region) which largely corresponded to short interspersed nuclear elements, 
visualised using the RepeatMasker track on UCSC Genome Browser. Coverage for the re-sequenced 
region for MPDZ-NFIB is presented in Figure 5.10. 
A total of 403 variants were called across the MPDZ-NFIB locus. Thirty-nine variants in high LD with 
risk allele at the top SNP (rs7851770) were highly prioritised following variant filtering, including three 
deletions and 36 SNPs (Table 5.13). Two SNPs, rs12003602 and rs34074476, obtained CADD scores 
above 10, which is suggestive of functionality. The FATHMM scores for the same variants confirm this 
potential for rs12003602 (0.75). This variant removes a CpG site, however further investigation of this 
variant using the tracks available on the UCSC Genome Browser were unremarkable. 
The reported SNP from the literature at the MPDZ-NFIB locus (rs1324183) was in high LD with the 
top SNP identified in the fine-mapping experiment (rs7851770) with a D’ of 1 (LOD = 91.2), however, 
the alternate allele was observed less frequently in our keratoconus patients (66.3%) compared to our 
controls (79.0%). The frequency of this variant in the control group is consistent with the allele 
frequency reported in the non-Finnish European population of gnomAD (80.5%). Therefore, this variant 
was not included in the highly prioritised list of variants at this locus. 
Almost all of the highly prioritised variants at this locus were located within regions annotated as 
heterochromatin in all nine cell lines included in the chromatin state segmentation from 
ENCODE/Broad, however, seven SNPs overlap an enhancer in at least one of the cell lines: rs11999938, 
rs34813744, rs35638627, rs35641278, rs1324186, rs35846464 and rs34759288. Six of these are located 
within a 3 kb window at the 3’ end of the re-sequenced region, surrounding a region with strong 
evidence of a regulatory region (Figure 5.11). Five of these variants are also located within DNase1 
hypersensitivity clusters identified in at least seven cell types. Based on these findings, it is likely that 
the functional variation at the MPDZ-NFIB locus is located within this 3kb region. 
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Figure 5.10 – Coverage of the re-sequenced region at the MPDZ-NFIB locus. 
The black line indicates the mean depth, the red horizontal line indicates a depth of 10 (the minimum depth required for variant calling) and the blue shaded 
area indicates the area between the mean ± 1 standard deviation. The position of the top SNP is indicated by the purple dot. 
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Table 5.13 – Highly prioritised variants at the MPDZ-NFIB locus. 
      Alternate allele frequencies  
Position Ref Alt Variant ID CADD FATHMM Cases Controls gnomAD max D' (LOD) r2 
9:13534850-13534850 G A rs71507380 3.22 0.10 0.1545 0.0887 0.0855 0.98 (26.87) 0.98 
9:13534994-13534994 A G rs36052788 7.57 0.17 0.3090 0.1774 0.2898 0.99 (79.59) 0.99 
9:13536083-13536083 G A rs12002959 0.80 0.06 0.3090 0.1613 0.2723 0.99 (76.90) 0.99 
9:13537768-13537768 G A rs12003602 14.84 0.75 0.3006 0.1613 0.1834 0.99 (72.66) 0.99 
9:13543094-13543094 C G rs13295903 1.28 0.17 0.0393 0.0161 0.0148 1.00 (6.10) 1.00 
9:13543646-13543646 C T rs13296965 8.21 0.95 0.3118 0.1613 0.2208 1.00 (82.13) 1.00 
9:13544779-13544779 A G rs67878159 2.54 0.07 0.3146 0.1613 0.2361 0.99 (79.59) 0.99 
9:13544878-13544881 CAAA - rs67012432 2.26 0.00 0.3062 0.1613 0.2306 0.99 (75.15) 0.99 
9:13546790-13546790 C A rs12686335 2.80 0.11 0.3118 0.1855 0.1954 1.00 (86.67) 1.00 
9:13548060-13548060 C A rs10491754 2.06 0.13 0.3118 0.1613 0.2712 1.00 (82.13) 1.00 
9:13548561-13548561 A G rs77767334 2.66 0.08 0.0590 0.0403 0.0430 0.93 (8.20) 0.93 
9:13550069-13550069 C A rs2224860 0.59 0.04 0.3174 0.1613 0.2891 0.98 (78.26) 0.98 
9:13550541-13550541 A G rs977580 3.12 0.11 0.3258 0.2016 0.2971 0.98 (91.35) 0.98 
9:13551273-13551273 C T rs7855460 6.28 0.16 0.3230 0.2016 0.2378 0.94 (76.6) 0.94 
9:13555074-13555074 G A rs13294011 0.78 0.16 0.3202 0.1774 0.2962 1.00 (89.59) 1.00 
9:13555912-13555912 G T rs11999938 1.23 0.16 0.3258 0.1774 0.2114 0.98 (85.37) 0.98 
9:13557504-13557504 G T rs7851523 0.88 0.09 0.3258 0.1774 0.2967 1.00 (92.86) 1.00 
9:13557747- 13557747 G T rs7851770 10.25 0.19 0.3258 0.2016 0.3112   
9:13558378-13558378 G A rs13291445 0.22 0.05 0.3258 0.2016 0.2474 1.00 (99.73) 1.00 
9:13558455-13558455 A G rs12686184 0.77 0.07 0.3371 0.1935 0.3089 0.96 (79.68) 0.96 
9:13559717-13559717 T A rs66720556 1.54 0.15 0.3230 0.1774 0.2469 1.00 (91.17) 1.00 
9:13559821-13559821 G T rs10491756 0.59 0.19 0.3202 0.1774 0.2447 1.00 (89.29) 1.00 
9:13561657-13561658 AT - rs35928895 5.90 0.00 0.3230 0.1774 0.2002 1.00 (91.17) 1.00 
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      Alternate allele frequencies  
Position Ref Alt Variant ID CADD FATHMM Cases Controls gnomAD max D' (LOD) r2 
9:13562146-13562146 A C rs12004620 0.31 0.09 0.3287 0.2016 0.1967 0.99 (93.41) 0.99 
9:13563513-13563513 G T rs66592246 0.80 0.07 0.3174 0.1774 0.1954 1.00 (87.49) 1.00 
9:13563660-13563660 G T rs13290289 0.67 0.07 0.3258 0.1694 0.2416 1.00 (90.87) 1.00 
9:13565084-13565084 A - rs35870971 6.04 0.00 0.3230 0.1855 0.1905 0.98 (85.37) 0.98 
9:13565222-13565222 G T rs34944131 0.08 0.05 0.3202 0.1935 0.1680 0.92 (70.75) 0.92 
9:13565696-13565696 C G rs60613246 0.46 0.13 0.3258 0.1694 0.1897 0.98 (83.58) 0.98 
9:13565965-13565965 G T rs34416482 0.25 0.11 0.3258 0.1694 0.1892 0.98 (83.58) 0.98 
9:13566456-13566456 G A rs34074476 13.02 0.13 0.3258 0.1694 0.1893 0.98 (83.58) 0.98 
9:13566852-13566852 C T rs61183216 2.06 0.05 0.3258 0.1694 0.2394 0.98 (83.58) 0.98 
9:13566987-13566987 G A rs12684945 0.71 0.03 0.3258 0.1774 0.2445 0.98 (85.07) 0.98 
9:13567440-13567440 G A rs12685187 3.37 0.06 0.3230 0.1694 0.2416 0.99 (85.24) 0.99 
9:13567822-13567822 C T rs34813744 4.13 0.06 0.3202 0.1774 0.1889 0.98 (82.47) 0.98 
9:13567945-13567945 A G rs35638627 3.90 0.18 0.3202 0.1774 0.1897 0.98 (82.47) 0.98 
9:13567984-13567984 G A rs35641278 0.71 0.14 0.3202 0.1532 0.1875 0.98 (77.96) 0.98 
9:13568063-13568063 C T rs1324186 5.60 0.18 0.4045 0.2581 0.3272 0.94 (52.96) 0.94 
9:13568184-13568184 A G rs35846464 2.55 0.16 0.3202 0.1774 0.1885 0.98 (82.47) 0.98 
9:13570462-13570462 G C rs34759288 0.01 0.14 0.3146 0.1532 0.1934 0.98 (75.58) 0.98 
Ref = the reference allele. 
Alt = the alternate allele. 
Variant ID = the variant identifier from the avsnp147 database. 
CADD = the scaled CADD score.  
FATHMM = the FATHHMM-MKL or FATHMM-indel score. 
gnomAD max = the maximum frequency of alternate allele observed across the populations available in the gnomAD database. 
D' (LOD) = the pairwise D prime value for this variant and the top SNP. The LOD score for the D prime value is presented in the parenthesis.  
r2 = the pairwise r squared value for the variant and the top SNP. 
The row containing the information for the top SNP is shaded grey. 
Variants that overlap an enhancer in at least one of the cell lines in the chromatin state segmentation data from ENCODE/Broad are bold. 
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Figure 5.11 – A screenshot from the UCSC Genome Broswer highlighting the location of highly prioritised variants at the MPDZ locus surrounding a regulatory region at the distal end of the re-sequenced region. 
The red line on the schematic of chromosome 9 (indicated by the red arrow) shows the location of the ~ 3 kb region displayed in the plot (chr9:13,567,661-13,570,621). The green vertical highlights indicate the position of the highly 
prioritised variants identified. The tracks from top to bottom are: layered H3K27Ac marks on 7 cell lines from ENCODE, where blue peaks indicate regions identified in Human umbilical vein endothelial cells (HUVEC); DNaseI 
Hypersensitivity Clusters in 125 cell types from ENCODE (V3), where the number to the right of the grey box indicates the number of cell types the cluster is found in; transcription factor ChIP-seq (161 factors) from ENCODE, where 
the darker the shade of grey the more transcription factors that bind to the region indicated; Chromatin State Segmentation by HMM from ENCODE/Broad (‘pack’ display mode), where promotors are red, strong enhancers are orange, 
weak or poised enhancers are yellow, weakly transcribed regions are light green, dark green indicates transcriptional transition or elongation, blue identifies an insulator, dark grey indicates polycomb-repressed DNA and light grey 
represents heterochromatin, repetitive DNA or copy number variation; and CADD v1.3 where the higher the pink peak, the higher the scaled score. 
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5.6.2.3 Re-sequencing results for the RXRA-COL5A1 locus 
The re-sequenced region at the RXRA-COL5A1 locus obtained a mean coverage of 90.6 (sd = 30.6). A 
coverage plot is presented in Figure 5.12. Thirty-six regions had insufficient coverage for variant calling 
(7,254 bases in total), corresponding to 15.12% of the re-sequenced region. Many of these regions 
overlap repetitive elements as observed on the RepeatMasker track on the UCSC Genome Browser. 
The largest of these regions with insufficient coverage was 2,865 bp in length (chr9:137478643-
137481507) and co-located with a long interspersed nuclear element. Conversely, a ~2,200 bp region 
(9:137464558-137466773) within the re-sequenced region was obtained a mean depth greater than 200 
reads. This region overlaps an insulator – a long-range regulatory element that functions by blocking 
enhancers from acting on promotor regions – as annotated in the chromatin state segmentation track 
available on the UCSC Genome Browser. 
A total of 356 variants were identified across all individuals in the re-sequenced region for the COL5A1-
RXRA locus. Five SNPs were highly prioritised following variant filtering, including rs1536482, the 
SNP reported in the literature that originally implicated this locus in keratoconus (Table 5.14). These 
SNPs are all within a 750 bp window, just upstream of the top SNP identified in the fine-mapping 
analysis (rs1536483). All five SNPs are located in a region that is weakly transcribed in embryonic stem 
cells (H1-hESC), human skeletal muscle myoblasts (HSMM) and normal human lung fibroblasts 
(NHLF) and is repressed or forms heterochromatin in the remaining six cell lines available in the 
chromatin state segmentation track on the UCSC Genome Browser. The variants also all overlap 
DNase1 hypersensitivity clusters in at least five of the 125 cells lines, with rs3118517 overlapping 
clusters in the most cells types (14). While none of the highly prioritised variants obtained CADD or 
FATHMM scores indicative of functionality, rs3118517 obtained the highest scores for both algorithms 
with a CADD score of 5.52 and a FATHMM score of 0.10. 
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Figure 5.12 – Coverage of the re-sequenced region at the RXRA-COL5A1 locus. 
The black line indicates the mean depth, the red horizontal line indicates a depth of 10 (the minimum depth required for variant calling) and the blue shaded 
area indicates the area between the mean ± 1 standard deviation. The position of the top SNP is indicated by the purple dot. 
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Table 5.14 – Highly prioritised variants at the RXRA-COL5A1 locus.  
      Alternate allele frequencies   
Position Ref Alt avsnp147 CADD FATHMM Cases Controls gnomAD max D' (LOD) r2 
9:137439792-137439792 G A rs3118516 0.36 0.04 0.5028 0.3065 0.4172 1.00 (101.44) 0.95 
9:137439905-137439905 C T rs3118517 5.52 0.10 0.5028 0.3065 0.4238 1.00 (101.44) 0.95 
9:137440083-137440083 G A rs3118518 0.66 0.05 0.5056 0.3065 0.4205 0.99 (98.68) 0.94 
9:137440212-137440212 T C rs3132306 3.72 0.09 0.5084 0.3065 0.4205 0.98 (96.83) 0.93 
9:137440528-137440528 G A rs1536482 0.39 0.05 0.5028 0.3145 0.4708 1.00 (102.82) 0.96 
9:137440684-137440684 C T rs1536483 1.95 0.06 0.5169 0.3145 0.5194   
Ref = the reference allele. 
Alt = the alternate allele. 
Variant ID = the variant identifier from the avsnp147 database. 
CADD = the scaled CADD score.  
FATHMM = the FATHHMM-MKL or FATHMM-indel score. 
gnomAD max = the maximum frequency of alternate allele observed across the populations available in the gnomAD database. 
D' (LOD) = the pairwise D prime value for this variant and the top SNP. The LOD score for the D prime value is presented in the parenthesis.  
r2 = the pairwise r squared value for the variant and the top SNP. 
The row containing the information for the top SNP is shaded grey. 
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5.6.2.1 Re-sequencing results for the KERA-LUM-DCN locus 
A mean depth of 104.6 (sd = 30.3) was obtained for the re-sequenced region at the KERA-LUM-DCN 
locus. A total of 4,675 bases across fifty-one regions had insufficient coverage for high confidence 
variant calling, corresponding to 3.6% of the re-sequenced region. This locus was the most 
comprehensively captured locus included in the re-sequencing experiment. A coverage plot is presented 
in Figure 5.13. 
1,039 variants were identified across the re-sequenced region. It is noteworthy that all of the variants 
identified at this locus were non-coding despite the re-sequencing region encompassing three genes 
(KERA, LUM and DCN). Ten variants were highly prioritised following variant filtering, including 
seven SNPs, two insertions and one deletion (Table 5.15). All of these are low frequency variants with 
maximum frequencies in the gnomAD database below 4%. None of these variants obtained CADD or 
FATHMM scores indicative of functionality, however, one of the insertions, rs535582722, is located 
in the 3’ untranslated region of decorin (DCN) in six transcripts available in NCBI RefSeq genes track 
on the UCSC Genome Browser (NM_001920.4, and NM_133503.3- NM_133507.3, NM_133504.3, 
NM_133505.3 NM_133506.3, and NM_133507.3). This variant is also located within a region that is 
annotated as a weak enhancer identified in two cell lines (HUVEC and NHLF) and overlaps a ChIP 
peak for a transcription factor, making it the most likely putatively functional variant at this locus. All 
other variants are located in intronic or intergenic regions. The variants 12:91500467insA and 
rs538786536 were also located in a weak enhancer region in one of the nine cell lines (NHLF and 
HSMM, respectively). The 12:91500467insA is absent in the gnomAD database, but is present in both 
our cases and controls, suggesting that it is either a common, population specific polymorphism or a 
sequencing artefact. 
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Figure 5.13 – Coverage of the re-sequenced region at the LUM locus. 
The black line indicates the mean depth, the red horizontal line indicates a depth of 10 (the minimum depth required for variant calling) and the blue shaded 
area indicates the area between the mean ± 1 standard deviation. The position of the top SNP is indicated by the purple dot. 
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Table 5.15 – Highly prioritised variants at the LUM locus. 
       Alternate allele frequencies   
Position Ref Alt Location Variant ID CADD FATHMM Cases Controls gnomAD max D' (LOD) r2 
12:91483743-91483743 T - KERA-LUM rs776115787 0.80 0.00 0.0140 0.0000 0.0033 1.00 (2.34) 0.04 
12:91483745-91483745 T C KERA-LUM rs747712265 0.73 0.19 0.0140 0.0000 0.0033 1.00 (2.34) 0.04 
12:91491354-91491354 A C KERA-LUM rs73197102 1.24 0.07 0.0815 0.0323 0.0375 1.00 (17.84) 0.30 
12:91500467-91500467 - A LUM (intronic) novel 0.67 0.01 0.1404 0.1129 0.0000 1.00 (2.15) 0.04 
12:91507561-91507561 A G LUM-DCN rs3759221 2.52 0.03 0.2247 0.1290 0.6409   
12:91515237-91515237 G A LUM-DCN rs73198626 0.54 0.03 0.0197 0.0000 0.0082 1.00 (3.48) 0.06 
12:91537633-91537633 - TA DCN (3’ UTR) rs535582722 0.06 0.01 0.0281 0.0081 0.0170 1.00 (4.91) 0.09 
12:91541802-91541802 C G DCN (intronic) rs143915956 0.40 0.13 0.0281 0.0081 0.0164 1.00 (4.91) 0.09 
12:91549814-91549814 A G DCN (intronic) rs538786536 0.63 0.15 0.0169 0.0000 0.0066 1.00 (3.06) 0.05 
12:91564805-91564805 T G DCN (intronic) rs73198634 6.21 0.14 0.0618 0.0000 0.0173 1.00 (11.53) 0.19 
12:91566250-91566250 C T DCN (intronic) rs3138185 4.53 0.18 0.0787 0.0161 0.0334 1.00 (16.22) 0.27 
Ref = the reference allele. 
Alt = the alternate allele. 
Variant ID = the variant identifier from the avsnp147 database. 
CADD = the scaled CADD score.  
FATHMM = the FATHHMM-MKL or FATHMM-indel score. 
gnomAD max = the maximum frequency of alternate allele observed across the populations available in the gnomAD database. 
D' (LOD) = the pairwise D prime value for this variant and the top SNP. The LOD score for the D prime value is presented in the parenthesis.  
r2 = the pairwise r squared value for the variant and the top SNP. 
The row containing the information for the top SNP is shaded grey. 
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5.6.2.2 Re-sequencing results for the FOXO1 locus 
Mean coverage across the re-sequenced region for the FOXO1 locus was 92.2 (sd = 28.6). A total of 
2,751 bases had insufficient coverage for high confidence variant calling, corresponding to 9.57% of 
the re-sequenced region. A plot of the coverage for the re-sequenced region at FOXO1 is presented in 
Figure 5.14. 
A total of 198 variants were identified across the FOXO1 locus. Nine variants were prioritised for 
further investigation following variant filtering, including eight SNPs and a small insertion (Table 5.16). 
The reported SNP in the literature for the FOXO1 locus, rs2721051, was included in this filter. The nine 
highly prioritised variants largely clustered in the second intron of the ENST00000636651.1 transcript 
of FOXO1, around the single exon gene AL133318.1 (Figure 5.15).  
AL133318.1 (ENSG00000269120.1) is a newly discovered gene located at chr13:41111138-41111323, 
which only appears to be in the most recent release of the GENCODE Project259 (V28lift37; April 2018). 
This gene encodes an uncharacterised protein consisting of 62 amino acids. According to the GETx 
database, the mRNA for AL133318.1 is expressed at very low levels in all tissues assessed, with 
relatively high expression in sun exposed skin, the most relevant tissue to cornea. Within the ~31 kb 
region presented in Figure 5.15 that encompasses all highly prioritised variants, there are seven 
expression quantitative trait loci (eQTL) for AL133318.1. Of these eQTLs, three were identified in five 
or six tissues including sun exposed skin (rs58104999, rs7333246 and rs7332960), one is an eQTL in 
subcutaneous adipose tissue (rs17446593) and three are eQTLs in the basal ganglia region of the brain 
(rs79703116, rs80223071 and rs1078892). All nine of the highly prioritised variants identified in the 
present study are within a 1.5 kb window of an eQTL for AL133318.1 in at least one tissue type and 
five – 13:41110554insTTTTCTTTC, rs2721051, rs74948688, rs79728429, rs1078892 – are within 250 
bp of the eQTLs rs58104999, rs7333246 and rs1078892. 
Of the nine highly prioritised SNPs, rs79728429 is most compelling putatively functional variant as it 
is located in an enhancer region annotated in eight of the nine cell lines avaliable in the chromoatin state 
segmentation by Hidden Markov Model from ENCODE/Broad and overlaps ChIP seq peaks for 14 
transcription factors. The SNP is also located within a strong H3K27Ac histone mark in Human 
umbilical vein endothelial cells (HUVEC) and overlaps DNase1 Hypersenitivity clusters in 92 of the 
125 cell types from ENCODE. This SNP was also the second most associated SNP in the fine-mapping 
analysis of this locus described in Aim 2. Taken together, these annotations suggest that this variant is 
located in a likely regulatory element. An eQTL for AL133318.1, rs7333246, is also located within this 
same regulatory region, just 132 bp away from rs79728429, and has been shown to significantly affect 
the expression of the AL133318.1 protein in five of the tissues in the GETx database, including sun 
exposed skin.  
142 
 
 
 
Figure 5.14 – Coverage of the re-sequenced region at the FOXO1 locus. 
The black line indicates the mean depth, the red horizontal line indicates a depth of 10 (the minimum depth required for variant calling) and the blue shaded 
area indicates the area between the mean ± 1 standard deviation. The position of the top SNP and second top SNP are indicated by the purple and orange dots 
(respectively). 
 
 
  
143 
 
Table 5.16 – Highly prioritised variants at the FOXO1 locus. 
      Alternate allele frequencies   
Position Ref Alt Variant ID CADD FATHMM Cases Controls gnomAD max D' (LOD) r2 
13:41110270-41110270 T C rs2755238 2.40 0.15 0.2247 0.0887 0.0926 0.97 (17.07) 0.21 
13:41110554-41110554 - TTTTCTTTC NA 0.09 0.00 0.1910 0.0806 0.0299 0.96 (12.60) 0.18 
13:41110884-41110884 C T rs2721051 11.62 0.34 0.2247 0.0887 0.0925 0.97 (17.07) 0.21 
13:41110922-41110922 C T rs74948688 15.43 0.33 0.1713 0.0484 0.0606 0.96 (12.22) 0.14 
13:41114572-41114572 C T rs79728429 14.84 0.34 0.1573 0.0565 0.0556 0.95 (10.52) 0.13 
13:41115586-41115586 A C rs2701857 0.17 0.07 0.2247 0.0887 0.0922 0.97 (17.07) 0.21 
13:41119466-41119466 G A rs11616662 0.08 0.03 0.2247 0.0887 0.1467 0.97 (17.07) 0.21 
13:41126936-41126936 C G rs2701894 1.76 0.12 0.4916 0.3629 0.4695 0.92 (58.16) 0.69 
13:41137784-41137784 G A rs80070740 4.66 0.26 0.2247 0.0968 0.0968 1.00 (20.21) 0.23 
13:41137804-41137804 A C rs2755209 2.65 0.13 0.5393 0.4113 0.7667   
Ref = the reference allele. 
Alt = the alternate allele. 
Variant ID = the variant identifier from the avsnp147 database. 
CADD = the scaled CADD score.  
FATHMM = the FATHHMM-MKL or FATHMM-indel score. 
gnomAD max = the maximum frequency of alternate allele observed across the populations available in the gnomAD database. 
D' (LOD) = the pairwise D prime value for this variant and the top SNP. The LOD score for the D prime value is presented in the parenthesis.  
r2 = the pairwise r squared value for the variant and the top SNP. 
NA = the variant did not have a variant ID available in the avsnp147 database. 
The row containing the information for the top SNP is shaded grey. 
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Figure 5.15 – A screenshot from the UCSC Genome Broswer highlighting the location of highly prioritised variants at the FOXO1 locus in high LD with rs2755209 that were identified by re-seqeuncing. 
The red line on the schematic of chromosome 13 (indicated by the red arrow) shows the location of the ~31 kb region displayed in the plot (chr13:41,109,745-41,140,649). The green vertical highlight indicates the position of rs79728429, 
the putatively functional variant at this locus. All other highly prioritised variants are highlighted in yellow. The tracks from top to bottom are: UCSC genes; GENCODE V28lift37 genes, note the small blue square indicating the position 
of AL133318.1 on the top left; combined expression QTLs (eQTLs) from 44 tissues from GTEx (midpoint release, V6), where the position of SNPs that are eQTLs for AL133318.1 in multiple tissues (including sun exposed skin) are 
indicated in red; SNPedia; layered H3K27Ac marks on 7 cell lines from ENCODE, where blue peaks indicate regions identified in Human umbilical vein endothelial cells (HUVEC); DNaseI Hypersensitivity Clusters in 125 cell types 
from ENCODE (V3), where the number to the right of the grey box indicates the number of cell types the cluster is found in; transcription factor ChIP-seq (161 factors) from ENCODE, where the darker the shade of grey the more 
transcription factors that bind to the region indicated; Chromatin State Segmentation by HMM from ENCODE/Broad, where promotors are red, strong enhancers are orange, weak or poised enhancers are yellow, weakly transcribed 
regions are light green, dark green indicates transcriptional transition or elongation, blue identifies an insulator, dark grey indicates polycomb-repressed DNA and light grey represents heterochromatin, repetitive DNA or copy number 
variation; and CADD v1.3 where the higher the pink peak, the higher the scaled score. 
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 DISCUSSION 
Aim 1 of this study identified a novel keratoconus-associated locus at rs2268578, located in the first 
intron of the lumican gene (LUM), by assessing CCT-associated loci in our keratoconus cohort. This 
stage of the study used CCT as an endophenotype for keratoconus, an approach that had previously been 
shown to be an effective method for identifying keratoconus-associated loci and was integral in the 
identification of three of the four GWAS hits for keratoconus reported to date.87 The present study 
contributed to a large publication that conducted a cross-ancestry GWAS for CCT and subsequently 
screened novel CCT-associated loci in disease cohorts, including keratoconus.249 While the CCT GWAS 
included in the published work informed SNP selection in this dissertation, the published study only 
assessed the sentinel SNP at each CCT-associated locus in the keratoconus patients (36 SNPs), and a 
number of SNPs were excluded as they were not available in the other keratoconus cohorts. In the 
published work, the LUM locus was represented by rs7308752, located between LUM and DCN, and 
showed a suggestive association (p = 6.33 x10-3) with keratoconus following a meta-analysis of our 
cases (n = 711), keratoconus patients from Northern Island (n = 135) and a cohort of keratoconus 
patients from the USA (n = 240).249 In this dissertation, this work was extended by fine-mapping the 
LUM locus in our cohort of cases and controls using genome-wide imputation data (Aim 2) which 
identified a broad association peak that encompassed not only LUM, but also keratocan (KERA) and 
decorin (DCN). The present study also demonstrated that the top SNP at this locus was rs3759221.  
All three genes at the KERA-LUM-DCN locus belong to the small leucine-rich proteoglycan family,260 
and together encode three of the four small leucine-rich proteoglycans present in the stroma of the adult 
cornea.32, 261 Proteoglycans are macromolecules composed of a protein core with at least one covalently 
linked glycosaminoglycan chain. In the cornea, proteoglycans play crucial roles in collagen fibril 
assembly, matrix organization, and ultimately, corneal transparency,32, 262 however they also perform 
diverse functions beyond these roles. Decorin binds growth factors allowing it to modulate a number of 
biological pathways, including TGF-β;263 plays a role in cell growth and differentiation and inhibits 
apoptosis;264 is involved in cutaneous wound healing and angiogenesis;265 and the expression of DCN 
is known to be regulated by cytokines, including TNF-α,266 IL-1267 and IL4-4,268 suggesting a dynamic 
role in inflammation. Lumican has similar roles in apoptosis;269, 270 corneal epithelial wound healing;271 
cell migration and invasion;270, 272 inflammation;272 and angiogenesis.273 There is also evidence that 
lumican is involved in the expression of KERA.274 While there are fewer studies that examine the 
function of keratocan, it has been shown to modulate cell differentiation and bone formation,275 and 
plays a unique role in the overall development and shape of the cornea with keratocan-null mice 
displaying narrow iridocorneal angles (the angle between the iris and the cornea), thin stromas with 
abnormal packaging and organisation of the collagen fibrils, but normal corneal transparency.262 
Clearly, this locus is highly relevant to the normal development, structure and maintenance of the cornea 
and therefore is a highly plausible keratoconus-susceptibility locus. 
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Variation within KERA, LUM and DCN have previously been linked to ocular diseases and/or corneal 
abnormalities, which adds additional evidence for their important roles in the cornea. Truncating 
variants in DCN cause congenital stromal corneal dystrophy (OMIM 610048) which features opaque 
flecks in the stroma and abnormal organisation of the lamellae, although normal corneal thickness.276 A 
number of variants located in LUM have been associated with high myopia in studies largely conducted 
in the Han Chinese population,277-287 although other studies in the Han Chinese, as well as, Korean and 
Japanese populations do not support this association.288-293 Though less relevant to the cornea, LUM has 
also been implicated in the pathogenesis of glaucoma with one study demonstrating a 1.5-fold increase 
in LUM expression trabecular meshwork of individuals with primary open-angle glaucoma compared 
to healthy controls.294 KERA has previously been linked to two autosomal recessive corneal dystrophies. 
The first is cornea plana type 2 (OMIM 217300), which is caused by homozygous or compound 
heterozygous variants in KERA and features flattened corneas, corneal opacities and indistinct limbus, 
resulting high hypermetropia (long-sightedness).295 Similarly, homozygous or compound heterozygous 
variants in the gene encoding carbohydrate sulfotransferase 6 (CHST6), which encodes the enzyme that 
mediates the sulfation of keratocan in the cornea, results in macular corneal dystrophy (OMIM 
217800).296 This dystrophy is characterised by progressive punctate opacities of the cornea, which 
ultimately results in bilateral vison loss.296 Increased expression of KERA has also been observed in the 
stroma of keratoconic corneas, compared to healthy controls.297 Interestingly, though the re-sequenced 
region in Aim 3 of the present study encompassed all three genes, no protein-coding variants were 
identified in any of the cases or controls. This suggests that the functional variant at this locus is likely 
to be located in a regulatory region. Following variant filtering, ten variants were highly prioritised at 
this locus, and while evidence of the functionality of these variants was limited, a low frequency variant 
(rs535582722) located in the 3’ UTR region of LUM showed the most promise. Further investigations 
are required to determine the functional variant and target gene(s) at this novel and compelling 
keratoconus-susceptibility locus. 
Three additional loci were significantly associated with keratoconus in the first stage of the present 
study including two SNPs between RXRA and COL5A1 – rs1536482 (p = 7.24 x10-7) and rs3132303 (p 
= 2.4 x 10-5) – and two known keratoconus-susceptibility loci: FOXO1 (rs2755238; p = 1.0 x 10-6) and 
MPDZ-NFIB (rs66720556; p = 6.9 x10-5). While this study lacked power to reach genome-wide 
significance, it should be highlighted that the most significantly associated locus was RXRA-COL5A1, 
with rs1536482 surpassing the well-known genome-wide associated keratoconus loci. This suggests 
that variation within the RXRA-COL5A1 locus is likely to be important in keratoconus susceptibility, 
which is further supported by the fact that COL5A1 encodes an alpha chain for collagen type V, a fibril-
forming collagen that is highly expressed in the corneal stroma.298 The significant association we 
observed in our cohort is in line with previous studies conducted in similar populations. The SNP 
rs1536482 was associated with keratoconus in a candidate gene study which assessed 44 SNPs in or 
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nearby COL5A1 in two independent case-control cohorts and a familial cohort from the USA (p = 6.5 
x10-3).299 The same SNP showed suggestive association with keratoconus (p = 2.6 x 10-7) in the study 
by Lu and colleagues,87 which included both our cohort of keratoconus patients and the USA cohort 
included in the discovery phase of the USA study described previously.299 In contrast, a small replication 
study did not show a significant association at rs1536482 in an independent Australian cohort of 
keratoconus patients (n = 157; p = 0.4).88 When these three studies were considered together in a recent 
meta-analysis, taking into account the overlapping cohorts, the association at rs1536482 with 
keratoconus surpassed genome-wide significance (2.5 x10-9).300 It is also worth noting that this SNP has 
not shown association with keratoconus in additional small cohorts (108-210 cases) from non-Caucasian 
populations such as such as a Han Chinese cohort (p = 0.3),159 a cohort from Saudi Arabia (p = 0.4),301 
and a recent study in a Czech cohort (p = 0.07).302 While these findings could be attributed to lack of 
power due to the small number of keratoconus patients included, it is also possible that the functional 
variant is absent or considerably rarer in these populations and therefore this locus may not play a large 
role in keratoconus susceptibility within these populations. 
Our Australian keratoconus patients of European descent have been pivotal in the identification of the 
vast majority of previously known keratoconus-associated loci.84, 86, 87 It was therefore unsurprising that 
two of the CCT-associated SNPs (rs2755238 and rs66720556), located at well-known keratoconus-
associated loci, were significantly associated with keratoconus in Aim 1 of this study. This finding was 
however encouraging as both these SNPs had hard-typed genotyping data available for the cases and 
imputed genotypes for the controls, highlighting a key limitation for this stage of the study. Hard-typed 
genotype data were available for all 72 SNPs in the cases and approximately half of the SNPs in control 
cohort, with imputed genotype data available for remaining SNPs in the controls. Without consistency 
across the case and control data it is possible that any identified associations were due to the differences 
in the data, rather than true associations with disease. Further evidence that the significant associations 
were not affected by these differences include the fact that two SNPs at the same locus (RXRA-
COL5A1), one with, and one without, imputed genotypes in the control data also surpassed the 
Bonferroni-corrected significance threshold. Together, these findings suggest that the imputation in the 
control cohort was of high quality and had minimal influence on this association study. This limitation 
was eliminated in Aim 2 of the study as genome-wide imputation was performed for both the cases and 
controls and used to fine-map keratoconus-associated loci. This second stage of the study also allowed 
for confirmation of the associations identified in Aim 1, albeit in a smaller cohort.  
The fine-mapping analysis identified strong association signals in our case-control cohort at five of the 
fine-mapped keratoconus-associated loci: FOXO1, FNDC3B, MPDZ, RXRA-COL5A1, and the novel 
locus KERA-LUM-DCN. This experiment was used to identify trends in the data and explore the extent 
of the association signals at each keratoconus-associated locus, rather than focus on the significance of 
the associations in a small cohort with low power. The only keratoconus-loci that didn’t display a clear 
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association peak was the RAB3GAP1 locus. This locus was originally implicated in keratoconus in 
cohorts from the USA,85 and reached genome-wide significance following replication and meta-analysis 
with our cohort.86 While the top SNP identified in the present study, rs4954218, was the same SNP that 
was previously reported,85 no surrounding SNPs were in high LD with this SNP. In fact, only five SNPs 
within the fine-mapped region obtained pairwise r2 values with rs4954218 above 0.2, but all were below 
0.4. Despite this, the association at rs4954218 observed in the present study (p = 0.002) was similar to 
our previously published findings (p = 0.003),86 with the difference likely due to slight differences in 
the included cases and controls. In isolation, our data suggests that this keratoconus-associated locus is 
a false positive, however, our cohort only contributed marginally to the genome-wide association with 
keratoconus,86 with the majority of the signal coming from the USA cohorts.85 Based on these findings, 
this region was not pursued further in our cohort of keratoconus patients. Further studies in large 
independent cohorts should be conducted to confirm the role of rs4954218 in keratoconus susceptibility, 
and if the association is a true positive, investigation of this locus in the cohorts from the USA may help 
elucidate the functional variant and the potential mechanism of disease. 
To aid the identification the functional variants at keratoconus-associated loci, keratoconus patients 
carrying the risk-associated allele at the top SNP at one or more of the selected loci were re-sequenced 
in Aim 3, along with a small cohort of unaffected controls. As the cases were specifically selected based 
on their genotype at risk-associated loci, the risk-associated haplotypes were artificially enriched in this 
group. For this reason, no formal statistics based on the frequency of variants were conducted, however, 
this artificial enrichment was exploited when prioritising variants in high LD with the top SNP. In 
contrast to the cases, the controls were not selected based on genotype and therefore variants identified 
within this cohort should resemble the normal population frequency. This allowed variants that were 
observed at similar frequencies in both the cases and controls to be excluded as they were not likely to 
be carried on the disease-associated haplotype or contribute to keratoconus risk. Variants were also 
excluded during filtering if they were not enriched, albeit artificially, in our cases compared to the 
maximum population frequency reported in gnomAD as there is no evidence that any of the populations 
in this database have a higher prevalence of keratoconus than individuals of European descent, and 
therefore, these variants were considered unlikely to contribute to disease.  
As is the nature of targeted enrichment, some regions were not included in the design or obtained poor 
coverage (such as GC-rich regions and repetitive sequences) and therefore variants located in these 
regions were not able to be assessed in the re-sequencing study. While on average the remaining regions 
had sufficient depth for variant calling, not all individuals obtained high confidence genotypes at all 
sites due to variations in the read depth and genotype quality. To ensure all prioritised variants were 
real, all variant sites were required to obtain high confidence genotype calls in at least 50% of the re-
sequenced cohort, including multiple high confidence variant calls. While this method inevitably 
included some low confidence variant calls and this was likely to affect the variant frequency estimates 
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in our cases and controls, these estimates were already limited by the small cohort size, particularly the 
control group, and the biased selection method used for the cases. We therefore suggest that the essential 
next step for any variants of interest identified in Aim 3 should be genotyped in a much larger cohort of 
cases and controls to determine more accurate variant frequencies in these groups and confirm the 
enrichment in cases compared to controls. 
Due to the requirement for prioritised variants to be observed more than once in the re-sequencing data 
and limited size of the cohort, particularly the control group, the re-sequencing study was biased against 
rare variants (MAF < 1%). Despite this, the filtering strategy was designed to include low frequency 
variants (MAF < 5%) as they are currently difficult to impute accurately,303 but are hypothesised to play 
an important role in the susceptibly to complex disease.304, 305 To ensure both low frequency and 
common variants in high LD with the top SNP were prioritised, D’ values were used instead of r2 values 
which are heavily influenced by differences in allele frequencies. In addition, only variants with a D’ 
value with a corresponding LOD score of at least 2 were included to ensure the LD estimates were of 
high confidence. 
To further investigate the highly prioritised variants identified in the re-sequencing analysis (Aim 3), in 
silico tools such as CADD and FATHMM, as well as ENCODE data and eQTL data from the GETx 
database were used to identify putatively functional variants. All of the highly prioritised variants 
identified in this stage of the study were non-protein-coding variants and across all five loci, five highly 
prioritised variants obtained a CADD score above 10, and only two scored within the pathogenic range 
using the FATHMM-MKL algorithm (0.5 – 1.0). While the low scores obtained for these variants may 
suggest that they are unlikely to be functional, it also could reflect the limited understanding of the role 
non-coding regions of the genome within the broad field of genetics. 
A compelling putatively functional variant, rs79728429, was identified as at the FOXO1 locus. This 
variant was highly prioritised following re-sequencing and further investigations revealed that 
rs79728429 is located within a likely enhancer region and obtained a scaled CADD score indicative of 
pathogenicity. Furthermore, we propose the newly discovered gene, AL133318.1, as the target gene for 
rs79728429. This is based on the observation that rs7333246, 132 bp downstream of rs79728429 and 
located within the same enhancer region, is a known eQTL for AL133318.1 in five tissues assessed in 
the GETx database, suggesting that this enhancer is important in the appropriate expression of 
AL133318.1 in specific tissues. One of the tissues associated with AL133318.1 expression at rs7333246 
was sun exposed skin, which is the most relevant tissue for the cornea available in the GETx database, 
given that the database does not include any ocular tissues. From this it was hypothesised that the 
enhancer region is important for corneal expression of AL133318.1, and that the variant at rs79728429 
alters this expression, contributing to an increased susceptibility to keratoconus. This gene has only 
recently been identified and therefore is not present in key databases such as the Ocular Tissue Database 
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(https://genome.uiowa.edu/otdb/), therefore determining corneal expression of AL133318.1 should be a 
high priority. If AL133318.1 is expressed in corneal tissue, functional analyses to determine the normal 
function of the protein and characterise any differences in keratoconic corneas should be conducted, 
including determining cellular/extracellular localisation and identifying interactions (with other 
proteins, RNA molecules, or DNA). Combined with bioinformatic analyses such as determining 
homology to other proteins, identifying key structural features, domains and potential targets, this would 
greatly improve our understanding of this protein in both normal biology and any potential role in 
disease. 
 
 CONCLUSION 
Across three aims, this study thoroughly investigated the role of common SNPs and small indels in 
keratoconus susceptibility in our cohort of Australian keratoconus patients of European descent. Using 
a strategic endophenotype approach, a novel keratoconus-association was identified at rs3759221 at the 
KERA-LUM-DCN locus (Aim 1). To investigate the extent and strength of the association signal, this 
novel locus, along with five well-known keratoconus loci (RAB3GAP1, FNDC3B, MPDZ-NFIB, RXRA-
COL5A1 and FOXO1) were fine-mapped in Aim 2. This analysis showed strong association signals for 
all loci except RAB3GAP1. The remaining five loci were selected for re-sequencing in Aim 3. This work 
identified putatively functional variants at each locus, and for the first time in keratoconus genetics, 
proposed rs79728429 as a functional variant at the previously identified FOXO1 locus. As the variant 
was located within an enhancer region that also contained a known eQTL for AL133318.1 we went on 
to hypothesise that rs79728429 alters the expression of AL133318.1 and that this is the mechanism of 
keratoconus-susceptibility at this locus. While the variant and gene require focused functional analysis 
to confirm the potential role in keratoconus susceptibility and pathogenesis, these novel findings are an 
essential foundation for elucidating the mechanisms of disease and key disease processes. Overall, the 
work outlined in this chapter clearly demonstrates that non-protein-coding variation is important in 
keratoconus susceptibility. 
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CHAPTER 6: FINAL DISCUSSION AND CONCLUSIONS 
 
 SUMMARY OF THE FINDINGS 
It has long been hypothesised that rare protein-coding variants play a significant role in keratoconus 
development and pathogenesis, particularly in families with strong Mendelian inheritance patterns of 
disease. In contrast, genome-wide association studies (GWAS) have identified common non-coding 
variants associated with keratoconus susceptibility. To address this dichotomy, this dissertation 
employed multiple methodologies to elucidate variants involved in keratoconus susceptibility under two 
distinct, yet complementary hypotheses. 
The first hypothesis – that rare, highly penetrant protein-coding variants contribute to keratoconus 
development – was addressed using both a case-control study and a family-based study. Chapter 3 
described the case-control study, which demonstrated that rare coding variants in 22 literature-based 
candidate genes for keratoconus were unlikely to play a substantial role in disease. The analysis of two 
families with multiple cases of keratoconus was described in Chapter 4 and identified two novel linkage 
regions and replicated a third. One of the families displayed likely digenic inheritance of keratoconus; 
with two linkage regions demonstrating equal evidence of association with disease and all affected 
individuals carrying both disease-associated haplotypes. While no rare protein-coding variants were 
considered putatively disease-causing in either family, non-protein-coding putatively disease-causing 
variants were identified and prioritised, including a compelling variant located in and untranslated 
region (UTR) of SMOX (c.-224C>T) in one of the families. From this, we propose SMOX as a novel 
keratoconus-candidate gene and both the specific variant, and the gene, warrant further genetic analysis 
and functional studies to confirm their role in disease. While it is possible that rare protein-coding 
variants located within both the candidate genes in Chapter 3 and the linkage regions in the families in 
Chapter 4 were missed due to biases in the sequencing technologies and platforms or the informatic 
tools used, these studies did not support the original hypothesis and instead suggest that alternative 
hypotheses should be explored to aid the identification of specific genetic factors involved in 
keratoconus susceptibility. 
The second hypothesis states that variants associated with keratoconus indicate haplotypes that harbour 
functional variants which directly contribute to keratoconus susceptibility. Using case-control cohorts, 
Chapter 5 addressed this hypothesis in three sequential aims. This work led to the identification of a 
novel keratoconus-susceptibility locus, rs3759221, at KERA-LUM-DCN and identified and prioritised 
putatively-functional variants at this locus, as well as at four previously published keratoconus-
associated loci. From this work, we propose rs79728429 as a novel functional variant at the rs2721051 
(FOXO1) locus. We further hypothesise that AL133318.1 is a regulatory target of rs79728429 as the 
SNP is located 133 bp downstream of an established expression quantitative trait loci (eQTL) for 
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AL133318.1 (rs7333246) and both variants are located within the same enhancer region. Based on these 
findings, rs79728429 and AL133318.1 should be further investigated to confirm their role in 
keratoconus susceptibility. Overall, the findings from this chapter indicate that non-coding variation is 
likely to play an important role in keratoconus susceptibility. 
 
 A LIMITED ROLE FOR RARE PROTEIN-CODING VARIATION IN 
KERATOCONUS SUSCEPTIBILITY 
In the family study described in Chapter 4, no rare protein-coding variants were classified as putatively 
disease-causing variants in either of the families. In fact, only one exonic variant was identified within 
the region of homozygosity in KSA197; however, this variant was too common to account for disease. 
Similarly, 23 protein-coding variants segregated within the two linkage regions identified in 
KCNSW01, but only one was rare. This single rare variant, however, wasn’t investigated further as it 
did not affect the amino acid sequence of the protein and obtained low predictions of deleteriousness 
and pathogenicity. While these findings did not support the original hypothesis, they are consistent with 
previous publications. To date, only one linkage study has identified a rare putatively disease-causing 
variant within a protein-coding region, specifically in the dedicator of cytokinesis 9 gene (DOCK9; 
rs191047852),29, 64 but further analyses are required to confirm the role of this variant in disease. In 
contrast, two published family studies have proposed non-protein-coding variants as the likely disease-
causing, including a variant located within a non-protein-coding RNA gene, mir184, that co-segregates 
with disease in two unrelated families.65, 66, 77, 143 Studies of families with keratoconus have largely 
restricted their search for likely-causative variants to those that are located within protein-coding regions 
of candidate genes that map to linkage regions, however, the vast majority of families in the literature 
remain unsolved.28, 71-76, 78-80, 113 Together, these findings suggest rare protein-coding variants are 
unlikely to play a substantial role in keratoconus development, even in families with multiple cases and 
strong Mendelian inheritance patterns, and that alternative hypotheses should be investigated. 
Further evidence for a limited role of protein-coding variants in keratoconus is presented in Chapters 3 
and 5. Chapter 3 described a large study that screened 22 genes that had been proposed as candidates 
for keratoconus based on genes located within linkage-regions identified in family studies, the known 
function of the gene, or proximity to keratoconus-associated loci. This study demonstrated no difference 
in the frequency of rare protein-coding variants that were predicted to be potentially pathogenic between 
keratoconus patients compared to controls, suggesting that rare protein-coding variants within these 
genes do not play a substantial role in disease. Though it was not the primary focus of the analysis, the 
re-sequencing experiment presented in Chapter 5 further highlighted that protein-coding variants 
located within genes near GWAS hits do not to contribute to keratoconus susceptibility as none had the 
potential to be the functional variant across the five loci assessed. In fact, no protein-coding variants 
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were identified in cases or controls at three of the re-sequenced loci – MPDZ-NFIB, RXRA-COL5A1 
and KERA-LUM-DCN – despite the capture of multiple genes. Only three protein-coding variants were 
identified at the FNDC3B locus, and five within the FOXO1 locus, however these variants were either 
too rare, or not in high linkage disequilibrium (LD; with high confidence) with the risk alleles and 
weren’t prioritised. This phenomenon is not unique to keratoconus, with a recent study that investigated 
more than 6,000 significant associations from 920 GWAS for complex diseases and traits demonstrating 
that less than 5% of the associations were in coding regions and that while more than 41% of the trait-
associated SNPs were located within introns, less than 11% of these variants were in high LD (r2 ≥ 0.8) 
with any coding variants.306 Based on our findings, we now hypothesise that non-coding variants play a 
substantial role in keratoconus susceptibility by regulating or altering the expression of key genes. For 
this reason, we propose that future keratoconus studies should ensure appropriate capture and analysis 
of non-coding variation. 
Another hypothesis worthy of future investigation in keratoconus cohorts is that structural and copy 
number variation contribute to keratoconus susceptibility. Structural and copy number variants include 
large insertions or deletions, as well as, more complex changes in the DNA sequence such as inversions 
or tandem duplications. Due to the large genomic regions affected by these variants, purpose-developed 
variant calling algorithms are required to call these variants from short read-sequencing data and 
therefore these types of variants may be present within protein-coding regions but have not yet been 
investigated. Evidence from obesity studies support the hypothesis that rare structural variants are 
important in complex disease,307, 308 however it is worth noting that the associated regions were 
identified in case-control studies involving individuals with extreme phenotypes, with no overlapping 
signal identified in large GWAS.307 For this reason, the investigation of such variants in keratoconus 
families should be of primary interest. This is further supported by the fact that copy number variations 
have been previously linked to other ocular diseases, including severe developmental ocular 
malformations309 and a partial gene duplication was found to co-segregate with isolated congenital 
cataract in a large family.310 Therefore, to extend the work presented in Chapter 4, these variants should 
be called from the WGS data generated for the families and analysed. To the best of our knowledge, 
structural and copy number variation has not previously been explored in keratoconus cohorts, and 
therefore, the data generated in this project presents a novel opportunity to explore the role of these 
variants in keratoconus susceptibility. 
 
 CHALLENGES WITH DETERMINING THE FUNCTIONAL IMPACT OF 
NON-PROTEIN-CODING VARIANTS 
Non-protein-coding regions make up approximately 97% of the human genome and include the 
untranslated regions of genes; introns; non-coding RNA molecules; and intergenic regions that harbour 
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a complex suite of regulatory elements such as promotors, enhancers, silencers, insulators, and many 
other genomic features that we do not yet fully understand. Non-coding regions are also important for 
the appropriate the structure of DNA, allowing for looping of distal regulatory elements into close 
proximity to the target genes, as well as regulating the access of transcription factors and proteins to the 
DNA. The challenge with non-coding variation is identifying which parts of the DNA are likely to be 
important in disease, a task that is further complicated by the fact that these regions may only be 
functional in specific cell types or for transient periods of time. It is anticipated however, that our ability 
to prioritise and identify functional non-coding variants will continue to improve as the field develops 
a deeper understanding of the function of non-coding regions, and as public datasets continue to grow. 
To aid the prioritisation of non-protein-coding variants in the present study, highly prioritised variants 
were manually assessed using tracks available on the University of California Santa Cruz (UCSC) 
Genome Browser, primarily by visualising data from the Encyclopedia of DNA Elements (ENCODE). 
ENCODE is a public research project that aims to identify functional elements within the human 
genome using a wide variety of assays and methods and in a selection of cell lines and tissue types. 
These data were used to identify likely regulatory elements such as enhancers and were complemented 
by data available from the Genotype-Tissue Expression Project (GTEx). GTEx aims to build a 
comprehensive resource containing eQTLs, identified in non-diseased tissues across almost 1000 
individuals. Given the available data, non-coding variants located within likely enhancer regions were 
prioritised in both Chapters 4 and 5, though this method had a few caveats. It is important to highlight 
that neither of these databases include corneal tissue, and therefore these data may not be representative 
of the cornea. Sun exposed skin is likely the most relevant tissue in the GTEx database and data from 
epidermal keratinocytes (NHEK) is likely to be the most relevant in the ENCODE data. Another 
limitation of this strategy was that variants located in enhancer regions or DNaseI hypersensitivity 
regions that were observed across multiple cell types were more highly prioritised than those identified 
in fewer cell types as it provided more confidence in the prediction of the element. This methodology 
therefore biases top ranked variants toward those that affect non-tissue specific regulatory elements and 
therefore variants within these regions may be less likely to cause a tissue-specific phenotype such as 
keratoconus. Despite these limitations, by combining these data along with in silico predictions of 
pathogenicity and deleteriousness, this dissertation proposed two non-protein-coding variants as 
putatively functional variants in keratoconus susceptibility: a variant located in the 5’ UTR of SMOX 
(c.-224C>T) was found to co-segregate with disease in a large family with multiple cases of keratoconus 
and a novel putatively-functional variant (rs79728429) was identified at a common keratoconus-
susceptibility locus near FOXO1. 
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 STRENGTHS AND LIMITATIONS OF CASE-CONTROL STUDIES 
One of the major strengths of this dissertation was our large cohort of keratoconus patients consisting 
of over 620 cases. To reduce the influence of population stratification, ethnically matched controls were 
selected for the case-control studies. Another strength was the use of older control cohorts consisting of 
individuals who were unaffected by keratoconus, where possible. While keratoconus can develop at any 
age, it typically develops during adolescence or early adulthood, and therefore keratoconus cohorts are 
generally skewed toward younger participants. Therefore, the use of substantially older control groups 
reduces the risk that these individuals will later develop keratoconus and minimises the miss-
classification of these individuals as controls. It is important to note, however, that this strength does 
not extend to the Anglo-Australasian Osteoporosis Consortium cohort as these individuals were not 
specifically examined for eye disease. Together, the large case cohort and strategically selected control 
cohorts facilitated the replication of previously published gene-screen studies in the largest cohort to 
date in Chapter 3 and thoroughly investigate keratoconus-associated loci in Chapter 5.  
While the most appropriate control cohorts available were selected for analysis throughout this 
dissertation, some of the control individuals were affected by eye diseases other than keratoconus, which 
represents a potential limitation of the studies. The initial concern was around the potential of glaucoma 
as a confounding factor given both keratoconus and glaucoma share thin CCT as a risk factor.31, 311-314 
Most notably, this may have affected the analysis of ZNF469 in Chapter 3 as the screened control cohort 
consisted of individuals from the Australian and New Zealand Registry of Advanced Glaucoma, who 
were almost all affected by primary open-angle glaucoma (POAG). In addition, the control cohorts from 
Anglo-Australasian Osteoporosis Consortium and the Blue Mountains Eye Study were expected to have 
the normal population frequencies of eye disease, including glaucoma. Despite the fact that CCT is 
phenotypic risk factor for glaucoma, a large study of 22 extended pedigrees enriched for POAG 
demonstrated that there was no significant genetic correlation between CCT and POAG-risk (p = 
0.27).315 This finding is further supported by two studies that assessed CCT-associated variants in 
cohorts of keratoconus and POAG patients, which led to the identification of novel keratoconus-
associated loci (including the ZNF469 locus), but neither study identified any variants associated with 
POAG.87, 249 From these studies we propose that CCT and POAG, and by extension POAG and 
keratoconus, do not share substantial genetic overlap and therefore suggest that the inclusion of control 
individuals with glaucoma are unlikely to affect our findings. 
While quite a few family-based studies have included families from other ethnicities, all published 
keratoconus GWAS signals have been identified in European populations, despite a higher prevalence 
of disease in Asian populations.19 Differences in prevalence of disease across populations may be 
indicative of a region-specific environmental factors, however, could also be driven by genetic risk 
factors. As all the case-control studies presented in this dissertation were conducted in cohorts of 
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Australians of European descent there is a possibility that some of the findings from this work may be 
population-specific. Some of the findings, particularly those presented in Chapter 5, may not be 
applicable to keratoconus more broadly due to differences in variant frequencies and LD structures 
across populations. For example, in the recent cross-ancestry meta-analysis for CCT, two loci identified 
in Europeans were monomorphic in the Asian cohorts and therefore do not contribute to CCT in this 
population.249 While population-specific susceptibility variants are likely to exist, the underlying 
biological pathways and mechanisms involved in keratoconus should converge across populations. 
Considering our limited understanding of biological underpinnings of keratoconus, studying 
keratoconus genetics in other populations would lead to a more complete understanding of specific 
genetic factors involved in the disease and may help to elucidate key biological pathways or mechanisms 
of disease. Better understanding of this would aid the development of biomarkers for early diagnosis 
and less invasive therapies, improve management strategies for patients and ultimately improve 
outcomes for keratoconus patients. 
 
 FUTURE DIRECTIONS 
This study identified two novel keratoconus-candidate genes of great interest: SMOX and AL133318.1. 
The SMOX protein is induced by inflammation,211-213 plays a role in apoptosis and the cellular response 
to both oxidative stress and ultraviolet radiation.210 As keratoconus is characterised by progressive 
corneal thinning, likely due to the loss of stromal keratocytes and extracellular matrix degeneration,316 
these biological pathways are highly plausible in keratoconus development and pathogenesis. By 
extension, it has been hypothesised that variants that alter the expression of SMOX in the cornea are 
involved in keratoconus susceptibility and thus further genetic studies and functional analyses should 
be explored. The identification of the specific variant identified in KCNSW01 (c.-224C>T) in additional 
keratoconus patients would be strong evidence for the involvement of this variant and gene in the disease 
process, however, considering the rarity of the variant (maximum frequency of 0.4% in the African 
population of gnomAD) this is unlikely. For this reason, we propose a gene-based association study – 
similar to that which was conducted in Chapter 3 but ensuring that non-protein-coding regulatory 
regions are included – to determine if there is an enrichment of c.-224C>T, and other similar putatively 
disease-causing variants, in cases compared to population controls. In contrast, there is very little known 
about the single exon gene, AL133318.1, apart from the fact that it encodes a polypeptide consisting of 
62 amino acids. For this reason, determining if AL133318.1 is expressed in the cornea should be of 
primary focus. Any differences in expression between healthy and keratoconic corneas should also be 
determined. If AL133318.1 is expressed in corneal tissue, laboratory experiments to determine the 
localisation of the protein and any interactions, including protein-protein interactions, to develop an 
understanding of the function of the protein. Considering the likely digenic inheritance in KCNSW01, 
157 
 
the family in which the SMOX variant was identified, similar analyses would also be worth pursuing for 
SMOX, as these analyses in corneal tissue may help elucidate candidate genes and aid the prioritisation 
of putatively disease-causing variants located within the 17q12 linkage region. 
As both the SMOX 5’ UTR variant (c.-224C>T) and rs79728429 near AL133318.1 are hypothesised to 
have a regulatory role, the expression of SMOX and AL133318.1 should be explored in corneal tissue 
or relevant cell lines with and without the relevant variants and the results compared. This could be 
achieved using corneal tissue or through an induced pluripotent stem cell model, from variant carriers 
and individuals without the variants of interest. This type of analysis may be more feasible for the more 
common variant, rs79728429, as the rarity of the c.-224C>T in the 5’ UTR of SMOX realistically limits 
this type of analysis to the family members themselves. Despite this, family members of KCNSW01 
have already demonstrated a willingness to participate in research and interest in understanding their 
disease, and therefore, may be willing to provide tissue samples. This would allow for the analysis of 
the SMOX variant, and other variants located within the two linkage regions in KCNSW01, alongside 
the individuals’ full genetic background. Alternatively, gene editing technologies such as clustered 
regularly interspaced short palindromic repeats (CRISPR)/cas9 may be used to insert the variants of 
interest into cells that do not natively carry the variant, allowing for the investigation of the impact of 
the variants of interest on gene expression without the need for participants’ samples.  
 
 FINAL CONCLUSIONS 
This dissertation used both case-control and family-based study designs to elucidate variants involved 
in keratoconus susceptibility in a cohort of Australians of European ancestry. This work identified two 
novel linkage regions, replicated a third and proposed putatively disease-causing variants for further 
investigation in two families. Further analysis of the keratoconus-associated regions led to the 
identification of a novel keratoconus-candidate gene, SMOX, which warrants further investigation to 
confirm its role in this disease. In the case-control studies a novel keratoconus-susceptibility locus at 
KERA-LUM-DCN was identified and we proposed a functional variant (rs79728429) and novel target 
gene (AL133318.1) at a previously identified keratoconus-associated locus: rs2721051 (FOXO1). This 
dissertation also demonstrated that rare coding variants in 22 candidate genes for keratoconus were 
unlikely to play a substantial role in disease. Overall, this work highlights the limited contribution of 
rare protein-coding variation in keratoconus and suggests that non-coding or regulatory variants are 
likely to play a substantial role in disease susceptibility. This work also highlights the truly complex 
nature of keratoconus genetics, even in families with apparently Mendelian inheritance patterns of 
disease.  
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APPENDICES 
 
Appendix 1 – An example of the command for adding confidence tags to genotypes in a 
VCF file using the VariantFiltration tool from GATK. 
## This script was developed by Dr. Blackburn 
java -Xmx4g -jar /path/to/program/GenomeAnalysisTK.jar \ 
-R reference.fa \ 
-T VariantFiltration \ 
-o output_file.vcf \ 
--variant input_file.vcf \ 
--genotypeFilterExpression "DP >= 10 && GQ >= 20" \ 
-–genotypeFilterName "High_Confidence" \ 
--genotypeFilterExpression "DP < 10 && GQ < 20" \ 
--genotypeFilterName "Low_Confidence" \ 
--genotypeFilterExpression "DP < 10 && GQ >= 20" \ 
--genotypeFilterName "Low_coverage_High_quality" \ 
--genotypeFilterExpression "DP >= 10 && GQ < 20" \ 
--genotypeFilterName "High_coverage_Low_quality" 
 
Appendix 2 – R script for converting genotypes with low coverage or low quality scores 
to missing. 
This method relies on the addition of confidence tags to the VCF as described in Appendix 1. 
## This script was developed with help from Dr. Blackburn and Dr. McComish 
# Load the VCF (with confidence tags added to the genotypes) 
geno <- read.table("input_file.txt", sep = "\t", header = T, as.is=TRUE, 
                   na.strings = ".") 
  
# Subset to just the genotype fields of the VCF 
geno_only <- geno[,10:ncol(geno)] 
  
#Converts all low coverage/quality/confidence calls to "./." (missing) based on 
#the VariantFiltration tool from GATK 
geno_only < - as.data.frame(sapply(geno_only, gsub, pattern = "./.(:.*Low.*)", 
                            replacement = "\\./\\.\\1")) 
  
# Add back the other columns 
geno_clean <- cbind2(geno[, 1:9], geno_only) 
 
# Write table for re-merging with the VCF header 
write.table(geno_clean, file = "output_file.txt", sep = "\t", row.names = F, 
            col.names = F, quote = F, na = ".") 
 
## to create a VCF file again, concatenate a copy of the header from the 
input_file.vcf onto the output file. 
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Appendix 3 – Custom script used to annotate VCF files with ANNOVAR, including 
producing an output file containing a complete header line with the 
sample IDs present in the VCF file. 
#To annotate VCF files with the 2017Jun01 version of ANNOVAR 
#The start of the input filename (without the last two fields which for my files 
#is the date of creation and the file extension) will be used as the output file 
#name with "_Annotated_<date>" added at the end 
## ie. if the input file is file_05082016.vcf, the output will be 
#file_Annotated_07082016 (ANNOVAR produces a .vcf, .txt and .avinput files) 
#The number of threads to use is indicated by the first argument 
#Use a thread of 1 unless told otherwise (it can slow down the annotation if >1) 
#The annotated TXT ANNOVAR output file does not contain the sample IDs. 
#The output file with the suffix "_Annotated_with_Header_<date>.txt" has a 
#complete header including sample IDs and is otherwise identical.  
 
#Usage: bash ANNOVAR_2017_2.sh <number_of_threads> <filename_or_filenames> 
module load annovar/2017Jun01 
now=`date +"%d%m%Y"` 
 
## Run ANNOVAR on one or more VCF files 
for file in "${@:2}" 
do 
filename=`echo ${file} | cut -d "." -f 1` 
filename_start=`echo ${filename} | rev | cut -d _ -f 2- | rev` 
table_annovar.pl $file \ 
/gd/apps/annovar-2017Jun01/humandb -buildver hg19 \ 
-out ${filename_start}_Annotated2017Jun01_${now} \ 
-remove -otherinfo -thread ${1} \ 
-protocol refGene,avsnp147,popfreq_max_20150413,\ 
1000g2015aug_all,1000g2015aug_eur,1000g2015aug_afr,1000g2015aug_amr,\ 
1000g2015aug_eas,1000g2015aug_sas,esp6500siv2_all,esp6500siv2_ea,esp6500siv2_aa,\ 
exac03,exac03nontcga,exac03nonpsych,kaviar_20150923,hrcr1,gme,gnomad_exome,\ 
gnomad_genome,clinvar_20170130,cadd13,avsift,gerp++elem,dbnsfp31a_interpro,\ 
spidex,dbscsnv11,mitimpact24,dbnsfp33a,gwava,eigen,fathmm \ 
-operation g,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f \ 
-nastring . -vcfinput 
# Add a header line to the annotated TXT file including the sample IDs 
grep -w "#CHROM" ${file} | cut -f 2- > VCF_header.txt 
head -1 ${filename_start}_Annotated2017Jun01_${now}.hg19_multianno.txt \ 
> ANNO_header.txt 
paste -d'\t' ANNO_header.txt ~/Scripts/ANNOVAR_Additional_Column_Headings.txt \ 
VCF_header.txt > full_header.txt 
tail -n+2 ${filename_start}_Annotated2017Jun01_${now}.hg19_multianno.txt | \ 
cat full_header.txt - > ${filename_start}_Annotated_with_Header_${now}.txt 
#remove unnecessary intermediate files 
rm VCF_header.tzt 
rm ANNO_header.txt 
rm full_header.txt 
done 
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Appendix 4 – An example command for extracting regions from a variant caller format 
(VCF) file using BCFtools. 
bcftools view -R region_file.txt -S Sample_List.txt -c 1 -O v -o output_file.vcf \ 
input_file.vcf.gz 
 
Appendix 5 – R code for plotting the first two principle components from the principle 
components analysis (PCA) using data from the keratoconus families and 
HapMap Phase III. 
#read in the data 
PCA <- read.table("Separate_Family_Colours_merge-data.hapmap3r2.pruned.pca.evec", 
                   header = FALSE ,skip=1) 
 
# Add column names 
colnames(PCA) <- c("Sample ID", "PC1", "PC2", "Population") 
 
# Generate scatter plot  
library("ggplot2") 
ggplot(PCA, aes(x = PC1, y = PC2, color=Population)) + 
       geom_point() + theme_bw() + 
       scale_x_continuous(limits = c(-0.1,0.05)) + 
       scale_y_continuous(limits = c(-0.05,0.1)) + 
       scale_colour_brewer(palette = "Dark2", direction = -1) 
 
Appendix 6 – Example R code for generating 3D plots to visualise IBD estimates using 
plotly in R. 
#Load the plotly package 
library(plotly) 
  
#Link to a plotly account 
Sys.setenv("plotly_username"="your_username") 
Sys.setenv("plotly_api_key"="your_api_key") 
 
# Read in the file 
IBD <- read.table(file="plink_IBD_estimates.txt", header=T, sep = "\t") 
  
# Generate a 3D plot of Z0 vs Z1 vs Z2 
p <- plot_ly(IBD, x= ~Z0, y = ~Z1, z = ~Z2, color = ~Relationship, colors = 
c("#0072B2","#D55E00", "#CC79A7", "#F0E442", "#009E73"), hoverinfo = 'text', 
text = ~paste(IID1, ' vs ', IID2, '(PI_HAT = ',PI_HAT,')')) %>% add_markers() %>%  
layout(legend = list(x= 0.8, y = 0.8, z = 0.01), title = "Plot title", scene = 
list(xaxis = list(title = "Plink Z0", range = c(0,1), minorgridcount = 5, 
minorgridwidth = 2), yaxis = list(title = "Plink Z1", range = c(0,1), 
minorgridcount = 5, minorgridwidth = 2), zaxis = list(title = "Plink Z2", range = 
c(0,1), minorgridcount = 5, minorgridwidth = 2)))  
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#Create online interactive plot 
chart_link = api_create(p, filename="output_filename") 
 
Appendix 7 – R code for plotting homozygosity scores for all autosomes in a single plot. 
# Read in the file downloaded from HomozygosityMapper 
HomScores <- read.table(file = "homozygosity_scores.txt", sep = "\t", header = T) 
 
## Plot all autosomes in a single plot 
library(ggplot2) 
 
ggplot(data=HomScores, aes(x=position, y=score)) + 
  geom_bar(colour = "black", stat="identity") + 
  labs(y = "Homozygosity Score", x ="Chromosome") + 
  scale_y_continuous(limits = c(0,350), breaks = seq(0, 350, 50), expand = c(0,0)) 
+ 
  facet_grid (~ chromosome, scales = "free_x", space = "free_x", switch = "x") + 
  theme(axis.text.x=element_blank(), axis.ticks.x=element_blank(), 
        panel.grid.minor = element_blank(), strip.background = element_blank(), 
        panel.grid.major.x = element_blank(), panel.spacing = unit(0, "lines"), 
        panel.border = element_rect(size = 0.25, color = "grey80")) + theme_bw() 
 
Appendix 8 – The PLINK command for identifying runs of homozygosity.  
The ‘--homozyg group’ option was used to generate a report of homozygous regions that overlap in at 
least two individuals. This command produces a file with the name convention 
‘<familyID>.hom.overlap’. 
plink --bfile ~/path/to/family-specific/independent_SNPs --homozyg group --out 
<familyID> 
 
Appendix 9 – Method for remove duplicate cM positions from Merlin format Map files 
for linkage analysis.  
Prior to reading the Merlin format map files into R, a sed command was used to convert any white-
space to tabs to ensure the files were tab delimitated: 
sed -i 's/ \+ /\t/g' merlin_map.01 
 
The following R commands, developed by Johanna Jones and Michael Sumner, were then applied to 
the Merlin format map files to identify and alter duplicate cM positions. 
# Load in the map file 
map <- read.table("merlin_map.01", sep = "\t", header = T, 
                  as.is=TRUE,na.strings=".") 
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## To see if there are duplicate positions 
# a “TRUE” result means there's no duplicates 
# a "FALSE" result means there's duplicates in the positions column 
length(unique(map$POSITION)) == nrow(map) 
 
#load the dplyr package 
library(dplyr) 
 
# To add a very small value to the second SNP in the pair with duplicate values so 
they are # no longer duplicates 
input_order <- unique(as.character(map$POSITION)) 
altered <- bind_rows(lapply(split(map, map$POSITION), 
                                 function(x) { 
                                   if (nrow(x) > 1) { 
x$POSITION <- x$POSITION + 
cumsum(c(0,rep(0.0000001,nrow(x) - 1))) 
                                       } 
                                       x 
                                       })[input_order]) 
  
#Check it worked 
length(unique(altered$POSITION)) == nrow(altered)  
# If it worked the output will be "TRUE" 
  
# Write the table to a file (saving over the old file) 
write.table(altered, file = "merlin_map.17", sep = "\t", row.names = F,  
            col.names = T, quote = F) 
 
Appendix 10 – Haplotype estimation based on the most likely pattern of gene flow using 
MERLIN.  
Ensure genotype errors are removed in MERLIN prior to this analysis. 
merlin -d <chr_of_interest>_wiped.dat -p <chr_of_interest>_wiped.ped -m 
merlin_map.<chr_of_interest_number> --best 
 
 
Appendix 11 – Example commands for determining the mean depth and standard 
deviation across a region in multiple individuals and extracting a file 
containing regions with a mean depth below 10. 
This was a three step process. The first step used SAMTools to extract the region of interest from the 
aligned BAM files for the relevant individuals using the following command; where the region of 
interest is in the format ‘chr#:1234-2345’ and bam.txt contains a list of the aligned BAM files and the 
path for each included individual in the format ‘/path/to/bam/finename.bam’: 
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samtools depth -a -r <region_of_interest> -f bams.txt output_filename.txt 
 
The second step used R to calculate the mean depth and standard deviation across the region and all 
individuals. Bases with a read depth below 10 are then written to a BED format file. 
# Read in the annotated variants file 
depth <- read.table(file = "output_filename.txt",  
                    sep = "\t", header = FALSE, as.is = TRUE, na.strings = ".", 
quote = "") 
 
## Create column headings, using the list of BAM files ‘bams.txt’ as above 
# Read in sample IDS 
bams <- read.table(file = " bams.txt",  
                   sep = "/", header = FALSE, as.is = TRUE, na.strings = ".", 
quote = "") 
 
# Extract the file names (what ever is present before the "." and the extension) 
samples <- gsub("\\..*", "", bams[,8]) 
 
# Add column names 
colnames(depth) <- c("CHR", "POS", unlist(samples, use.names = FALSE)) 
 
## Calculate the mean depth and standard deviation for each position 
# make sure to change the relevant columns as required (depending on the number of 
people) 
depth$depth_mean <- rowMeans(depth[,3:7]) 
depth$depth_sd <- apply(depth[,3:7], 1, sd) 
 
## Calculating the mean and sd of the means (across all samples and bases in the 
region) 
mean(depth$depth_mean) 
sd(depth$depth_mean) 
 
## Extracting Regions with less than a depth of 10 ## 
poor_cov <- depth[(depth$depth_mean<10),] 
 
#Create a BED file 
# Make sure to use the right columns for the mean depth (in particular) 
poor_cov_bed <- poor_cov[,c(1:2,2,8)] 
colnames(poor_cov_bed) <- c("CHR", "START", "END", "MEAN_DEPTH") 
 
# write out into a BED file (without headers): 
write.table(poor_cov_bed, file = "Regions_with_depth_below_10.bed",  
            sep = "\t", row.names = F, col.names = F, quote = F, na = ".") 
 
The final step uses BEDTools to merge consecutive positions with a mean depth below 10 into single 
regions. An example of the command is as follows: 
bedtools merge -i Regions_with_depth_below_10.bed >  
Regions_with_depth_below_10_ranges.bed 
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Appendix 12 – Custom script for detecting and removing genotyping errors using 
Pedwipe and conducting parametric linkage analysis using MERLIN. 
# Usage: bash merlin_linkage_autosomes.sh | tee -a Log.txt 
# Load MERLIN 
module load merlin 
 
# Create a log file 
date > Log.txt 
 
# Do the following for each autosome 
for chr in {01..22} 
do 
 
if [[ -f merlin_map.${chr} && -f merlin_ped.${chr} && -f merlin_data.${chr} && \ 
      -f merlin_model ]] 
 
then 
    echo "starting chr$chr" 
    echo "chr${chr}_wiped.dat and chr${chr}_wiped.ped are absent" 
    echo "MERLIN input files merlin_map.${chr} , merlin_ped.${chr} , \ 
          merlin_data.${chr} and merlin_model are present" 
     
   # Run PEDSTATS 
    echo "Running PEDSTATS for chr$chr" 
    pedstats -d merlin_data.${chr} -p merlin_ped.${chr} 
    mv pedstats.markerinfo chr${chr}_pedstats.markerinfo 
 
# Error identification and make a copy of the data labelled by chromosome in  
#the merlin.err file 
    echo "Running an error check for chr${chr}" 
    merlin -d merlin_data.${chr} -p merlin_ped.${chr} -m merlin_map.${chr} --error 
    cp merlin.err chr${chr}_merlin.err 
 
    echo "merlin.err has been renamed chr${chr}_merlin.err" 
 
    # Fixing errors with PEDWIPE 
    echo "Removing problematic SNPs with PEDWIPE for chr${chr}" 
    pedwipe -d merlin_data.${chr} -p merlin_ped.${chr} 
    # This uses merlin.err (the output of the error identification), which will be  
    #re-written for each chromosome, but I have copied this for each chromosome in 
    #a file starting with "chr", followed by the chromosome number 
 
    # Remove the generic named error file 
    rm merlin.err 
 
    # Rename output PEDWIPE files 
    mv wiped.dat chr${chr}_wiped.dat 
    mv wiped.freq chr${chr}_wiped.freq 
    mv wiped.ped chr${chr}_wiped.ped 
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    echo "wiped.dat has been renamed chr${chr}_wiped.dat" 
    echo "wiped.freq has been renamed chr${chr}_wiped.freq" 
    echo "wiped.ped has been renamed chr${chr}_wiped.ped" 
 
    # Run parametric linkage analysis with MERLIN 
    echo "Running parametric linkage analysis with MERLIN for chr$chr" 
    merlin -d chr${chr}_wiped.dat -p chr${chr}_wiped.ped -m merlin_map.$chr \ 
    --model merlin_model --tabulate --markerNames --pdf --quiet 
    mv merlin.pdf chr${chr}_merlin.pdf 
    mv merlin-parametric.tbl chr${chr}_merlin-parametric.tbl 
 
    echo "merlin.pdf has been renamed chr${chr}_merlin.pdf" 
    echo "merlin-parametric.tbl has been renamed chr${chr}merlin-parametric.tbl" 
    echo "Done with chr$chr" 
 
else 
    echo "starting chr$chr" 
    echo "WARNING - At least one of the required input files is absent" 
    echo "Skipping chr$chr" 
fi 
done 
 
# Removing unnecessary clutter from the log file 
sed -i '/Right Conditional:/d' Log.txt 
sed -i '/Singlepoint:/d' Log.txt 
sed -i '/Scanning Chromosome:/d' Log.txt 
 
Appendix 13 – R code for plotting parametric linkage results for all autosomes in a single 
plot. 
Merlin outputs separate files for each chromosome. Prior to plotting, these files need to be concatenated 
together.  
## Loading in my data 
LODs <- read.table("Merlin_output_all_autosomes_concatenated.txt", header = F, sep 
= "\t") 
  
#Add column names 
colnames(LODs) <- c("CHR","POS","LOD") 
## NB the POS is in Morgans 
 
## Convert Morgans to cMs 
LODs$POS <- LODs$POS * 100 
 
library("ggplot2") 
 
# Create the plot 
ggplot(data = LODs, aes(x = POS, y = LOD)) + geom_line(size = .75) +  
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labs(y = "LOD score", x ="Chromosome") + geom_hline(yintercept = -2, colour = 
"red") +  
  geom_hline(yintercept = 0, linetype = 5) + 
  facet_grid (~ CHR, scales = "free_x", space = "free_x", switch = "x")  
  + theme_bw() + 
  theme(axis.text.x=element_blank(), axis.ticks.x=element_blank(), 
        panel.grid.major = element_blank(), panel.grid.minor = element_blank(), 
        strip.background = element_blank(), panel.spacing = unit(0, "lines"),  
        panel.border = element_rect(size = 0.25, color = "grey80")) 
 
Appendix 14 – Identity-by-descent estimates for KSA197 and KCNSW01. 
Each row outlines the data for a pair of individuals where the ID1 and ID2 columns contain the 
individual IDs; the EZ is the expected identity-by-descent (IBD) proportion based on the reported 
relationship; Z0, Z1 and Z2 are the probabilities that the individuals share zero, one or two alleles 
identity by descent at a given locus (respectively); and the PI_HAT represents the overall IBD 
proportion. 
ID1 ID2 Reported Relationship EZ Z0 Z1 Z2 PI_HAT 
KSA197.0 KSA197.1 Parent-Offspring 0.5 0.00 0.62 0.38 0.69 
KSA197.0 KSA197.2 Full Sibling 0.5 0.12 0.32 0.56 0.72 
KSA197.0 KSA197.3 Parent-Offspring 0.5 0.00 0.62 0.38 0.69 
KSA197.0 KSA197.4 Parent-Offspring 0.5 0.00 0.63 0.37 0.68 
KSA197.1 KSA197.2 Parent-Offspring 0.5 0.00 0.62 0.38 0.69 
KSA197.1 KSA197.3 Second Cousins 0.03 0.58 0.05 0.37 0.40 
KSA197.1 KSA197.4 Grandparent-Grandchild 0.25 0.27 0.36 0.37 0.55 
KSA197.2 KSA197.3 Parent-Offspring 0.5 0.00 0.61 0.39 0.70 
KSA197.2 KSA197.4 Avuncular Pair 0.25 0.27 0.36 0.37 0.55 
KSA197.3 KSA197.4 Grandparent-Grandchild 0.25 0.33 0.31 0.37 0.52 
KCNSW01-1 KCNSW01-2 Parent-Offspring 0.5 0.01 0.79 0.20 0.60 
KCNSW01-1 KCNSW01-3 Full Sibling 0.5 0.20 0.40 0.41 0.60 
KCNSW01-1 KCNSW01-4 Parent-Offspring 0.5 0.00 0.81 0.19 0.59 
KCNSW01-1 KCNSW01-5 Parent-Offspring 0.5 0.00 0.81 0.19 0.60 
KCNSW01-1 KCNSW01-6 Full Sibling 0.5 0.20 0.45 0.34 0.57 
KCNSW01-1 KCNSW01-7 Full Sibling 0.5 0.23 0.43 0.34 0.55 
KCNSW01-1 KCNSW01-8 Full Sibling 0.5 0.22 0.40 0.38 0.58 
KCNSW01-1 KCNSW01-9 Full Sibling 0.5 0.22 0.37 0.41 0.60 
KCNSW01-1 KCNSW01-10 Full Sibling 0.5 0.25 0.40 0.35 0.55 
KCNSW01-1 KCNSW01-11 Full Sibling 0.5 0.22 0.40 0.38 0.58 
KCNSW01-2 KCNSW01-3 Avuncular Pair 0.25 0.39 0.41 0.20 0.40 
KCNSW01-2 KCNSW01-4 Grandparent-Grandchild 0.25 0.41 0.39 0.20 0.39 
KCNSW01-2 KCNSW01-5 Grandparent-Grandchild 0.25 0.39 0.41 0.20 0.41 
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ID1 ID2 Reported Relationship EZ Z0 Z1 Z2 PI_HAT 
KCNSW01-2 KCNSW01-6 Avuncular Pair 0.25 0.43 0.37 0.20 0.38 
KCNSW01-2 KCNSW01-7 Avuncular Pair 0.25 0.45 0.36 0.19 0.37 
KCNSW01-2 KCNSW01-8 Avuncular Pair 0.25 0.41 0.40 0.20 0.40 
KCNSW01-2 KCNSW01-9 Avuncular Pair 0.25 0.34 0.47 0.19 0.43 
KCNSW01-2 KCNSW01-10 Avuncular Pair 0.25 0.40 0.40 0.20 0.40 
KCNSW01-2 KCNSW01-11 Avuncular Pair 0.25 0.41 0.40 0.19 0.39 
KCNSW01-3 KCNSW01-4 Parent-Offspring 0.5 0.00 0.82 0.18 0.59 
KCNSW01-3 KCNSW01-5 Parent-Offspring 0.5 0.00 0.81 0.19 0.60 
KCNSW01-3 KCNSW01-6 Full Sibling 0.5 0.15 0.42 0.43 0.64 
KCNSW01-3 KCNSW01-7 Full Sibling 0.5 0.23 0.34 0.42 0.60 
KCNSW01-3 KCNSW01-8 Full Sibling 0.5 0.16 0.40 0.44 0.64 
KCNSW01-3 KCNSW01-9 Full Sibling 0.5 0.13 0.41 0.45 0.66 
KCNSW01-3 KCNSW01-10 Full Sibling 0.5 0.17 0.35 0.48 0.65 
KCNSW01-3 KCNSW01-11 Full Sibling 0.5 0.14 0.43 0.42 0.64 
KCNSW01-4 KCNSW01-5 Unrelated 0 0.81 0.00 0.19 0.19 
KCNSW01-4 KCNSW01-6 Parent-Offspring 0.5 0.00 0.81 0.19 0.60 
KCNSW01-4 KCNSW01-7 Parent-Offspring 0.5 0.00 0.82 0.18 0.59 
KCNSW01-4 KCNSW01-8 Parent-Offspring 0.5 0.00 0.82 0.18 0.59 
KCNSW01-4 KCNSW01-9 Parent-Offspring 0.5 0.00 0.80 0.20 0.60 
KCNSW01-4 KCNSW01-10 Parent-Offspring 0.5 0.00 0.80 0.20 0.60 
KCNSW01-4 KCNSW01-11 Parent-Offspring 0.5 0.00 0.81 0.19 0.59 
KCNSW01-5 KCNSW01-6 Parent-Offspring 0.5 0.00 0.81 0.19 0.60 
KCNSW01-5 KCNSW01-7 Parent-Offspring 0.5 0.00 0.81 0.19 0.59 
KCNSW01-5 KCNSW01-8 Parent-Offspring 0.5 0.00 0.80 0.20 0.60 
KCNSW01-5 KCNSW01-9 Parent-Offspring 0.5 0.00 0.82 0.18 0.59 
KCNSW01-5 KCNSW01-10 Parent-Offspring 0.5 0.00 0.81 0.19 0.59 
KCNSW01-5 KCNSW01-11 Parent-Offspring 0.5 0.00 0.81 0.19 0.59 
KCNSW01-6 KCNSW01-7 Full Sibling 0.5 0.25 0.41 0.34 0.54 
KCNSW01-6 KCNSW01-8 Full Sibling 0.5 0.24 0.39 0.37 0.56 
KCNSW01-6 KCNSW01-9 Full Sibling 0.5 0.23 0.39 0.37 0.57 
KCNSW01-6 KCNSW01-10 Full Sibling 0.5 0.25 0.41 0.35 0.55 
KCNSW01-6 KCNSW01-11 Full Sibling 0.5 0.13 0.41 0.45 0.66 
KCNSW01-7 KCNSW01-8 Full Sibling 0.5 0.16 0.39 0.44 0.64 
KCNSW01-7 KCNSW01-9 Full Sibling 0.5 0.21 0.35 0.44 0.61 
KCNSW01-7 KCNSW01-10 Full Sibling 0.5 0.20 0.40 0.40 0.60 
KCNSW01-7 KCNSW01-11 Full Sibling 0.5 0.22 0.40 0.38 0.58 
KCNSW01-8 KCNSW01-9 Full Sibling 0.5 0.22 0.39 0.39 0.59 
KCNSW01-8 KCNSW01-10 Full Sibling 0.5 0.18 0.41 0.42 0.62 
KCNSW01-8 KCNSW01-11 Full Sibling 0.5 0.24 0.39 0.37 0.56 
KCNSW01-9 KCNSW01-10 Full Sibling 0.5 0.15 0.39 0.46 0.65 
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ID1 ID2 Reported Relationship EZ Z0 Z1 Z2 PI_HAT 
KCNSW01-9 KCNSW01-11 Full Sibling 0.5 0.16 0.40 0.44 0.64 
KCNSW01-10 KCNSW01-11 Full Sibling 0.5 0.20 0.37 0.43 0.62 
 
Appendix 15 – An example PLINK command for standard association analysis (chi 
squared tests). 
plink --file <input_file_prefix> --assoc --ci 0.95 --mind 0.1 –geno 0.1 --hardy --
hwe 0.001 --out <output_file_prefix> 
 
Appendix 16 – An example of the SAMtools command used to extract the depth 
information from multiple BAM files. 
The  file ‘List_of_bams.txt’ is a file containing the file names, and path to, all of the BAM files to be 
included. 
samtools depth -a -r <chromosomal_region> -f List_of_bams.txt > \ 
<locus>_Coverage_All_Samples.txt 
 
 
Appendix 17 – An example of the R script for determining mean depth and the standard 
deviation across all samples and plotting these data using ggplot2. 
### Calculating variables for plotting ### 
# Read in the file 
depth <- read.table(file = "<locus>_Coverage_All_Samples.txt", sep = "\t", header 
= FALSE, as.is = TRUE, na.strings = ".", quote = "") 
 
## Adding column names 
# Read in sample IDs 
samples <- read.table(file = "Sample_IDs.txt", sep = "\t", header = FALSE, as.is = 
TRUE, na.strings = ".", quote = "") 
 
# Add column names 
colnames(depth) <- c("CHR", "POS", unlist(samples, use.names = FALSE)) 
 
## Calculate values for all individuals 
depth$depth_mean <- rowMeans(depth[,3:242]) 
depth$depth_sd <- apply(depth[,3:242], 1, sd) 
depth$depth_meanMINUSsd <- depth$depth_mean - depth$depth_sd 
depth$depth_meanPLUSsd <- depth$depth_mean + depth$depth_sd 
 
# write out into a file: 
write.table(depth, file = "<locus>_Coverage_All_Samples_with_Header.txt", sep = 
"\t", row.names = F, col.names = T, quote = F, na = ".") 
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### Plotting mean and sd across the region ### 
library("ggplot2") 
 
ggplot(data=depth, aes(x = POS, y = depth_mean)) +  
  geom_line() + 
  geom_ribbon(aes(ymin= depth_meanMINUSsd, ymax = depth_meanPLUSsd), alpha = 0.3, 
fill= "blue") + 
  labs(y = "Depth", x ="Position on chromsome 9 (bp)") + 
  scale_x_continuous(limits = c(<region_start-500bp>, (<region_end+500bp>), 
  expand = c(0, 0)) + #the re-sequenced region +-500bp 
  scale_y_continuous(limits = c(0,450), expand = c(0, 0)) + 
  geom_hline(yintercept = 10, colour = "red") + theme_bw() 
 
 
